var title_f0_60_960="Carpal tunnel view of the wrist";
var content_f0_60_960=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 520px\">",
"   <div class=\"ttl\">",
"    Carpal tunnel view of the wrist",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 500px; height: 325px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFFAfQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5umdvMb5m6nvUW9v7zfnTpv8AWt9TUdADt7f3m/Oje395vzptFADt7f3m/OlDOf4m/OkC08LQAAv/AHm/Oly/95vzpQKcBQA3Lf3m/Oly395vzpwWjFACZb+8350bn/vN+dLilxQAzc/95vzo3N/eb86cRSYoAbub+8fzpNzf3m/OnYpMUAJvb+8350m5v7zfnSkUmKADc395vzpNzf3m/OlxSUAG5/7zfnSFm/vN+dLSEUAJvb+8350b2/vN+dBFJigBd7f3m/Oje395vzpuKKAHb2/vN+dG9v7zfnTaMUAO3t/eb86N7f3m/Om4oxQA7e395vzo3t/eb86TFGKAHB3/ALzfnRvf+8350lGKAF3t/eb86N7f3m/OkxRigBd7f3m/Oje395vzpMUYoAN7f3m/Oje395vzpMUYoAXe395vzo3t/eb86TFJQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzo3t/eb86bRQA7e395vzoDt/eb86bQKALtszGM/O3X1opLX/AFZ+tFAFeb/WP9TUdPm/1jfU00DNACCpFWlRalVfSgBoWnBaeFxS7aAGbaXFSYpMe1ADQKCKfjikxQAwiin4o20AMox60/FG2gCKkIqQrSYoAjxSEU8ikxQAyinY4pMcUANpKdijFADaQinUlADcUYp1JigBMUYp1JigBMUUuKMUAFFLRQAlFLigCgBKMU7FGKAG4oxTsUYoAbijFPxSYoAbijFOxRigBmKMU7FGKAGYpKkxSEUAMopxFNxQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUCigUAXbX/Vn60UWv8Aqz9aKAImjJkbPqaAmK07iDbI4x3NVWTHFAESrUirSqoBqYLQBGE4o2GptvNP2HFAEATNGyrIHHbNOWLPbNAFXZzSiL25q4IsHnGKUqBzjigCkY+OlGz0q0SPSmlaAK2zrTdlWCp9KaykUAVytNxVgiomHNAERFNxUppuKAIyKaRUjCjFAERFJipStNI5oAZikNPxxSEUAMpKeRSYoASilApRQA3FGKdilxQA0CjFOxS4oAbijFOxRQA0ClxS0tADcUYp1GOaAFggluJ44beN5ZpGCIiDLMxOAAO5JrqfiF4MPgq60+wu9RguNWlthPe2sS82btysbNnBO3B7flgnt/Btlb/DLwpH421uCOXxFfoV0CwlGdgIwbpx6AH5R3yPUEeS6heXOoX1xeX0zz3Vw7SyyyHLOxOSSfXNAFbFIRTwKMUAMxSYp+KMUAMxSEVJikxQAzFJin4pCKAIyKaRUpFNIoAZRSkUlABRRRQAUUUUAFFFFABRRRQAUCilFAFy1/1Z+tFFr/qz9aKANm+X94596zn61tXcO6V856mqDxBTgCgCqiZFWEjzUkUWT0q4kXGAM5oAp+URg4pNhJ6cVpCIHjHP0p6wc9BQBmLEc9OlSAEGtN7YCPjrUX2XKkg/N6UAUGBJ4puw5FXFt2Ung8d6kWHsRQBn7R1pduTV82xP3V6Vq6dpAIDzA59MdKAOaMTc8Go2THSvQjpsCqQVBz0rJ1bR4zGWhwHHP1oA5Ar61Gyg1bkiZWIIwelROmBQBTZeaaV5q1t4JppQ0AVSKMVKUppGDQAwimkZp5pMelADCKaVqbFJtoAhIoxUpXmm7aAGYpcU7FLigBmKUCnYoxQA3FJinkUmKAEAop2KMUANxS4paXFADa9J+FvhXT/sN14z8YqV8MaW2EhPDahcdVhX1Gfvf4ZI3NC+A2tXenaDrGo3dva6JeQG7v5mba9lCAXyQepKAEehPIwMnlfil4xh8R3trpuhQmy8LaShg060HHHeVvV26knn8ckgGH458Vah4y8SXOr6q48yQ7Y4l+5BGPuxqOwA/M5PU1gYp2KMUANxRinYpcUAMxRingUmKAGEUEU/HSkxQAzFJipCKQigCMimkVIRSEUARGmkVKRTCKAI8UU8imkUAJRRRQAUUUUAFFFFABSikpRQBctf9WfrRRa/6s/WigDsL5CHcYxyazZEyeetbl8v7xgemTWW65egCKKPgCrkSdAKZHGTV6KM+nFADEi55xn1qeOA5wRUkUXzcircUe4jnFAFUWxbpzQtmzfStNYsDBxnpVhI8AMccUAZa2mOCAaGs1YkhSK1vLGBzxT4kzkDHNAGdY6cfM3Mvyqe/eugt7RdrNgZA4qWKIhVjxj+tWQm07QAePpigDNeAibkfLj8Ko3Fsw8xmH0xW0UPG48YpUAYOrKNv0oA831y0Mc4kC4DfzrIkjJJ44r0LxJpoe3EqDgc1x7253UAY+NvUUrKScjpV2WAjPpVcDBwaAK7R55xVd05q+6k42imGEn86AKHlkngUojOav8AkkcUxo8CgCnsoZMdqtbMYprJ2oAqbeaNvarBSkCUAV8UmKnKc01koAixQBxUu3mgLigCPbT44i54p2K0rOBdgOOtAFaGyZhkAD60s1gcEr1HWtqCMeXwORQjYY5GQetAHLFSrEEYIrsfhH4TPjPx/pelMjNZ7/PuyO0Kctz2zwufVhVS70pLtfNhIV+4ra8GeLtQ8B6Tqi6FbhNavyIjfOA3kQjnCL/eJPJPTaPwAPqr4qfFTQfh/ZNay7L3Vmj/AHWnxEDAxwZD/Av6nsK+ItZvjqurXd81tbWpuJGk8i2j2RR5OcKvYVHez3F1dTXF5LLNcSsXkklYszsepJPJNQUANxRinUUANxRinYoxg0AMopxFFADcUYp1BFADcUhFPxSYoAjIppFSkUhGaAISKaRUpFMIoAjIppFSEU0igCOkp5pMUANooNFABRRRQAUopKUUAXLX/Vn60UWv+rP1ooA72/H718etZjj5iea1b/h2xjqazWHzAigCaBenFaNugxwOaoQcevrWjbk5FAFggKBxkmrCIoVT/Skjj3MTjjFW1RQBkdaAI1GSvHB9qlHXAU8/pUnllTjHB9amSLpj69OKAIF5B/IVJaxl5kUdCeTUyx4I44q/ZwBUMjD73AxQBKAqv0z6AU0glXBPPTFSgBACCeG4pRBnLqwYjGaAKLLtX5WbI5zUJklD5HIfjmtTy0dWQL8x9OlV/sR/hHIPWgCrMv2iKRGO5elcdJAEllTAJBxXctE0aEcHNYV1ZSNdt5Y4POaAOaks9/Ax71Te0CMRXdRaWoCgYYn2ou9DR1LKuGHagDhPs/XimPDg9K35rQqxVgcg4PFUpYMNjGaAMd4yDTTDkYxzWtJANuCKhMOP4aAMww8HiongPpWmYse9I8eRx+VAGUIifrR5WO1aLW5HPFNMBHbrQBmvF+NMZMDoa0ni5xULR9ulAFALQVq40XtTGjOOKAKwXitHTZB90547VVCDHNPhHluGBoA34YwrZGeRVadNiDHOasWjiRo+pU0ahb+VMckgUAU4ZmR+laEbRzKN4P49RVCOAFS5Py56GpmOAcY/pQBLJpkMwJQr+NVZdCjK7s8e1WPOKoCR8w4BU9acJC3GWX6GgDLfRcISrYxVG406SHk811MEwGBJjHtT7i3WZCIzlqAOIK7Tg0ba1L+yMbEntVNU9s0AQBM8EVKsHIzVhIycEjirUUWfvCgCktuGHSlNlnkVsQWu45AqfyVQEMpFAHNS2rJVcr2PWukuIdykgZHrWXNb56cmgDOIptTOpU4IqMigBhFRkVKaaaAIiKYRUpphFAEZFNIqQimkUAMIpuKfikIoAbRQaKACgUUCgC7a/wCrP1ootf8AVn60UAekXVnczyExoduSMms64sLiE/NGSD3Fd3P8nmblxg8D0rOmnwDhc+lAHLwLlh1FalvHjqOauy26TMMxru6nHBp8dmynI5XHTvQA6GHnB79zU6qQOBkDrSxA7cY/OrMceVoAIogcFhke1TLFgEDOPenqPlwf0qRQxXgfLQA2GPzpFRePU1peUv3F+70BptiirE0mOTxVlEIAPqKAK0qHeFAUjvipGITGcDPYCpuAOuB60OFYgrkr15FADFdFIwAB61XldRkKCBnr61PIpLPwCM4GRTFg8w7fyoAltrUXJKkED1pNRsUilUIBwK3bSNIYFUDLHqazrl/MnYk8A4oAykTIUYGM9uKibJLY6g4wa1o4o1O7A61VuIgUZgpGTk4oA5G9iLXT9Oaha0DDGK0pIPMnL8/jTxHgHvntQBz11pzpkoSR3FZsikHBGPeuvZAeO3pVWaxjmXDJk+tAHKumenBpDEcjit59GYcxn86rXFhLF99G/CgDLMeQehFNEeVJxWj5GT0xmkWEgbW6DvQBlSR5HpUBiz1FbksAK9ATVaS3IPI60AZJiHQVE0ZHvWs0A7D2qCSLtt5oAyvLAPvS7M5q20YAPGTTUQu4UDk0AXtBjM0wUYO05rY1RYyxLDrUnhi2EDMzKc7fSkvWDsylShP3cigDBkcLlQOlV3Rm+YjBrReEK4Dgk555pwhCOQoDsTkdwKAKccJUAD5nxU0UbRREMRjPfqatGPMhKkB8dB0pUg3qVwN46k0AQMRswTyewFXNPjMsmM8+p61VdD5+0YIA5IrV0pRldgOVGcnpQBR16x2JvHIPU1zQhOflQ/lXe66pGlBnUYzXKLAxC/MRk8GgCmkBwDj6itOC1UnIODjkUsFsQSDk5qyIWC7kGO3NAD4Y1VMkcjmob1kAYLjn+VLuLJ0OR+tRfZ2Zyy8HsD2oAokkNwDt9KbLGMZHGKv/AGckFVwD1xULxlDhueOQaAMO+gPl+YOg61nkV0hQPuRh8p7GsO7gMErKRx2oAqkcGmEVMw4qM0AREc00ipDTSKAIzTSKkIppFAEZFIRTyKaaAGGmmnmkIoAbQKKUCgC5a/6s/Wii1/1Z+tFAHveoEDzMtz2xXPMw81txAOPu1s6gcuW7LkcGskKrz5Kj34oAliTcPl7859K04o8Io54qvbxx4GwblJ5Het2O28uMZUbSOT3FAGY8HPyj8RSopAIPB+laqWwXjIwaGtwdxCjb2NAFBFyvIwfepRwCVxn2pzJ85Ujgd6cicBeMGgC9bKRbjOef0pzfeHHT0qWBd0CKoxn1qTy/m5zx096AK3ljdnGeuR6U7ywihc4Har1vb5OcfL61YNkjADgd6AM11Y4XbyT26VNYWoe5IKnr271ekt41UYGTWjpMI3Mcc4oAq3aeXFwtZhhUg8fe61ralkSlRylV1iBIwenNAFWG2Uxkds5xWdrLKsflAkMfvV0RQJGZDjaBXL3TebOznBz0oAzGTaBxnI/KoTGNxwvX3rXitJ7tyltC8z9kjUsf0qK8sriyujDdxNDKAPkb73PIqPaw5/Z3XN26/cO3Uy/LJOdo68UJHhj3NXjFvOF70giK8EECrEVSvYHn0NDxblG4ZA61MyFm6gDpUm3amQM5oAzJrCGRfubfpVCbSnUtsb35roFUMevSneWCORxQByctpIg2lCffFNa2YD7px9K6loeSQc49aBCpHC5JoA46S14J7H2qq9sy43A8128sKA8oPpVqy0yORDNNHhB0zQB58mlvIcuCqHt61padpcMcjMRuAHU9q7qXSoZQNqjHvVd9H8tSYQMk80AZEDRqxC49KparD5hDDbz0x2rWuNNMMrlE4NU5EbaA64x7UAcrKjR3BSTNPiCgnPB7mr99GvLqBmmpETGCB82MkUAU3UN8yEVNGgEIyoLn36VPHHsyXAVz0GO1PWJVjwOXPvQBVjgWNvmUk7uMVp6fbsSr44zkgDqKijtmyFY5x71tabFJ5WQec9aAM7xCN1okZGPmzg1iW9qpGG+7jit7WwJZQrkE+nrVBFcIECj6UAQLbhXVl+U4xj1pJojEgZlJU8/KavSyhUBjQehB7VRmJLlxnbj7tAFFzwcDg9qeUaVQDgcdaeD+9ywGCOKesLKFMm3aeetAFcoqnjBIxhqguD83GCvfjmtBtuFMYwBznHWq04AckDrzn1oAzSp3ZyP8KS7s/tVv28wdKuSLE4wBtY9D2qS2R0OGUMvsaAOLniaFyjjBFQt1rsNU05LlCyjDj9K5S4haFirDpQBXIphFSGmGgBhFNNPNNNADCKaaeaQ0AMNNNPNNNADKcKKcooAs2o/dn60U+1X92frRQB7HdOzySA5HvUCxAzAI+7jpmrVyA87OcouNv1qGNBA25VLZOMjtQBq6fbybkICqp7muptoGKqrZbA6jvWDpkKyHcTiNRnBPeut0/DKFB4x2oAzJbbYcgYyOh7GoNh2DI6Dmul1C2OwMOV78VgXKsMtyMUAZ9yU5UZz1xTFA4JCj+dI3MhYZz2qZF3cnNAGnY7ZYsjqvHWrkQG4g9vXtWZp7NHJ8gx2rUbcwyqnHfFAFiNwAQAMe9KZzsxgVW5J+XIzUMzsuSOPagCeS85wOM9sVoQ3UkdrhcZPXFYCq80gA4Ud60iCFAHQ9sUAPd2Jwx69DT7dR5uWAOeKiJKgA8g8cipLcgyAgEY4oAs6qNlg2zv1xVLRr/RbRk+36V5zDjzDJv/8AHDgVqamnmacdvXvXLPGTjAzXNi8JDF0/Z1G0vJtfk1+JUZOLuj1LTPEGivGI7eeK2H/PN18sD+lcv4tvNI/tub7Ro4vZCq5mW7ZNw2jHA4rmCqkYHXvTAm0ZH0xXzmC4Rw2DxLrwqTs01bmafT7UXF/I1lXclaxoDUtCA2/8I5jv/wAf0n+FKdU0BUOPD3HvevWbJDuQnmoHtvlA6iva/smh/NP/AMGVP/kzPnfl9yNRNT8PvKf+Kb59ft0nP6VW1WbT7kRiw037Cy5Lnz2k3eg56VTijXfgrUnk5YfKwB7VpRy+lRmpxcrrvObX3OTT+4Tm3p+iKRhABf1NNcfuiRkitZLGaQkLHnjOajmtJI0wUx68V3EmOTgYPAPWkVRgjv25q5PGBkYGB196YI/k9DQAtjZmeTcfuitKbA2RlTyO1SaTFi3bAOTyame2y4IHK0AVSzLGytgY9KsRHKceg5p7WmIzv6+tIiFQCeOKAJFijlXBUZ96zrnRhJlgckdq2LaP5AccH1q3FCXUFeBQB55f6KcMhXaevTmsr7ILRv3m4semO1ep3FkGJaRQT6CsK60hGm3qufagDiTbu8u5uR2Jo+zs5ZSACO1dFc6b5a7pMkDnbWXKpJwOG6fQUAMhiAeNDt+UcgVJcXUMEeyM4yOgqeGJYrJpCAXPfviuamldrhg4yT09qAJpCZ5gXUkjpV0QsgDIoOf0pllGzOgIGD0PpV+aNkT5PvUAYV2UD9SGHGKrvE4VjuBB71alVWLZ5bpkd6jXGSJYyExjINAFbYGibeRv7AUwR7goJ+Q8E5qy21HEe3IA+9UKgIHIDEdPoaAIiWWM+XnAPFRK/mZDkVGZHE21gSvXNO/dryAcUAI1shbLuQPemGFlBKvkZ6d6kZ1PyuCykcHpilZML0znpQA6xkV2KPwegzVfV9JVxnA5pQ2GAKsrVdgu/wCCcZ9DQBwl5YSQklRkVQP616Ne2CyIHC5U81zOpaWAxKg0Ac4aaasT28kZ5BIqA+9ADaQ0ppDQAw0hpxppoAb3qRRTKlQUAXbRf3R+tFS2a5iP1ooA9gu2JOSoZgTg9KitGdZTbld6kZDE8g0hkUXThwCpPbtTrUmObBGc9z6UAdBoUWImXBOetdZpUe9lGcYrF0WFQqunIJxzXRW4KspQYbsKANye232Bx19K4HVyVk2Zwe4r1XSozNaqducjnNee+L9MnttYZRETG/KkUAYATzMBAc/zrTstLkdssQq+1XNLsSg4Use5I6Vu29qyIMIT9aAKENnHAiqqhj0NWY4dnBA2mrTw/LgcHqaLaAO24gjHvQBJBZoV5UZHtUsmmwt9+MEHrgVYgQccnk9a0PL+Qbe/rQBzzaTGh+QBcjioWs+DxlfWuoEC7MnqOKqzQ7UAx78igDlpoSGATPWoUyHyR35rfniVnxgfhVGa1KupByvTFAFi0RZrQgYz71zt/amCZgcnnjFdVYxFMYHBFN1CwDKGIFAHH8YPQcc5qBmXdxjPrWteaa2SIyfpWTNbPAxDDJHegByngAcA04oMnB7VHC7KxyKuRgucr1NAEFvbNIRtHNbmn6X3kBJNWdJslQBtufU1uhFRM4A+lAFGOzRFwRTbuwjmiYKvOOtWpZOOMnHamwyGTO7A5oA4fVLEwMd33e1Z7wgDKn2FdrqlssmQRuH8q5ma3aGUp6HigC9pVvI0SonGBk+9a/2YQ/Ntzkc8VPocA+xhu5FWpYt5HUrQBktbCVfmGFJ61SntQr88L3rbkTcCDwtJcW8bRrt644oAx1ykwXGUNaMSAJvHSq80WzcGXkdKtafMGQxP68ZoAjcEgE4FZ8ibHL/fOeFrZKckgYHvWZIhiLPjJJoApyQIVO9dxPUVmXunB8eUFAb25rYVW3ZznPPFNeLrjkCgDkr+2aC3CdVHU1xl8u2YEc+uK9YltjJA2VG36Vw2v6WDJmLCjntQBFojBQNxzz39Ku6gpWXPIGOKraMu0bZVwV71r38cbxCTlhjGDQBzN3ASVZCA55wBS+UzI/G44/KrLx5+YOF9KBllGDtHcetAGbNb+WBt5b+VUbhZIdyDktzmtryQwO7+dU7qDJBIJB696AMKTexBA7c0kRCKxcZU9jVmWER52gg+hqtGuWZWPPoaAJCVYYk6DoaMDyyFPTpk81A8mzGP5UqkE5DY9aAITISSHJp3mYA3HjtSt9zkDdVWYZPBx6UAbVjfRqNkgYof0qzcWUc674mDAjNc5DORkA9PWr9rfFGG1jg+9AFW905cHC/pWHd6avOFOa7GaXKGVBlccjuKz7jDqZIgD6igDiZ7OSMnuKqng811UxiclWXaf51n3dkjcp0oAwzSGrM1pIh4BIqsQR1FADamjFQ96njoA1LL/U9O9FLZ/wCp/GigD1O5CecZFcYJyBjpVm0Qo2c5B7HtUhtoyZvlJcnoPrWhp9n5mFweCOaAOk8PQ5gjL8LjjNdFCitMMcY7iqWn6a0cAYDgDgVbgb5sHI5waAOv8OygloiMdxmtS8sYboZkRWYdMisXQMrMDn5cVvXNysfXrigDKbT4EGFjUAc8VnXYVScntxWpcXO4E9AemaxrhizdMZoAoznJAGBnqKfBHtLMDxmldScZ4I46VYhhG0HBx70ATRHgDHT8OauR5KgYOe9NWMgLhcAjrU9upB245FACrnAplwgeMZzntVhVJbGQAO1JcZK4agDIltdzDOdo60G33DC/dArQMZXHPymldSQPlAGOtAGakRjYYxt7VZVkkXa2N1EsYUDnjNV3UoSwByTQBHJbxmQknDCsjWNNDQF1HPXNbzLvQEdTUdwoWAgjJ6UAcE0eARjn1q1pcTGYYwQDUs8TCchR34FbelWBjjywBLc4oA0rGLEXIwD+tLdAgblbA6Cp5T5EAAGM9OKy5HZn3lsAdjQBYIAC/wC13pICgmLKOvB9qgil8w8k47e1Wdp8slFG7OeO9ACXUat8o6elc9qkIWcHHGOa6hYiVDYyRWVq8AEnI5NAFrQlH2Zl6Y6Grc0TAEg4HaoNEGVwMAdMVryoMYJ47UAY7xDIGcgUq7MnPIq1JHtPyrz6+tQpuyd6jrmgCrdQiUnC8nvWZJiGVcjmuj2BjkdD0NUNQs2cbkHIPI9qAIy6NFuH3sdjVKcA555PtTk3wyNkDHQU5wrKHzknjHpQBn9CAmM96rbmSRtuTk81eRTGcnDGq77iWyPegB8IEke05/xrnfEEHljc3Bzit+z3CQ/MMDmq+vWyzWjsQSw5oA4+1IjmTOCpODmtu4tFlixnIHSsPaRkY4Nbljco9uN3UcUAYd1ZhAGIPy9Riqsioz5QYx27V1M0CzDO7g81l3di4UlUHqfegDH2qDx/EOap3EJxjfgdQK1pYyU+dB07cVSWMD5HB9j6UAZEqHayv8wI6+lZM8DqVYDoeorqpLIMpwcEjisiVJIso/HagDEfc4yR0PSmZO/AFaTxkZHp3qqYwknYg80AViykn1qrKTzgEGrMq4LVWkfjnr0oArebtBzknNSxv8vFQPkelCybQcGgDTtL82p3bdwPUHpV9fs1wvmwsI3bqp6VzYlqaxuNshST7h60AXrqy85C4A3DrjpWeilXKuuauLJJDOMNuB6ehFbunJb7XkaMM20naaAOfaGLy8zYVTwSazLqzsmztLZ7fStO+vLWcuiIY5N38XQ1nRwNkmU4XHQUAZkmmvnMQ3L6inxaZPwSpA9a2LOSOJ12LkYwAx710tokNzEFkVRng4PQ0AcjbWU6x4C5GetFd1b6UEQhDuXOQQKKAOtURvKHBxz81dHo1iXIK/cYg8V5nZ635cphm4UdSa9I8FXizPGomVwewNAHoMFsUgRRzgVXls8MTGOT1roba2LIvy44qT+zQZdwx64oAo6FH5SFjn2zUmosPMUZznitHygnyIvAqKe1Mq5I+YUAZN05NuzL95eBVCOcPCpb7/cYrUktZCHAU/SoGtdifd5+negCAoDgjGPcVagiJQBcEelVwp4X/Oa07aJtoJGKABU+YnpjrzVhVxtYdP51GFYE5HB61YQ5wAQPUUAIsYGWIz3pTHuXJ61IoAf1HSpAgPzdqAKrRAAYIPtTSpA+YZq0w54IBpphJbLcg9qAM6WIOCVGQDjiq0jYjIKnHqe1bnkYyRxVOdSQwZQV68CgDOto8jrgU3UItsWEyT9K07W23KGUYANPv4lWPcefpQBzFppitLvc5PWtm3tkBUg5wOmOlRRpliQdtadlCxAyuB/OgCvdoAmGAyazJIECkMOvSty7tC+CCcjt6VAlkdgDjOOKAMa3tAWDdvT1q5BH8xGNpHr3rQS2KtuQYGMYpIoAG3OCeaAIBH2xWZq8IKFwOnOa6Fog3Odo9qpXNus0TqMdM/WgDN0UcBgB71t7AyglazLFTHx0AraVQyg9AR0FAGdNGxHAwegpjW5IznOB0q/LGQo25zVeRGClicZoAjSBvL/pS7FyVXBOeQacjHy8DJNOVB97PJ9KAMLVLRoi0iqcdqqCENHkcZ7V1F1GJISh5/Wsj7OOeOBQBhzRqJTzgjiq8sSgHGRgda3ru1VlyvB96yJFYZJPGaAKcaqAWJyfYUl83+iyA/LkVLGDu57n8qg1Zh9mYDGelAHHSLnPcU2ORos7cg9wasyKFzgfTFROoOeoOexoAnhvwuAdw9gOlTPqMLIQzFOeDjrWa442p0J/Oq8qFvw6CgC9OI5QTlQT0OarSWrMBnbwPzrOlDKcqSPoelVzf3UajD5A7GgDWitGdcLwV9T1qlqlnIBv2Hp19abBr7Rn96gz/erZtNas7lPLYqR6UAchJCzL1OO1U5YMA7hziuw1ixilBktiAD1A7Vz1xbtH95TigDnp4SGODxVeVMjnr9K2ri23ZKghveqTQHJ3fiKAMSVMD0FV2Pp09K2LiAHgc1nSRFGIP4UAVh97mkz82AakkUgGowp4NAFgTkooY9Ohq3b33kyKZM+hqio3LTJTmMFzwpxjNAD7hY/tB8rLZbPNWneBo8MuZQO3asq54uBtcKMVIkm/k44HbvQBNEgY/wCs78etbunyLkKUya5iIhZgcnOcit6ykKkNvyuOfagDu9KnP2Nfk7+lFYtrdjyhhiBRQBkXEaecSGypyCK0/Ct9Nb6jD9mZkYPisWeXM7BcgA1peG1X+04WycDkigD6Q0PxQwhjS7xuwMMK6q31FJwGVgfpXlMYzZIeCNoqew1O5siNp3LjoTQB6wsylc7sU4XCYx+FeenxescaK6tuxnAqld+K7qRsQoFHXnrQB6jI6EYBBqlcDC9eK86ttavWlDtO2O6jpXQ2eqPNGNz5PYGgDXhhVpjl+vNWXPzDOQR6d6zrWf5umWq8j7hjv2zQBOoJkx264qVV7ng54IpkaZwRkY4JqwqLz/e6igByoARt780/pwc9aRFywPYjBqYDg5HNADdg3ZIzinFQBuB/GpkQnGOtK6fL04oAptgKMnOagWMluu0CrEy9P6UipnPrQA5EHUEVT1QjZtAwavqACOKo3qh2A6Y5oAoxRHcq+tawXYoUfSq1rES6cdBzitAR8ZOSaAIGjYnhuKlWMjg9Dz0qRFGcgcetOYHigCAx9c9e1RtHkEkcYq3jjleO1RspH3efWgCmyt5Rx0BqAx/Mewxyavbc53ZwOlMMfycA0AZXlbW4HFaEGXA64HFRTgEg9/5VZgUYGOCOtAEE4O5jzioVjHlncTz3q5OvI7iq5BUZPT0oAhSIlTzTlTY2ADnHep41y4bGFx3p7kjqMgdCKAKkiFhuyVYVQuI+euBnvWo/OBnHtUM0BlUkjgd6AMtj8oDDIHP0rMvkViG25z6Gtk25zwRnvWdqUJjUdAo9KAMR12kgjkelY2pSb3IBrakbkhMg+9Yt9Dhi1AGZJDlPlNVSp39eO1XjHjqcEVCULuNuAaAKEq4PANVnUgkkYPStSW3kyCOT7VSlRv4l4x3oAzpUySB1qjKm3gg4rWk+7hVA55qnPGSMigDIniD1nzKYzlc5z61tTgKBk81RuEzkjFADLTWZ7Y4mLNH6+laaahDdEKcEdjWBIhKkEjHpWXM81sd0JPBzigDq5o3AIUZHbFUJoyeoPvVPTNdErASMVb0rfiuIZcMyg59KAMTyd6n1xWXep0yOldlLZx43RZyecVh6pYsMkKR3oA5mQ5PI4qJV+Yenar0sBDciq08LhcgUAQSMBJntUBTdkg8davG0klHA5NVriCS3jJNAGdMd1GSCNpz60mS2cjmmDI6daAJ0f5yM4I6Vt2O9Y8r8wxlq5+Jst8w79q3dMDRkBCSD1FAHR2SiSDcwPXtRVy1EXlDOQfQUUAczO2JmLDJJ6itvwmB9sBHWueuG+aTPXJrc8IZ+0hjwOlAHtlj81lHkAnFMmiIByRlulQ6C4eyxnp3NS3jlUz/F2FAGVKoWc4PAGKchG7Oc1DJJliOOtSwYZ1GMCgDQt8dQefSr8DSA7gSDVSFDGSeMHsKtx8KDnvQB0+kXAmj2E/OOhrVtjhvmPNcxpgdJNyrwe+a34N7EFuB1zQBvQAEjk/41YCndzkY9aqWDZUg8sOKv7OD6UAC8kAcDtUyjPvUKgg+mKsQ/e4HFAE8a4p7rkYpAQDj9afnIoApOmG6UzA6KDU8p2k1Fu4PFADTnHPOKqSkO3GM96tOxwcdPeqkKkynIz60AWYotqjHepwcZDGgAqMEcUKu7nuD1oAVFYgZ6U/acGncDAxTsHBxQBGV4JPSomUg89Ksdxmm7MnnJoAh28jPShoxtwo4qfZtXIP50wqc+3tQBnTKNzAHHHpUkS4iB68U6RSG+X61KqEBc9D60AQScqMfSoSGLhevFWDGcEg00KeGxxQA1YSDluaikJCkKcEVZJOMHmqzg5PAIoAgBwwV/zqaNWdSOhPAqNQS5LY5q1DkD3oArS2+VPy49ay7+zLoyZ4rowpfvmobu3DRtheSKAPP57BkYAHv3rP1SHHRTn6V2dzCw6gVj6nCxCkYPPWgDkhaM4JIwKiMYTheW9cdK1rkHO0ZANRNGCvQg+9AGU0ZU9eRVS4j8xSGwPTNa80eWJ6/Ss64OGOF57UAc9OTHlQQefyqq7EnIBrQ1Bds/IxuGapHjk4GaAM25BOQoqrLkJgjFac64OcA1nz89BQBmTcMT3rNuhlW7+las4B54z3rPnGQc0AczeIY5dynB9qsWGtS25CyEsvrUmoJuU8c1iScE5oA7/T9bWVRtk/Ot9ZoryEI+OR1rx+OaSFw0bEVvaV4gZGCy0AdHqelvESy5dPUVkpFILsDBxjoa6jSdSjuAAWGCMYpPEWniPyri2ONw+bA6UAc5PJ5GVAzJnr6VmXkzcbgCcYYGr2ofuyOTu71mzMGPPzE9KAMqRQTkUzryRg1ZuFYc7cfSodjScoCTQBCPlcGuq0u034+YAkDkHtXOwWkrzomB712Ol6ZICCW6dhQB0ul2aLagEh+ep5orb02wC2iAIfXrRQB5NIQzOOpycVv+GFdUfPQcYrkLa4zc/NyuTmu+8LRh4VP949aAPSfDxAt0TI+7k0+/kLfd5FZFvdfYiqo4LMcAe1a0i71HuMmgCgEO/FWLUBX6cjvUExcOBnnHbipYH/e/MD9aANWJvmGTzW1YWauA7/d649axbNQ7jb34NbkchGFT6UAaDOAUEYG38qtQ3BRzkYHvWfExIIxVvaDgKck80Ab2nXShgR3roYwGXcOnrXDW8pjYEA8n9K6zSbtZYguccUAXRHyc1NGp69KeACemRTgo6DNADT3xTl5GTRsxxSk/LzQBBJ+dRYPPpU0nXI6VGQSOKAI3yE+bk9qgi+96VLL97nr0pIlyCDjigCd8nAqSNeBTUHBz+VTqM0AAUZJNO24HvTwv504D8qAI9hK800jB6VOeOKRh3AoAhxke9NIAB9am+lMYd6AKUg+YdqcQBgHpUjrk4IpNp3ZPegCLGcnHFNPoOMVOB+Qpp6kcZoAryjKZOQOlQ+WX6cA9atFMkbhxT0TryMUAUTHjGcfWpYQA+B171M6Z5A/CnwxfxDqaAHIhOMY5qVogQRTo1x1qbbQBz2pRbXOF4I7CsC9QMwULjArs9Qi3x5A5rl72NlLYIyOmaAOWuovn65PWqhA3k/pW1eIGyTgMR+VZHlZG48FTQBRkBJIBwM9Kybtdre38q3LhtoJxWTec5xjNAHP6i2ZFyOQMVQkO3qauapuE457c4qocFR3oArMQc88VSmxsJU9OKvuCc/KfoKhNpKwbPGaAMGfoecVQn4OCa32sD5hDnIqGSxTceOaAOSvEIJwDisS6hcNnaa7q8tQAeOlZF5bblNAHJmJjnio2iNbLQgOR+tQyQ89KAG6PqEtpMoZyEz1r1i2i/tLT7cq247cHmvH3jAbFdn4I11rf/RZXAH8JPagDfu/DEckjNNLtI5APesi+0OMbGjkXHpXatLDdIrs+845ArB1RrcI6wPkjOAOtAHIXOniEFiAwJ9ag+yYIKLjd0q3cPK4JYHjpS6ckhY7iSp4xigCLTLMecfmwM967jTbVVRV6jsfWudtIiHbygpVTgg9c11WkRyAgSZUjkUAdnpasbJOFOO9FS2DKLZQMjHtRQB8trJtmYH1Neo+CZUFojyHCqO9eUyDMjfU10ljrMljZrAD1oA9IW7FxfFlOADwK7ixPnWSSBucYzXj+jagGYHd1969T8K3SyxiMt16CgCeaJS+ec/Soo0yODn1rXuLctnHSs1omicls7TzxQBfsGPmKv8PStdGw3yg7aybHiVc961ohwNoGTzQBdBHl7gMDNXYXUsBnnH5VnRZBCLjb3zVsYBJyBxQBf2EspAxx19au6c7RyjHXPesq3mbd6r3q5BMuQx7D1oA7K1nDKPWrYORXP6bd71AJAI962Ipg3fmgC0Kay8dOlCtk9aU+xoAhk/M1C2edtTSnFQSsBkdjQBGTvcVIi85qJPvjjn1q3Dlhg4oAeijA4wT6VKo7ikAGcVKvSgAUUvtTh0prHANADSf504c9s1TFwvmhSetXEORkdKAAjFMI4qUimMM8UAQFSPc0hAqUryfSoycN0xQA0LhcE0ySMZ608uOgpu3JyTQAICccVJsHpQi4HB71IozwaAISn1p0S4OKmC5NKFOOaAG9+KdTGIHA5oDYGCaAFkGQQelYGpWmHY4xnpW6zZ71XuIw6EHr2oA4m6tWYsGAzmsq8h6DoO9dTex7SxHJ71kXMYYneB6g+9AHPSwZT5uves2ezBbL55rpXiDggr1NZ17GFBGc/XtQByd1YxPMxKn86qGwCHIGFNb7qMndjNVJlwDkZHagDM+zKvHy+maryoEc5HB74rQdMgYznrUEwxjjpQBkXca7sDt+tUJV3cE8VqXJBySM1QlC45zn1oAxdQHXJ6Viuck7h+Fb2oZVSRXPzPiRjQBl3iBZCccVWYcZFadygZDtqiF7UAUJY8UkDGKUOvarUqA5qAJ1FAHX6LqTeWCrEDHJq8gjuLjMZwR1Ncjpkpik8sn5TWiJniYsjHYxoAv3drKHwy5DenrVw26R2yowEbL1I6k0aNMJbmCKRcr3Gelb2p2XzKYtu37xJoA522Vfte4Z2kDIFdjYIXjjKfdHrXOW1uoug7jgnGR0rrNLQq23aV479KAOqsI1+zjIA5oqzp8Z+zDjP0ooA+RgP3rH3pZW3yfSic7Wb6mmR8nNAF6wvHtpBz8ua9O8Ia4iyxsT0968m7VoaZfSWcqsh4B6UAfU1lLHcwpIvO8ZFQ3lqea88+H/AIrEs6W075Xt7V6xhZogUIKnnNAGHAvljnPXrWrFlUUs34VHNblXG3p1xirkcRaNAeuKACIlsDGAKvxLvwdvboKrRKVUkjnoKuQHaFx260AKsee+KciFVXpnOMU6RRtBUkZoXbxuPA9utAFuCQo2V4xWxbXpMYwwzWDGffr1qeOX5zjpmgDpob3kA9atC7TIHeuY80qowamjndjjjPpQBuyzq3eowd49BWSk7q/Pze1aMMo4BI56Z7UAWIBt5Oaux9Mj86qRuu3O4Gp4mYj2oAnA59jU6YxUcfK9MVIvSgBwqreOQAB3q12qrdA7gaAM5hmQkYrTtGLRjNUdoDgAHmrtmDyTQBZxxTSKf9KY3WgCCV9oqqZCzYFWJlJqs8fcDFAEkfPapcA4BGKjiA64qYYoAAuORUiEHtUZ4PFNaQqc9qALQoIpsR3IDTjQBE2Mk1A55xmppO4qu2M4oAQsRgn/APVQW3A03ksTnikLAHp7UAUbuMFyQO3NY11CAeeR6elb12Mr17VlTA4JwNtAGL5WWyo4z0rDvc+Y6sAfU11IjHLDlRzXL6hlbiQMOSetAGTIhDZPJqCZcdelW51JbOeegqsR/eJoApyA4G0D8aqTRMT0rTYACqkzkHnB9KAMe6iOTgDHQ1QljBQg8VrXa5A5APcVRnQYwcUAc7quVJ9hXMT8E+ldFq0pZ2UdvQ1l/wBnSSDezbB70AZknK8c1SkIVq3H01iP3coJHaqM2myvIM4AoAzwpcHAzVeRSj9K6ePTliRflyO9Mu7dNvyRqR3z1oA51SAQV6ir9tcKRtfle4q7Fp0U4wcI3qOlMuNDnjO6JgwoAt6MxXUoyGypPynNdgkrGR45MZPr2rzwfa7OVWaM/KcgiuofVJDGjqnzYzyKANm3tPLuRuxtPOa6rSYiy4fdx0rkNJ1NZyFuAA/t3rtNNlhVQyvycZHpQB01gNtuBgnHcUU21Y+VwcjPpRQB8d3TfvWHuaI+lRznMzfU09OlAEu6lV6ZSEYoA0tHvJLS+SWJsMpzXuXgrxatxAkUjgPwNp718/Wsm2YHtXU6LclGBVsEHPFAH03DKk6gqc5H5VqWtuGhA5zjqK8X8M+KJbdkSZyU9c16/wCGNWhvoOCCcUAX/JGQCOntSxR4LZHDCr2MsDx708wHarLyKAM+XAhUgH6YqNBlsdcVoXMZBIP3QO1UgmH46fzoAlRPY05V4Jx+NOU/wkHApBkZHagByyBRhsEdqsKc5YDkCqgB4BBxmpJSAVQEjd1oAsRtwPMHzZ61egIJ45HbNZqOGyM4xVu23Zxn8KANBC2R/dq/bkbAMc9azIy/FWYWYEgDpQBsR8qKmFULeTGM81eQ5HFAD6jkQHnHNSY5oxQBXMQbGRUyIB93pTwOaWgBDTHHepDTT1OaAIGGTkCo5FGBmrDYqE85oAjVRg0MSAQKcT0yMVG5OOPxoAbIzbfekDZ4pkrY5xSAnHPHvQBo25ylOP51XtpAOO1WfegCNh+dROozz1qxio3HWgCq68e1Rsvf3qdk4I9KjY4B70AU5+WORxis25zt4NaNw+FPuKzZVZxhQeaAKMjbFGc4I4rA1SJnlDDGG71001vwCx4Bway9UISMBVHFAGA1kNuXODUbQRLGQMHvmp55xjnOfas2Zzk5PB7UANnhQElCM9qy7iNl3MMEVfdwBnp6VDcrmPdjigDEuOcMcZqld5K7udo6YqSVyM4z16elQTMuzk8DtQBi/ZlEjSycsTkLVO5djkdgelad0C5Azt4yaxrpSkpDjC9vegBiEK4Y9ehIpbo4AKfd9KZEV8zrj0zSSyBFJ+8SOaADzz5eVONvBqlKFPzcknnnpU7bdpwp21ATvfBB+vagCGGTZLkqR6Vrw3LGLjBNYsrNz5ZwO+altbnavQ/X0oA2EdJAfNQZ78Vu6fDaXECJIqgiuUdm3ZZsg9MU+3naJvMWU5B6UAdzYaFbyXGQNuDnI9K6/TdCjXlMg+/cVxWgakHZCWIb09a9I0e5cqvIxigDVstIxAMH9KK1bO7/AHA3YzmigD4Kk/17fU1MnSoG/wBc31NWE6UAOHSkc8U6o5elABF1rZ02QryKx4h0rSszgZoA6jT7j5hk9K9I8AajLE0mScEjAzXkls5Vhg16H4KnbzAowTt6UAezaVqwlYlnyBxya6S2nWQLsPX3rye1lkiGXbGW7V02l6vIjfOeKAO2dfM+8P8A9VU54gsu4dKfY3ayxF81cKq4zjPrQBnkEYIHORnNScNnPAqeWD0oMWV6cUAV0UhgMHrVeVt13xxjir4yquSBgdKznTLhhmgCzCcn5gAavwJjkHJqrEgIGPxrTt9mAAKALEAOSDyfWrVuhbJIGKSKPKjnFWokEa460ACgDJxzUqM69qAOc4qRR68UATI+evWpKrkDPSnAkGgCYUVFvwOOaTeScGgCRmwaaXpucUmeKAA8imkcnmpByajZe4NAEPuTjBppBOeRilcnmmfMF6ZzQA18dG/Co3OAB3zUpVmXJHNNMTE5IoAkhORx2qykh6EVXSPaBxipVPXIoAlLA5waafrTBikBAzzzQAOe3aq7pk1MzrmozKvagCs9uCd2M5qOYLEM4+lWmkB5FVbh1fOeaAMW7l3M2BgZrn9RuPMfYDwOtdFf2/mxt5R29ua5C7ikheTzeOwoAqzEEEAnHv2qi6HaTwfepJZGIwDUTZCkgUARS5Ix3FW1tt+nyMRj0HpTIfnfao4HUGtry0Fk+4YwvagDze6G1mzjArLuZN6ADAJOata5cLEzk5xkjFYs8p8tOoyO3agBJpGO9STuz1HpWfcqGGWY5HQGrDb4lID5HrUNxGjKGRwVIwTnoaAKcZLkAocg9fakcj7o5YGpiyqVCsQemaq35Eau4PzZoA0fKEkYY4HqBWTLhZ8MGCe9XdMbzonJbAUVT1B2EpBG5e1AFKVNx4PSkjbZIvyEr3xQ7KQygYyaTYQ2VYDHbNAF1TuJLSbFPQelRSSxqeuRUBJI5GSfSmuD3oA3NIvW81SgOVr1Xwzq3mFFnAz615BojbbgHB616Lojgldx4NAHslnHHLbq8bAqfSisDTJ5Y7RVjYhR2zRQB8Vn/Wt9TVhKg/5at9TVhOlAD6hk61MahfrQBJCK0bccCqMC57VoxrwOMUAWomweTiu88DMfta4PBXA9a4GLrz26V3fgEkXYYAZA9KAPSBGUiTzADzn6U1GAlG1iKSeU/IR0K81Hab3bH3tvIoA6OyvXt1Rd3HU11Wkaikq8nGexrhoGbqwH41etpWjfEZ5oA9Ki2MgLYz0qTyQcAYIrmNO1Ij5XJOBwa6SznWbBU54oArajH5cBCjrxWTkbcnOa3NRZTgHPHWstowcdOe4oAdZOOA5xnpW1ZjJAwKwokMbDHIresEOwEkjNAFxcscDmrQBzj2qBMKeanGSP8aAHgYPXNPAJ60xetC/eNAEoPXPWlHIwetMH1p+eetAC44oPOcUo54paAG4owOlOpMc+9ABj1pu38jTyOaMc0AQlBu4o2VKcUmBn2oAiI9RSqn0+lKeppoJzQA4jHWmuSBSk9+9MbrzQAwsVz/OoHPGc81K4Bzg1XZCec/hQBC7EE5P0qF3OwkE5NTyKO3TpUW3AAHTPSgCJWbPDfWlcFgS3FKyDdkCmSFmXOOKAKV3KY4yFGcHmsO/VJ49zDJrX1DCR45z1rHfcAxP3emO9AHOXkDQtwCUzTCgByvTGa2byINbu4PbpWQ06lNqjPGKAFgZWdCwwuewrUmkAtZFySCuc1hwz/vPnGFH6VZe8SRWSMjBG1ge1AHlviVz9smB+6Dms2OcSTY3YUCl8b3SwyS7TzkjrWFYaiPLTIBGKAN17gLu3oJFJySKhuDbx7goKq4zisebVVDukS5z1yagl1ZDt3lCy9eaAL1zs42TAnsO9Z+qXe6Py3Xkd/WsyTU1MzNt+6eDmqdxdSTqTyB2NAG3oupfZ3eJzkP0HvV25kEoBYlSeuO1coI3CK5I6+tX7W7Yrsk/CgDQB+bGMj1ps2GU+3TFJESUypy2elOcPtUlSD3NAEVsQzBSxFWXX5iKrpneCBirmDtyeQKALekZWQZPGa9J0IEhCwOMcV5zou1rhRu4NemeHkJwjDOOhoA7WwyLZevNFTWiKlugJwcdKKAPjQW/7x/m7+lWEt+PvfpRRQA5rfj736VAbfk/N+lFFAFq3t8Y+b9K0Eg6fN+lFFAEogP8AfP5V3/gK3AQyZ5BxRRQB3N6mVRc8cVPpiBHwOcHrRRQBpRxgqc+uKsLEojyOoOKKKANS2T92eTwM1s6XK8MXyHoKKKALT3DySkNjpSQnzCwPQelFFAF6JAyjIFa9mgCriiigC00YzT+MYwKKKAH+ppV646iiigB6qCM0AYaiigBw4Ixxmg9cUUUAKOuKd2oooAQ049aKKAI26009cUUUANIwaTrRRQAdCajlOKKKAI8ZBFRLy2O1FFAEcgBOO1MY7XAHeiigBrqOCOM0hXcpB9KKKAMnUxtQdxWHqAKquD3oooAzLiVmideBwRXNROy7wDwDxRRQBVv7+SBxtCnIrKm1G4jdjuB5B6UUUAeR+ML2afUJ0JAXce1YMLSiMASkD6UUUAO8lmJJlP5UgtgBjd+lFFAE0NqHf5m49MU/7NkY3cemKKKALIssQqwk74xio5bX5dwfBB9KKKAJbbeMAvn04rQiLMSGbPPpRRQAICHAJBBPpWnaW++EnfgemKKKANrQ9MhklySQR3Fem+GrJIyvOR15oooA6m9URvGFAxsH8zRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiograph above shows a carpal tunnel view of the wrist. The palmar ridge of the trapezium can be seen in profile at the base of the first metacarpal (white arrow). This view also shows the hook of the hamate in profile (yellow arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Kevin E Burroughs, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_960=[""].join("\n");
var outline_f0_60_960=null;
var title_f0_60_961="Acute HP chest radiograph";
var content_f0_60_961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F84024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F84024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 398px; height: 451px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph of a patient with acute pigeon breeder's disease. Note bilateral lower lobe nodular opacities.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Schuyler M. Hypersensitivity pneumonitis. In: Baum's Textbook of Pulmonary Disease, 7th ed, Crapo JD, Glassroth J, Karlinsky JB, King TE (Eds). Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_961=[""].join("\n");
var outline_f0_60_961=null;
var title_f0_60_962="Annular elastolytic giant cell granuloma - close view";
var content_f0_60_962=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Annular elastolytic giant cell granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mulitiple annular erythematous patches and plaques were present on the neck and arms. A biopsy revealed findings consistent with annular elastolytic giant cell granuloma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Benjamin Ehst, MD, PhD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_962=[""].join("\n");
var outline_f0_60_962=null;
var title_f0_60_963="Seborrheic keratosis 3";
var content_f0_60_963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F58923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F58923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seborrheic keratoses",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 332px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These \"stuck-on\" appearing lesions are most often confused with malignant melanoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart HP. Goodheart's Photoguide of Common Skin Disorders, 2nd Edition, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_963=[""].join("\n");
var outline_f0_60_963=null;
var title_f0_60_964="Peptic ulcer disease";
var content_f0_60_964=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Peptic ulcer disease (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/60/964/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/964/contributors\" id=\"au2391\">",
"       Sheila E Crowe, MD, FRCPC, FACP, FACG, AGAF",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/60/964/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/964/contributors\" id=\"se6265\">",
"       Mark Feldman, MD, MACP, AGAF, FACG",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?0/60/964/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/964/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?0/60/964?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Peptic ulcers are sores or eroded areas that form in the lining of the digestive (gastrointestinal) tract. They usually occur in the stomach (gastric ulcer) or in the duodenum (duodenal ulcer), which is the upper region of the small intestine (",
"     <a class=\"graphic graphic_figure graphicRef55616 \" href=\"UTD.htm?28/22/29024\">",
"      figure 1",
"     </a>",
"     ). The two primary causes of peptic ulcers are infection with specific bacteria (Helicobacter pylori) and use of nonsteroidal antiinflammatory medications.",
"    </p>",
"    <p>",
"     Peptic ulcers affect more than 4 million people each year in the United States. Most ulcers heal while others worsen over time. Complications of peptic ulcers can be serious or even life-threatening. Fortunately, most people who develop peptic ulcers can be treated successfully and avoid long-term problems.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      HOW ULCERS DEVELOP",
"     </span>",
"    </p>",
"    <p>",
"     The stomach and duodenal lining have several mechanisms that help prevent ulcers from developing, including the following:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       A coating of mucus (mucous layer) protects the stomach lining from the effects of acidic digestive juices.",
"      </li>",
"      <li>",
"       Food and other substances in the stomach neutralize acid. Certain chemicals produced by the stomach protect the cells lining the stomach.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     If the mucous layer is damaged or if acid neutralizing substances are not present in normal amounts, digestive juices can cause irritation and breakdown of the stomach or duodenal lining, allowing an ulcer to form.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     People with peptic ulcers may have a wide variety of symptoms, have no symptoms, or, rarely, develop potentially life-threatening complications such as bleeding. Symptoms of ulcers may include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pain or discomfort (usually in the upper abdomen)",
"      </li>",
"      <li>",
"       Bloating",
"      </li>",
"      <li>",
"       An early sense of fullness with eating",
"      </li>",
"      <li>",
"       Lack of appetite",
"      </li>",
"      <li>",
"       Nausea",
"      </li>",
"      <li>",
"       Vomiting",
"      </li>",
"      <li>",
"       Blood in the stools",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Moderate to severe bleeding can cause foul-smelling black or tarry stools. Bleeding can also cause a low red blood cell count (anemia).",
"    </p>",
"    <p>",
"     Many of these symptoms can occur in people who do",
"     <strong>",
"      not",
"     </strong>",
"     have an ulcer. For this reason, anyone who has one or more of these symptoms should discuss their concerns with a healthcare provider to determine if further testing or treatment is needed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Gastric versus duodenal ulcer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Although there is much overlap, symptoms of a gastric ulcer may be different than those of a duodenal ulcer.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Duodenal ulcer",
"     </span>",
"     &nbsp;&mdash;&nbsp;\"Classic\" symptoms of a duodenal ulcer include burning, gnawing, aching, or hunger-like pain, primarily in the upper middle region of the abdomen below the breastbone (the epigastric region). Pain may occur or worsen when the stomach is empty, usually two to five hours after a meal. Symptoms may occur at night between 11 PM and 2 AM, when acid secretion tends to be greatest.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Gastric ulcer",
"     </span>",
"     &nbsp;&mdash;&nbsp;Symptoms of a gastric ulcer typically include pain soon after eating. Symptoms are sometimes not relieved by eating or taking antacids.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The two most common causes of peptic ulcers are:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Helicobacter pylori, a bacteria that is frequently found in the stomach (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"        \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Nonsteroidal anti-inflammatory drugs (NSAIDS) such as ibuprofen (and many others)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     In addition, smoking and certain other genetic and environmental factors (such as medications) may influence the course of peptic ulcer disease. Psychological stress and dietary factors were once thought to be the cause of ulcers, although these factors are no longer thought have a major role.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Helicobacter pylori infection",
"     </span>",
"     &nbsp;&mdash;&nbsp;Helicobacter pylori, also known as H. pylori, is the most common chronic bacterial infection in humans. Conservative estimates indicate that the bacteria are present in the stomach in approximately one-half of the world's population. Surprisingly, the importance of H. pylori was not appreciated until 1982. A researcher demonstrated that the bacteria were able to cause stomach problems after he voluntarily swallowed them. H. pylori is now recognized to be an important cause of gastric and duodenal ulcers.",
"    </p>",
"    <p>",
"     The presence of H. pylori causes a number of changes in the normal environment of the stomach and duodenum. In particular, it disrupts the mucous layer and causes the release of certain enzymes and toxins that may directly or indirectly injure the cells of the stomach or duodenum.",
"    </p>",
"    <p>",
"     The effect of these changes is that underlying tissues become more vulnerable to damage from digestive juices, such as stomach acid. This results in chronic inflammation in the walls of the stomach (gastritis) or duodenum (duodenitis). Most individuals with chronic gastritis or duodenitis have no symptoms. However, some people develop more serious problems, most commonly a stomach or duodenal ulcer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"      \"Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Nonsteroidal anti-inflammatory drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Nonsteroidal anti-inflammatory drugs (NSAIDs) are responsible for the majority of peptic ulcers not caused by H. pylori. A number of NSAIDs are available in both prescription and over-the-counter medications, including aspirin, ibuprofen (Advil&reg;, Motrin&reg;), naproxen (Aleve&reg;, Anaprox&reg;), and others. The risk of developing an ulcer depends upon the specific type of NSAID, the dose and duration of use, and individual factors. A few other drugs increase the risk of developing an ulcer, although these cause far fewer ulcers than NSAIDs.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Other contributing factors",
"     </span>",
"     &nbsp;&mdash;&nbsp;H. pylori infection or NSAID use alone may not be sufficient to cause peptic ulcer disease. Genetic and environmental factors may also contribute. For example, people with duodenal ulcers are more likely to have family members with duodenal ulcers compared to the general population. Another risk factor for developing an ulcer is use of tobacco (cigarette smoking); smoking increases the risk of developing ulcers and impairs their healing. Alcohol abuse also appears to interfere with ulcer healing.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Not everyone with ulcer symptoms has an ulcer. Similar symptoms can be caused by a wide variety of conditions such as functional dyspepsia (ie, the presence of ulcer-symptoms without a specific cause), abnormal emptying of the stomach, acid reflux, gallbladder problems, and, much less commonly, stomach cancer. Thus, the process needed to diagnose an ulcer depends upon the person's medical history and sometimes, use of specific tests. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"      \"Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"      \"Patient information: Gallstones (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      H. pylori testing",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many people with ulcer symptoms are tested for H. pylori with a blood, breath, or stool test. Those who test positive for H. pylori are treated for the infection and ideally re-tested after treatment to ensure that the infection has been cured. However, some providers recommend further testing only if symptoms recur.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Upper endoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;People who have certain \"alarm\" features such as weight loss, difficulty swallowing, or anemia, and particularly if the person is older, typically undergo more specific tests to better define the cause. The most common test is an upper endoscopy, in which a small flexible tube with a camera is passed through the mouth to examine the lining of the stomach and the duodenum. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     Peptic ulcers can heal spontaneously and may come and go. They can also be associated with serious, potentially life-threatening complications, sometimes without warning signs. This is most common in elderly patients and those who take NSAIDs. The most common complications of ulcers are bleeding and perforation.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Bleeding",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bleeding can be gradual or abrupt; abrupt bleeding often causes black, tarry, loose stools, and a drop in blood pressure. Most ulcer bleeding can be controlled with endoscopy, which allows a physician to cauterize the ulcer or inject it with epinephrine to stop the bleeding. Only about 2 to 5 percent of people with a peptic ulcer require surgery.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Perforation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Perforation is the medical term for a puncture of the stomach lining or duodenum caused by the ulcer. Perforation usually causes sudden severe abdominal pain and usually requires surgery.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Most ulcers can be healed with medications. Surgery is rarely needed, except when complications have developed.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Identify cause of ulcer",
"     </span>",
"     &nbsp;&mdash;&nbsp;The initial step in treating an ulcer is to identify the cause. NSAIDs should be stopped, regardless of the cause. People who have H. pylori are treated with antibiotics and a medication that reduces acid production.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h2\">",
"      Treating H. pylori",
"     </span>",
"     &nbsp;&mdash;&nbsp;No single drug effectively cures H. pylori infection. Treatment involves taking several medications for 7 to 14 days.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Most of the treatment regimens include a medication called a proton pump inhibitor. This medication decreases the stomach's production of acid, which allows the tissues damaged by the infection to heal. Examples of proton pump inhibitors include lansoprazole (Prevacid&reg;), omeprazole (Prilosec&reg;), pantoprazole (Protonix&reg;), dexlansoprazole (Dexilant&reg;), rabeprazole (AcipHex&reg;), and esomeprazole (Nexium&reg;).",
"      </li>",
"      <li>",
"       Two antibiotics are also generally recommended; this reduces the risk of treatment failure and antibiotic resistance.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Although the optimal treatment regimen continues to be investigated, the American College of Gastroenterology has recommended four regimens that use a combination of at least three medications. These regimens successfully cure infection in up to 90 percent of people. For the treatment to be effective, the entire course of all medications must be taken.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Up to 50 percent of people have side effects of H. pylori treatment. Side effects are usually mild, with fewer than 10 percent of patients stopping treatment because of side effects. For those who do experience side effects, it may be possible to make adjustments in the dose or timing of medication. Some of the most common side effects are described below.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Some of the treatment regimens use a medication called metronidazole (Flagyl&reg;) or clarithromycin (Biaxin&reg;). These medications can cause a metallic taste in the mouth.",
"      </li>",
"      <li>",
"       Alcoholic beverages (eg, beer, wine) should be avoided while taking metronidazole; the combination can cause skin flushing, headache, nausea, vomiting, sweating and a rapid heart rate.",
"      </li>",
"      <li>",
"       Bismuth, which is contained in some of the regimens, causes the stool to become black and may cause constipation.",
"      </li>",
"      <li>",
"       Many of the regimens cause diarrhea and stomach cramps.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Ways to help ulcers heal",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of other measures help to ensure ulcer healing and prevent ulcer recurrence.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stop smoking. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Avoid NSAIDs if possible. All medications should be reviewed with a healthcare provider to make sure that they do not contain NSAIDs. If it is necessary to continue NSAIDs, one or more medications may be added to aid in ulcer healing and prevent recurrence.",
"      </li>",
"      <li>",
"       If you had complications from your ulcer (such as bleeding or perforation), you should be retested for H. pylori to make sure that antibiotic therapy was successful. Although controversial, most experts recommend that a medication to reduce acid secretion is continued, even after a complicated ulcer has healed.",
"      </li>",
"      <li>",
"       Antacids are permissible during ulcer treatment if needed, although antacids should not be used within one hour before or two hours after taking ulcer medications since they can interfere with their absorption.",
"      </li>",
"      <li>",
"       Efforts to reduce stress can benefit your overall health and may have a small benefit in healing ulcers. However, most ulcers heal with medications, even in people who continue to live a stressful life.",
"      </li>",
"      <li>",
"       Herbal medications and supplements (such as licorice, marshmallow, and glutamine) probably have no role in the treatment of peptic ulcers. In addition, the manufacture of these treatments is not regulated and their safety and efficacy are not known.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H22\">",
"     <span class=\"h1\">",
"      PEPTIC ULCER FOLLOW-UP",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Duodenal ulcers",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with uncomplicated duodenal ulcers should have follow-up testing after treatment, especially if symptoms recur or do not improve. Follow up testing is also recommended for people who have had complications (such as bleeding or perforation) to ensure that H. pylori has been successfully cured.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Gastric ulcers",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with gastric ulcers usually undergo a repeat endoscopy to ensure that the ulcer has healed and to ensure that the ulcer does not contain cancer cells. Long-term treatment to suppress stomach acid is usually recommended if a person has a high risk of ulcer recurrence (eg, a history of ulcer complications or frequent recurrences).",
"    </p>",
"    <p>",
"     People with ulcers due to H. pylori who have been cured of the infection are unlikely to develop another ulcer if NSAIDs are avoided.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1784966632\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29858695\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/53/5971?source=see_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/31/19954?source=see_link\">",
"      Patient information: H. pylori infection (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/60/24515?source=see_link\">",
"      Patient information: GI bleed (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/46/1763?source=see_link\">",
"      Patient information: Gastritis (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29858774\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/58/14242?source=see_link\">",
"      Patient information: Helicobacter pylori infection and treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?5/24/5506?source=see_link\">",
"      Patient information: Upset stomach (functional dyspepsia) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?37/30/38373?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/21/7507?source=see_link\">",
"      Patient information: Gallstones (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13609?source=see_link\">",
"      Clinical manifestations of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40282?source=see_link\">",
"      Overview of the complications of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/21/24919?source=see_link\">",
"      Diagnosis of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/10/12455?source=see_link\">",
"      Management of duodenal ulcers in patients infected with Helicobacter pylori",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42281?source=see_link\">",
"      Overview of the natural history and treatment of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/36/3658?source=see_link\">",
"      Peptic ulcer disease: Genetic, environmental, and psychological risk factors and pathogenesis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/61/16345?source=see_link\">",
"      Refractory or recurrent peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33688?source=see_link\">",
"      Role of surgery in the management of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/5/40025?source=see_link\">",
"      Surgical management of complications of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24826?source=see_link\">",
"      Overview of the treatment of bleeding peptic ulcers",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/0/19466?source=see_link\">",
"      Unusual causes of peptic ulcer disease",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Centers for Disease Control and Prevention (CDC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (404) 639-3534",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 311-3435",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.cdc.gov/\">",
"      www.cdc.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (301) 654-3810",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Gastroenterological Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.gastro.org/\">",
"      www.gastro.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American College of Gastroenterology (ACG)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.acg.gi.org/\">",
"      www.acg.gi.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?0/60/964/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13306778\">",
"     <span class=\"h1\">",
"      ACKNOWLEDGMENT",
"     </span>",
"    </p>",
"    <p>",
"     The editorial staff at UpToDate, Inc. would like to acknowledge Dr. David A. Peura, who contributed to earlier versions of this topic review.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2011.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?0/60/964?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/964/abstract/1\">",
"      Graham DY. Nonsteroidal anti-inflammatory drugs, Helicobacter pylori, and ulcers: where we stand. Am J Gastroenterol 1996; 91:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/964/abstract/2\">",
"      Kochman ML, Elta GH. Gastric ulcers--when is enough enough? Gastroenterology 1993; 105:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/964/abstract/3\">",
"      Chey WD, Wong BC, Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/964/abstract/4\">",
"      Peura DA, Goldkind L. Balancing the gastrointestinal benefits and risks of nonselective NSAIDs. Arthritis Res Ther 2005; 7 Suppl 4:S7.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f0_60_964=[""].join("\n");
var outline_f0_60_964=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           PEPTIC ULCER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           HOW ULCERS DEVELOP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           PEPTIC ULCER SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           PEPTIC ULCER CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           PEPTIC ULCER DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           PEPTIC ULCER COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           PEPTIC ULCER TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H22\">",
"           PEPTIC ULCER FOLLOW-UP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13306778\">",
"           ACKNOWLEDGMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/22/29024\" title=\"figure 1\">",
"           Upper GI anatomy PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f0_60_965="Pancreatoscope on fluoroscopy";
var content_f0_60_965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F75248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F75248&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Introduction of a cholangiopancreatoscope into the pancreatic duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 502px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fluoroscopic image showing a cholangiopancreatoscope being passed through a therapeutic duodenoscope and into the pancreatic duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_965=[""].join("\n");
var outline_f0_60_965=null;
var title_f0_60_966="Chapter 6E: Prostaglandins and the kidney";
var content_f0_60_966=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 6E: Prostaglandins and the kidney",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/966/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/966/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/966/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/966/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/966/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/966/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/966/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/60/966/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins are derived from the metabolism of arachidonic acid, with the initial step being catalyzed by the cyclooxygenase (COX) enzyme (",
"    <a class=\"graphic graphic_figure graphicRef66146 \" href=\"UTD.htm?33/29/34269\">",
"     figure 1",
"    </a>",
"    ). These hormones are produced at a variety of sites within the kidney, including glomerular and vascular endothelium, the medullary and to a lesser degree the cortical collecting tubule cells, and the renomedullary interstitial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In general, the tubules primarily synthesize PGE2, while the glomeruli produce both PGE2 and prostacyclin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The renal prostaglandins have important local functions but little systemic activity, since they are rapidly metabolized in the pulmonary circulation.",
"   </p>",
"   <p>",
"    Two related isoforms of the COX enzyme have been described: COX-1, which is expressed in most tissues, but variably; and COX-2, which is usually",
"    <strong>",
"     undetectable",
"    </strong>",
"    in most tissues but is increased during states of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This section will primarily review the known renal actions of PGE2 and prostacyclin. Other arachidonic acid derivatives, such as thromboxane B2, the leukotrienes (which are formed via the lipoxygenase pathway), and the epoxyeicosatrienoic acids (which are cytochrome P450-dependent) also can affect renal function, but their clinical significance is at present incompletely understood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Thromboxane is similar to the prostaglandins in that its rate of production is relatively low in normal subjects and inhibition of its synthesis has little effect on renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/6\">",
"     6",
"    </a>",
"    ]. Thromboxane can, however, cause vasoconstriction and mesangial contraction, and may contribute to the fall in glomerular filtration rate and increase in protein excretion frequently seen in glomerular diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The intrarenal effects have important clinical implications because of the widespread use of nonsteroidal antiinflammatory drugs (NSAIDs) (",
"    <a class=\"graphic graphic_figure graphicRef71197 \" href=\"UTD.htm?20/45/21203\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Most traditional NSAIDs are nonselective inhibitors of both COX-1 and COX-2 and most of the renal toxicities described below have been associated with these agents. Selective COX-2 inhibitors are also available. Compared to the nonselective agents, they provide similar analgesic and antiinflammatory activity, but markedly lower gastroduodenal toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    COX-2 is constitutively expressed at low levels in the kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/13\">",
"     13",
"    </a>",
"    ], but its effect on renal function is unclear in adults. However, it appears to have a major role in renal development, as animals with deletion of the COX-2 gene have dysplastic tubules and immature glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/14\">",
"     14",
"    </a>",
"    ]. By comparison, mice without the COX-1 enzyme gene have minimal renal abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal prostaglandins have both vascular and tubular actions (",
"    <a class=\"graphic graphic_figure graphicRef71197 \" href=\"UTD.htm?20/45/21203\">",
"     figure 2",
"    </a>",
"    ). These effects result from the activation of distinct cell surface receptors, which are all members of the G-protein coupled family of seven-transmembrane receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/15\">",
"     15",
"    </a>",
"    ]. Different subtypes of these receptors exist, resulting in the varied actions of a particular prostaglandin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Renal hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal prostaglandins are primarily vasodilators (except for PGF2a and thromboxane). They appear to play no role in the regulation of renal perfusion in the basal state when their secretion rate is relatively low. However, prostaglandin synthesis is increased (mostly within the glomeruli) by vasoconstrictors such as angiotensin II, norepinephrine, vasopressin (acting via the V1 receptor), and endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Each of these hormones activates phosphatidylinositol turnover (",
"    <a class=\"graphic graphic_figure graphicRef70144 \" href=\"UTD.htm?19/31/19966\">",
"     figure 3",
"    </a>",
"    ), leading to the formation of diacylglycerol, which contains arachidonic acid at position 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/20\">",
"     20",
"    </a>",
"    ]. The latter can then be released from diacylglycerol by the action of phospholipase A2. The ensuing prostaglandin-induced vasodilation partially counteracts the neurohumoral vasoconstriction, thereby minimizing the degree of renal ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/18,21\">",
"     18,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net clinical effect is that nonselective NSAIDs do not impair renal perfusion in normal subjects, but can lead to",
"    <strong>",
"     reversible renal ischemia",
"    </strong>",
"    and renal insufficiency in a variety of disease states, particularly hypovolemic disorders in which angiotensin II and norepinephrine secretion are increased (",
"    <a class=\"graphic graphic_table graphicRef69369 \" href=\"UTD.htm?0/52/843\">",
"     table 1",
"    </a>",
"    ). These include true volume depletion and edematous states associated with effective circulating volume depletion, such as cirrhosis and congestive heart failure (",
"    <a class=\"graphic graphic_figure graphicRef78038 \" href=\"UTD.htm?10/25/10653\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/9,10,22\">",
"     9,10,22",
"    </a>",
"    ]. In both of the last two disorders, for example, increasing severity of the underlying disease is associated with increased secretion of the three \"hypovolemic\" hormones, angiotensin II, norepinephrine, and ADH and, at least initially, of the renal prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The likelihood of inducing acute renal failure with an NSAID is related to the intensity of the underlying renal vasoconstriction. Patients with marked sodium retention (and higher levels of angiotensin II, norepinephrine, ADH, and renal prostaglandins) often have a relatively large reduction in the glomerular filtration rate if NSAIDs are given [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. This deleterious effect is usually rapidly reversible with discontinuation of the offending drug.",
"   </p>",
"   <p>",
"    It is unclear whether the selective COX-2 inhibitors have a similar adverse effect. Preliminary clinical trials did not demonstrate significant changes in renal function, but most patients were not at risk for this complication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Systemic hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vasodilator activity of the renal prostaglandins also acts to lower systemic vascular resistance. Thus, the administration of a nonselective NSAID to a hypertensive patient treated with a diuretic, &szlig;-adrenergic blocker, or ACE inhibitor can raise the systemic blood pressure by an average of 3 to 5 mmHg and by as much as 5 to 10 mmHg in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. The NSAID-induced increment in vascular resistance can have an additional detrimental effect in patients with advanced heart failure. The associated increase in afterload in this setting can lead to a further reduction in cardiac contractility and in cardiac output [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Renin secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The stimulation of renin secretion induced by baroreceptors in the afferent glomerular arteriole and by the macula densa cells in the early distal tubule appears to be mediated in part by locally produced prostaglandins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These responses are blocked by an NSAID; as a result, prostaglandin synthesis inhibition can lead to hyporeninemic hypoaldosteronism (since angiotensin II is the major stimulus to aldosterone secretion) and an impairment in urinary K+ excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    .) The net effect is that the plasma K+ concentration rises by a mean of 0.2",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/34\">",
"     34",
"    </a>",
"    ] and 0.6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/35\">",
"     35",
"    </a>",
"    ], with the occasional development of overt hyperkalemia in the latter setting [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Antagonism of ADH effect",
"    </span>",
"    &nbsp;&mdash;&nbsp;ADH increases the production of renal prostaglandins, which then antagonize both its hydroosmotic and vascular effects [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/17,37,38\">",
"     17,37,38",
"    </a>",
"    ]. The clinical relevance of this relationship is uncertain. The administration of NSAID to humans removes the inhibitory prostaglandin effect, possibly leading to increased ADH-induced water reabsorption and an elevation in urine osmolality that can exceed 200",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The associated water retention can then cause a reduction in the plasma Na+ concentration. This is most likely to occur when there is nonsuppressible ADH release, due to volume depletion or the syndrome of inappropriate ADH secretion (see Chap. 25). In normal subjects, however, the initial fall in the plasma Na+ concentration will diminish ADH secretion, thereby minimizing the likelihood of water retention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Sodium excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The renal prostaglandins also may have a natriuretic effect, via reduced Na+ reabsorption in the thick ascending limb and in the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/9,41-43\">",
"     9,41-43",
"    </a>",
"    ]. It is unclear how applicable these findings are to humans, since there are major species differences in animals: as an example, prostaglandin E2 inhibits cortical collecting tubule Na+ reabsorption in rabbits but not in rats [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If prostaglandins do promote Na+ excretion, they will again do so only when their rate of production is increased. Thus, prostaglandins have little effect in the basal state, but may play a role in hypovolemic states where they may modulate the Na+-retaining as well as the renal vasoconstrictive effects of angiotensin II, norepinephrine, and possibly endothelin [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/45\">",
"     45",
"    </a>",
"    ]. Consequently, inhibiting prostaglandin synthesis with an NSAID can promote further sodium retention in this setting, both by reducing glomerular filtration rate and by increasing tubular reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/9\">",
"     9",
"    </a>",
"    ]. These effects also can limit the responsiveness of edematous patients to diuretic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/34,46\">",
"     34,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to regulating net Na+ excretion, the prostaglandins produced in the medulla may help to protect the thick ascending limb cells against ischemic injury when the patient is volume depleted. The medulla normally has a very low PO2, due in part to countercurrent exchange of oxygen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=see_link&amp;anchor=H6#H6\">",
"     \"Chapter 4A: Cell model for loop of Henle transport\", section on 'Passive Na+ reabsorption and medullary hypoxia'",
"    </a>",
"    .) This relative hypoxia is exacerbated when renal perfusion is diminished in hypovolemic states. By diminishing NaCl reabsorption in the thick ascending limb, prostaglandins reduce the energy requirement of these cells, thereby allowing them to better tolerate the decrease in oxygen delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/966/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/1\">",
"      Bonvalet JP, Pradelles P, Farman N. Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 1987; 253:F377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/2\">",
"      Farman N, Pradelles P, Bonvalet JP. PGE2, PGF2 alpha, 6-keto-PGF1 alpha, and TxB2 synthesis along the rabbit nephron. Am J Physiol 1987; 252:F53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/3\">",
"      Stahl RA, Paravicini M, Schollmeyer P. Angiotensin II stimulation of prostaglandin E2 and 6-keto-F1 alpha formation by isolated human glomeruli. Kidney Int 1984; 26:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/4\">",
"      DeWitt DL, Meade EA, Smith WL. PGH synthase isoenzyme selectivity: the potential for safer nonsteroidal antiinflammatory drugs. Am J Med 1993; 95:40S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/5\">",
"      Oliet SH, Bourque CW. Mechanosensitive channels transduce osmosensitivity in supraoptic neurons. Nature 1993; 364:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/6\">",
"      Remuzzi G, FitzGerald GA, Patrono C. Thromboxane synthesis and action within the kidney. Kidney Int 1992; 41:1483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/7\">",
"      Badr KF, Brenner BM, Ichikawa I. Effects of leukotriene D4 on glomerular dynamics in the rat. Am J Physiol 1987; 253:F239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/8\">",
"      Carroll MA, Balazy M, Huang DD, et al. Cytochrome P450-derived renal HETEs: storage and release. Kidney Int 1997; 51:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/9\">",
"      Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/10\">",
"      Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/11\">",
"      Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/12\">",
"      Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282:1929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/13\">",
"      Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998; 12:1063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/14\">",
"      Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995; 83:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/15\">",
"      Breyer MD, Jacobson HR, Breyer RM. Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 1996; 7:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/16\">",
"      Scharschmidt LA, Dunn MJ. Prostaglandin synthesis by rat glomerular mesangial cells in culture. Effects of angiotensin II and arginine vasopressin. J Clin Invest 1983; 71:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/17\">",
"      Yared A, Kon V, Ichikawa I. Mechanism of preservation of glomerular perfusion and filtration during acute extracellular fluid volume depletion. Importance of intrarenal vasopressin-prostaglandin interaction for protecting kidneys from constrictor action of vasopressin. J Clin Invest 1985; 75:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/18\">",
"      Oliver JA, Pinto J, Sciacca RR, Cannon PJ. Increased renal secretion of norepinephrine and prostaglandin E2 during sodium depletion in the dog. J Clin Invest 1980; 66:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/19\">",
"      Chou SY, Dahhan A, Porush JG. Renal actions of endothelin: interaction with prostacyclin. Am J Physiol 1990; 259:F645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/20\">",
"      Exton JH. Calcium-signalling in cells&mdash;molecular mechanisms. Kidney Int Suppl 1987; 23:S-68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/21\">",
"      Schor N, Ichikawa I, Brenner BM. Glomerular adaptations to chronic dietary salt restriction or excess. Am J Physiol 1980; 238:F428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/22\">",
"      Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/23\">",
"      P&eacute;rez-Ayuso RM, Arroyo V, Camps J, et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/24\">",
"      Mettauer B, Rouleau JL, Bichet D, et al. Sodium and water excretion abnormalities in congestive heart failure. Determinant factors and clinical implications. Ann Intern Med 1986; 105:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/25\">",
"      Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med 1984; 310:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/26\">",
"      Laffi G, Daskalopoulos G, Kronborg I, et al. Effects of sulindac and ibuprofen in patients with cirrhosis and ascites. An explanation for the renal-sparing effect of sulindac. Gastroenterology 1986; 90:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/27\">",
"      Zipser RD, Hoefs JC, Speckart PF, et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/28\">",
"      Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/29\">",
"      Wong DG, Spence JD, Lamki L, et al. Effect of non-steroidal anti-inflammatory drugs on control of hypertension by beta-blockers and diuretics. Lancet 1986; 1:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/30\">",
"      Sahloul MZ, al-Kiek R, Ivanovich P, Mujais SK. Nonsteroidal anti-inflammatory drugs and antihypertensives. Cooperative malfeasance. Nephron 1990; 56:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/31\">",
"      Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31:1402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/32\">",
"      Freeman RH, Davis JO, Villarreal D. Role of renal prostaglandins in the control of renin release. Circ Res 1984; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/33\">",
"      Ito S, Carretero OA, Abe K, et al. Effect of prostanoids on renin release from rabbit afferent arterioles with and without macula densa. Kidney Int 1989; 35:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/34\">",
"      Ruilope LM, Garcia Robles R, Paya C, et al. Effects of long-term treatment with indomethacin on renal function. Hypertension 1986; 8:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/35\">",
"      Whelton A, Stout RL, Spilman PS, Klassen DK. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison. Ann Intern Med 1990; 112:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/36\">",
"      Zimran A, Dramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J 1985; 291:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/37\">",
"      Clapham DE, Neer EJ. New roles for G-protein beta gamma-dimers in transmembrane signalling. Nature 1993; 365:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/38\">",
"      H&eacute;bert RL, Jacobson HR, Breyer MD. PGE2 inhibits AVP-induced water flow in cortical collecting ducts by protein kinase C activation. Am J Physiol 1990; 259:F318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/39\">",
"      Kramer HJ, Gl&auml;nzer K, D&uuml;sing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int 1981; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/40\">",
"      Berl T, Raz A, Wald H, et al. Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 1977; 232:F529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/41\">",
"      H&eacute;bert RL, Jacobson HR, Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 1991; 87:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/42\">",
"      Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/43\">",
"      Ling BN, Kokko KE, Eaton DC. Inhibition of apical Na+ channels in rabbit cortical collecting tubules by basolateral prostaglandin E2 is modulated by protein kinase C. J Clin Invest 1992; 90:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/44\">",
"      Chen L, Reif MC, Schafer J. Clonidine and PGE2 have different effects on Na+ and water transport in rat and rabbit CCD. Am J Physiol 1991; 261:F123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/45\">",
"      Zeidel ML, Brady HR, Kone BC, et al. Endothelin, a peptide inhibitor of Na(+)-K(+)-ATPase in intact renaltubular epithelial cells. Am J Physiol 1989; 257:C1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/46\">",
"      Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: Effect of dose of furosemide. J Pharmacol Exp Therap 1979; 210:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/966/abstract/47\">",
"      Silva P, Rosen S, Spokes K, et al. Influence of endogenous prostaglandins on mTAL injury. J Am Soc Nephrol 1990; 1:808.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7292 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.247-9662981F41-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_966=[""].join("\n");
var outline_f0_60_966=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Renal hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Systemic hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Renin secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Antagonism of ADH effect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Sodium excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7292\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7292|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/29/34269\" title=\"figure 1\">",
"      Prostaglandin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/45/21203\" title=\"figure 2\">",
"      Renal actions prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/31/19966\" title=\"figure 3\">",
"      Phosphatidylinositol turnover",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/25/10653\" title=\"figure 4\">",
"      NSAID lowers GFR in cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7292|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/52/843\" title=\"table 1\">",
"      NSAIDs renal failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/49/36630?source=related_link\">",
"      Chapter 4A: Cell model for loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_60_967="Scapular strength Y PI";
var content_f0_60_967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F51174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F51174&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Scapular strengthening exercise - \"Y\"",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 344px; height: 646px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) For these exercises, you should lie face down on an elevated surface, like a bed, exercise bench, or large exercise ball. The head should be held in line with the body, hanging over the edge of the bed or bench.",
"    <br/>",
"    (B) Let the arms rest below the body.",
"    <br/>",
"    (C) Extend the arms next to the head to form a \"Y\"; make sure your thumbs are facing up. Hold the position for a second or two, then let the arms return to the floor. Repeat 10 to 15 times. Movements should be steady, smooth, and pain-free.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_967=[""].join("\n");
var outline_f0_60_967=null;
var title_f0_60_968="Laboratory diagnosis of the hemoglobinopathies";
var content_f0_60_968=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laboratory diagnosis of the hemoglobinopathies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/968/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/968/contributors\">",
"     Abdullah Kutlar, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/968/contributors\">",
"     Ferdane Kutlar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/968/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/968/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/968/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/968/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/60/968/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11822024\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human hemoglobins (Hb) are tetrameric proteins composed of two unlike pairs of globin chains:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal adult Hb (HbA), is composed of two alpha chains and two beta chains (&alpha;2&beta;2), and constitutes approximately 97 percent of the total Hb in adult red blood cells (RBCs).",
"     </li>",
"     <li>",
"      Adult RBCs also contain a minor Hb (HbA",
"      <sub>",
"       2",
"      </sub>",
"      ), composed of two alpha chains and two delta chains (&alpha;2&delta;2), which accounts for approximately 2.5 percent of total Hb.",
"     </li>",
"     <li>",
"      Fetal Hb (HbF), composed of two alpha chains and two gamma chains (&alpha;2&gamma;2), is found in minute amounts (usually &lt;1 percent) in normal adults and is confined to a small proportion of RBCs, termed F-cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The number of hemoglobin variants (ie, hemoglobinopathies) discovered to date totals more than one thousand. The vast majority do not cause any clinical or hematologic problems, while others are associated with varying degrees of morbidity and mortality (eg, sickle cell anemia, beta thalassemia major). The laboratory diagnosis of the various hemoglobinopathies will be reviewed here. Overviews of the structure and function of normal hemoglobins and of hemoglobin mutations are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link\">",
"     \"Introduction to hemoglobin mutations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822052\">",
"    <span class=\"h1\">",
"     GLOBIN CHAIN PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Globin gene physiology is discussed elsewhere in UpToDate, but portions relevant to an understanding of the laboratory diagnosis of the hemoglobinopathies will be briefly reviewed here. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Globin genes are expressed in embryos as early as four to six weeks. Embryonic &alpha;-like chains are called &zeta; (zeta) chains, whereas &beta;-like globin chains are called &epsilon; (epsilon) chains. Tetramers of these chains form the three embryonic Hbs: Gower-1 (&zeta;2&epsilon;2), Gower-2 (&alpha;2&epsilon;2), and Portland (&zeta;2&gamma;2), which disappear around the eighth week of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link&amp;anchor=H13#H13\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Embryonic hemoglobins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The genes encoding &alpha;-like and &beta;-like globin chains are organized in clusters on different chromosomes (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"UTD.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ). The &alpha;-globin gene cluster is on the short arm of chromosome 16 (16p13.3) and the &beta;-like globin gene cluster is on the short arm of chromosome 11 (11p15.5). In both clusters, the genes are organized from 5&rsquo; to 3&rsquo; in order of their expression during different developmental stages (ie, embryonic to fetal to adult). In the &alpha;-globin gene cluster, the organization follows the order 5&rsquo;-&zeta;-&alpha;2-&alpha;1-3&rsquo;, whereas in the &beta;-globin cluster it is 5&rsquo;-&epsilon;-G&gamma;-A&gamma;-&delta;-&beta;-3&rsquo;.",
"   </p>",
"   <p>",
"    In both clusters, far upstream of the structural globin genes are DNAse I hypersensitive sites, which have important regulatory functions in controlling the expression of the genes located in the cluster. In the &beta;-globin cluster, 5 DNAse hypersensitive sites (HS1-5) are located approximately 20 kb upstream of the embryonic &epsilon;-gene and form the locus control region (LCR). Deletion of the LCR abolishes the expression of all &beta;-like genes.",
"   </p>",
"   <p>",
"    The duplicated &alpha;-globin genes, &alpha;2 and &alpha;1, encode identical peptides (globin chains). The &alpha;2 gene is expressed at a higher level (3:1) compared with the &alpha;1 gene.",
"   </p>",
"   <p>",
"    In the &beta;-cluster, G&gamma; and A&gamma; genes differ only in one position (codon 136). In G&gamma;, this position is occupied by glycine, while in A&gamma; chains this position is occupied by alanine. The ratio of G&gamma; to A&gamma; in HbF of newborns is 70:30; with the perinatal fetal to adult (&gamma; to &beta;) switch, the proportion of G&gamma; to A&gamma; chains in the minute amount of HbF present in adults changes to approximately 40:60 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=see_link&amp;anchor=H16#H16\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Structure of the gamma globin chain'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The synthesis of &alpha;-like chains and &beta;-like chains is balanced at all developmental stages, so that normally there are no excess globin chains [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/3\">",
"     3",
"    </a>",
"    ]. Disruption of this balance is a hallmark of thalassemia syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9129?source=see_link\">",
"     \"Molecular pathology of the thalassemic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822192\">",
"    <span class=\"h2\">",
"     Prevalence of the hemoglobinopathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobinopathies can be broadly classified into qualitative (Hb variants) and quantitative (thalassemias) disorders of globin synthesis. Although accurate prevalence data are not available for most of the developing countries (sub-Saharan Africa, Mediterranean region, Southeast Asia, India), limited population surveys conducted in these areas and estimates based upon these surveys suggest that the carrier state for certain variants (HbS, HbE, HbC) and both &alpha;- and &beta;-thalassemias can reach very high frequencies (up to 30 to 35 percent for HbS in some populations in Africa and India, up to 40 to 45 percent for HbE in parts of Southeast Asia, 80 to 90 percent for deletional &alpha;-thalassemia among some tribal populations in India, and up to 15 to 20 percent for &beta;-thalassemia), presumably as a result of selective pressure from malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link\">",
"     \"Protection against malaria in the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822149\">",
"    <span class=\"h2\">",
"     Public health issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobinopathies constitute the most common inherited disorders in humans as a result of selective pressure of endemic falciparum malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=see_link\">",
"     \"Protection against malaria in the hemoglobinopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While heterozygosity for HbS and &beta;-thalassemia may protect against malaria,",
"    <strong>",
"     homozygosity",
"    </strong>",
"    for variants such as HbS, and &beta;-thalassemias, as well as compound heterozygosity for HbS, HbC, HbE, and different types of &beta;-thalassemia alleles, produce clinically significant disorders and pose a huge public health problem in countries with limited resources [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/3\">",
"     3",
"    </a>",
"    ]. As a result of the large population movements of past several decades, hemoglobinopathies are now commonly seen in industrialized Western societies as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41783?source=see_link\">",
"     \"Community public health issues and the thalassemic syndromes: Lessons from other countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822059\">",
"    <span class=\"h1\">",
"     GLOBIN CHAIN MUTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of hemoglobin variants discovered to date totals more than one thousand. The vast majority of these variants do not cause any clinical or hematological problems, and therefore are mainly of interest to geneticists and biochemists. A compilation of the various hemoglobinopathies is available on the web (",
"    <a class=\"external\" href=\"file://globin.cse.psu.edu/\">",
"     Globin Gene Server",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most of the hemoglobin variants are missense mutations in the globin genes (&alpha;, &beta;, &gamma;, or &delta;) resulting from single nucleotide substitutions. Other uncommon mechanisms include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deletion or insertion of one or more nucleotides, altering the reading frame (eg, Hb Geneva &beta;114 &ndash;CT, +G)",
"     </li>",
"     <li>",
"      Fusion of adjacent globin genes with deletion of intergenic DNA sequences (eg, &gamma;&beta; fusion in Hb Kenya and &delta;&beta; fusion in Hb Lepore)",
"     </li>",
"     <li>",
"      Mutations of the termination codon leading to the production of elongated globin chains (eg, Hb Constant Spring, &alpha;142TAA&rarr;AAA, +31 residues) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822211\">",
"    <span class=\"h2\">",
"     Clinical consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemoglobin variants that significantly alter the structure, stability, synthesis, or function of the molecule have hematologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    clinical consequences. These can be classified into specific categories, as follows (",
"    <a class=\"graphic graphic_table graphicRef79795 \" href=\"UTD.htm?4/8/4236\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Change in physical properties",
"      </strong>",
"      &mdash; HbS and HbC are two examples of mutations on the surface of the hemoglobin molecule that alter both the charge and the",
"      <span class=\"nowrap\">",
"       physical/chemical",
"      </span>",
"      properties of the molecule. This leads to abnormal polymer formation in the case of deoxyhemoglobin S and crystallization in the case of HbC, with profound effects on the function, morphology, rheology, and lifespan of the affected red cells. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=see_link\">",
"       \"Sickle hemoglobin polymer: Structure and functional properties\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Globin instability",
"      </strong>",
"      &mdash; Several mechanisms account for the pathogenesis of unstable hemoglobin variants. The common mechanism involves the precipitation of the unstable hemoglobin molecule within the red cell, with subsequent attachment to the inner layer of the red cell membrane (ie, &ldquo;Heinz body&rdquo; formation). Red cells containing membrane-attached Heinz bodies have impaired deformability and filterability leading to their premature destruction (ie, congenital Heinz body hemolytic anemia). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=see_link\">",
"       \"Unstable hemoglobin variants\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Altered oxygen affinity",
"      </strong>",
"      &mdash; Mutations in certain globin chain residues alter the oxygen (O2) affinity of the hemoglobin molecule; a stabilization of the R (relaxed, oxy) state will result in high O2 affinity variants and erythrocytosis. Conversely, a stabilization of the T (tense, deoxy) configuration will result in a variant with low O2 affinity with enhanced unloading of O2 to the tissues with resultant cyanosis and anemia in certain cases (due to the suppression of the O2 sensing pathway). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=see_link\">",
"       \"Genetic disorders of hemoglobin oxygen affinity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Oxidation of heme iron",
"      </strong>",
"      &mdash; Mutations of the heme binding site, particularly those affecting the conserved proximal (F8) and distal (E7) histidine residues, lead to the oxidation of the iron atom in heme from ferrous (Fe++ ) to ferric (Fe+++) state with resultant methemoglobinemia (M-hemoglobins) and cyanosis (",
"      <a class=\"graphic graphic_figure graphicRef65311 \" href=\"UTD.htm?18/24/18821\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=see_link\">",
"       \"Genetics and pathogenesis of methemoglobinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Altered structure and synthetic rate",
"      </strong>",
"      &mdash; A group of mutations alter both the structure and the synthetic rate of the globin chain leading to a &ldquo;thalassemic&rdquo; phenotype. These include fusion hemoglobins (eg, Hb Lepore, where the 5&rsquo; &delta;-globin sequences are fused to 3&rsquo; &beta;-globin sequences with deletion of the intergenic DNA; this puts the &delta;&beta;-fusion gene under the transcriptional control of the inefficient &delta;-globin promoter with low expression of the fusion globin and hence the thalassemic phenotype), mutations that cause both a missense mutation and create an aberrant splice site (such as HbE, Hb Knossos, and Hb Malay), and &ldquo;hyper-unstable&rdquo; globins where the nascent globin chains are highly unstable, undergo rapid proteolytic degradation, and result in a reduction in the affected globin [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/1-4\">",
"       1-4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640222\">",
"    <span class=\"h2\">",
"     Expression of the abnormal hemoglobin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Except for the commonly occurring hemoglobin variants (eg, HbS, HbC, HbE, and HbD-Los Angeles), very few abnormal hemoglobins have been observed in the homozygous state. Accordingly, variant hemoglobins are usually found in the heterozygous state. Their expression will vary depending upon whether the mutation is in an alpha, beta, or gamma globin, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Gamma-chain variants are expressed in fetal life and their level gradually decreases as the &gamma; to &beta; (fetal to adult) globin switch progresses during the post-natal period.",
"     </li>",
"     <li>",
"      Alpha-chain variants are expressed throughout fetal, neonatal, and adult life.",
"     </li>",
"     <li>",
"      Beta-chain variants are expressed to a small extent at the time of birth, but become more apparent as the fetal to adult globin switch progresses.",
"     </li>",
"     <li>",
"      Delta-globin variants are expressed at very low levels and can be detected only after the switch to adult globin synthesis is complete.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640236\">",
"    <span class=\"h3\">",
"     Factors affecting the type and amount of abnormal hemoglobin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640300\">",
"    <span class=\"h4\">",
"     Alpha globin mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since &alpha;-globin chains are present in all of the hemoglobins expressed after the embryonic stage (HbF-&alpha;2&gamma;2; HbA-&alpha;2&beta;2, and HbA",
"    <sub>",
"     2",
"    </sub>",
"    -&alpha;2&delta;2), &alpha;-chain variants are associated with the production of variant HbF (&alpha;",
"    <sup>",
"     x",
"    </sup>",
"    2&gamma;2) and HbA",
"    <sub>",
"     2",
"    </sub>",
"    (&alpha;",
"    <sup>",
"     x",
"    </sup>",
"    2&delta;2) as well as HbA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640307\">",
"    <span class=\"h4\">",
"     Beta globin mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In heterozygous states, &beta;-chain variants constitute 40 to 50 percent of the hemoglobin in red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2\">",
"     2",
"    </a>",
"    ]. It should, however, be kept in mind that certain factors affect the amount of variant &beta;-chains in carriers. These include the stability of the variant, the surface charge of the variant &beta;-chain, and the presence of concomitant &alpha; or &beta;-thalassemia. The more unstable the variant, the lower the quantity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640293\">",
"    <span class=\"h4\">",
"     Surface charge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surface charge of the variant also plays a role in determining its quantity in red cells; this is because the formation of the &alpha;&beta;-dimers (&alpha;1&beta;1 and &alpha;2&beta;2 contacts) is the critical first step in hemoglobin tetramer formation. This step is primarily driven by electrostatic interactions between &alpha; and &beta;-chains. The &alpha;-globin chains have a relatively positive surface charge and therefore interact more readily with relatively negatively charged &beta;-globin variants to form &alpha;&beta;-dimers. This is reflected in the higher percentage of negatively charged &beta;-globin variants, such as HbN-Baltimore (&beta;95Lys&rarr;Glu), which is found at approximately 50 percent in heterozygotes compared with &beta;-globin variants with a positive surface charge, HbS (&beta;6Glu&rarr;Val) or HbC (&beta;6Glu&rarr;Lys), whose quantity in the heterozygote is 40 to 45 percent (",
"    <a class=\"graphic graphic_figure graphicRef72950 \" href=\"UTD.htm?0/58/942\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=see_link&amp;anchor=H4#H4\">",
"     \"Introduction to hemoglobin mutations\", section on 'Assembly of the mutant hemoglobin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640329\">",
"    <span class=\"h4\">",
"     Concomitant alpha thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the presence of &alpha;-thalassemia, negatively charged &beta;-globin variants compete more favorably for the available &alpha;-chains; this phenomenon is reflected in even lower percentages of HbS and HbC in heterozygous carriers of these variants in the presence of common deletional forms of &alpha;-thalassemia (HbS of 30 to 35 percent in individuals with heterozygous &alpha;+-thalassemia,",
"    <span class=\"nowrap\">",
"     -&alpha;/&alpha;&alpha;;",
"    </span>",
"    25 to 30 percent in homozygous &alpha;+-thalassemia,",
"    <span class=\"nowrap\">",
"     -&alpha;/-&alpha;)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef70184 \" href=\"UTD.htm?16/17/16667\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, the amount of a &beta;-globin variant will increase if there is a &beta;-thalassemia allele in trans; the percentage of the variant will be inversely proportional to the output of the &beta;-thalassemia allele; thus, the higher the variant the lower the output of the &beta;+-thalassemia allele. In the case of a beta(0)-thalassemia allele in trans, the variant will amount to &ge;90 percent of the Hb in red cells, with HbA",
"    <sub>",
"     2",
"    </sub>",
"    and HbF constituting the remainder. The quantity of &alpha;-globin variants is also variable depending on the &alpha;-globin gene involved and the presence of concomitant &alpha;- or &beta;-thalassemia. Since there are normally four &alpha;-globin loci",
"    <span class=\"nowrap\">",
"     (&alpha;&alpha;/&alpha;&alpha;)",
"    </span>",
"    and the 5&rsquo;&alpha;-globin genes (&alpha;2) are expressed at a higher level, some of the variation in the level of &alpha;-globin variants will depend on which &alpha;-globin gene carries the mutation; &alpha;2 globin mutations are usually present at 20 to 25 percent of the total hemoglobin, whereas &alpha;1-globin variants are expressed at a lower level (15 to 20 percent).",
"   </p>",
"   <p>",
"    Concomitant &alpha;-thalassemia results in a higher level of expression of &alpha;-globin variants. Observations on the different levels of expression of the common &alpha;-globin variant, HbG-Philadelphia (&alpha;68Asn&rarr;Lys), is a case in point [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/7\">",
"     7",
"    </a>",
"    ]. While this variant is found at approximately 25 percent in Northern Italians, its percentages in Americans of African descent can be either 33 or approximately 50 percent. This is clearly related to the different genotypes found in these two distinct populations; In Northern Italy and Sardinia, the genotype is",
"    <span class=\"nowrap\">",
"     &alpha;",
"     <sup>",
"      G",
"     </sup>",
"     &alpha;/&alpha;&alpha;",
"    </span>",
"    with an expression level of 25 percent, whereas in Americans of African descent, the G-Philadelphia mutation is commonly found on a hybrid &alpha;2&alpha;1 gene associated with the common 3.7 kb &alpha;+-thalassemia deletion",
"    <span class=\"nowrap\">",
"     (-&alpha;",
"     <sup>",
"      G",
"     </sup>",
"     /&alpha;&alpha;)",
"    </span>",
"    with approximately 33 percent expression. When there is an &alpha;+-thalassemia deletion in trans",
"    <span class=\"nowrap\">",
"     (-&alpha;",
"     <sup>",
"      G",
"     </sup>",
"     /-&alpha;",
"    </span>",
"    genotype), as expected, the level of Hb G-Philadelphia will be approximately 50 percent. Co-inheritance of &alpha;-chain variants with &beta;-thalassemia results in the reduction of the &alpha;-chain variant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822071\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of the over 1000 known Hb variants do not cause any clinical and hematologic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2\">",
"     2",
"    </a>",
"    ]. Nevertheless, many laboratories are referred specimens where clinically significant Hb variants such as HbS [&beta;6(A3) Glu&rarr;Val, GAG&rarr;GTG] or thalassemia mutations are found in compound heterozygosity with an &ldquo;unknown&rdquo; Hb variant. Thus, an important function of the reference laboratory is characterization of an &ldquo;unknown&rdquo; variant and delineation of its role, or lack thereof, in the clinical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hematological phenotype in question [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2\">",
"     2",
"    </a>",
"    ]. A stepwise approach and algorithm to the laboratory diagnosis of hemoglobinopathies is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef57389 \" href=\"UTD.htm?24/40/25227\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation of the hematologic picture, complemented by concise clinical information, is an important starting point. The ascertainment of the presence and type of anemia or erythrocytosis, red blood cell (RBC) indices [with particular emphasis on mean corpuscular volume (MCV)], and review of peripheral blood smears are simple initial steps that can provide useful information and guide the next step in laboratory evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=see_link&amp;anchor=H19#H19\">",
"     \"Mean corpuscular volume\", section on 'Causes of microcytosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822078\">",
"    <span class=\"h2\">",
"     Hemoglobin electrophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly utilized method for the detection of hemoglobinopathies has been hemoglobin electrophoresis. The initial screening is performed at an alkaline pH (pH 8.6) usually on cellulose acetate. This simple method provides separation of the normal hemoglobins, HbA, HbF, and HbA",
"    <sub>",
"     2",
"    </sub>",
"    , as well as the common variants HbS and HbC.",
"   </p>",
"   <p>",
"    On a cellulose acetate strip, HbA migrates the most toward the anode followed by HbF, HbS, and HbC. Although this is a simple, rapid, and inexpensive method, it has certain limitations. A significant number of Hb variants co-migrate with HbS and HbC on cellulose acetate, thereby decreasing the utility of this simple method in the definitive identification of variant hemoglobins. Variants that have the same mobility as HbS include HbD, HbG, and Hb Lepore. Variants that co-migrate with HbC include HbE and HbO-Arab (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef68806 \" href=\"UTD.htm?8/51/9023\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Such co-migration often necessitates the utilization of a second electrophoretic procedure on citrate agar in acid pH. This method is not solely charge-dependent. It also relies on the chemical interaction of the electrophoresis medium (agar) with Hb molecules in a pH-dependent manner.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HbF, HbA, HbS, and HbC have distinct mobility patterns on citrate agar, which are different from those on cellulose acetate.",
"     </li>",
"     <li>",
"      HbD and HbG co-migrate with HbS on cellulose acetate and have a mobility identical to HbA on citrate agar.",
"     </li>",
"     <li>",
"      HbE co-migrates with HbA on citrate, whereas HbO-Arab has a distinct mobility pattern (between HbA and HbS).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, application of cellulose acetate and citrate agar electrophoresis in succession leads to the definitive identification of HbS, HbC, HbE, and HbO-Arab [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822085\">",
"    <span class=\"h2\">",
"     Isoelectric focusing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Methods with higher resolution capacity than hemoglobin electrophoresis have been applied to the screening and diagnosis of hemoglobinopathies. These include isoelectric focusing on either acrylamide or thin layer agarose (",
"    <a class=\"graphic graphic_figure graphicRef52896 \" href=\"UTD.htm?42/6/43106\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Isoelectric focusing (IEF) is a method of electrophoresis in a medium in which there is a pH gradient established by the presence of ampholytes in the medium. Hemoglobinopathies are best detected within a pH range of 6.0 to 8.0. The method takes advantage of the mobility of the proteins (in this case, hemoglobins) based upon their isoelectric point (pI). When an electric current is applied to an IEF gel, Hb variants will migrate to a pH where they have a neutral surface charge (pI). The advantage of this method is its capability to separate Hb variants whose isoelectric points differ by as little as 0.1 pH units. Thus, this method has the distinct advantage of separating HbD from HbS and HbC from HbE and HbO-Arab (",
"    <a class=\"graphic graphic_figure graphicRef63606 \" href=\"UTD.htm?10/54/11108\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In many laboratories, electrophoresis on cellulose acetate and citrate agar have now been replaced with IEF on agarose gels, especially for neonatal screening for hemoglobinopathies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822099\">",
"    <span class=\"h2\">",
"     High performance liquid chromatography",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640398\">",
"    <span class=\"h3\">",
"     Cation exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step in evaluation of an abnormal hemoglobin after isoelectric focusing is usually cation exchange, either on a commercially available system (such as the Biorad Variant) or using a weak cation exchange column, SynChropak CM-300 (SynChrom Eprogen, Darien, IL, USA) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2,10\">",
"     2,10",
"    </a>",
"    ]. With these methods, a positive diagnosis of commonly occurring &beta; chain variants such as HbS, HbC, HbE, HbD-Los Angeles, and HbO-Arab, as well as the &alpha; chain variant HbG-Philadelphia can be established (",
"    <a class=\"graphic graphic_figure graphicRef72323 \" href=\"UTD.htm?20/56/21376\">",
"     figure 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef63052 \" href=\"UTD.htm?11/58/12199\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50316 \" href=\"UTD.htm?13/56/14215\">",
"     figure 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Quantitative data obtained from cation exchange high performance liquid chromatography (HPLC) will allow the initial diagnosis of &beta;-thalassemia trait as well as other &beta;-thalassemia syndromes and hereditary persistence of fetal Hb [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. The percentage of the uncommon or unusual variant on cation exchange HPLC will often yield clues as to whether the variant in question is a mutant &alpha;- or &beta;-globin: in most cases, &alpha; chain variants are 15 to 25 percent of the total Hb, whereas &beta; chain variants comprise 30 to 45 percent. However, there are many exceptions to this general rule, including unstable Hb variants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of concomitant &alpha;- or &beta;-thalassemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640405\">",
"    <span class=\"h3\">",
"     Reverse phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The next step if the diagnosis remains uncertain is the application of reverse phase HPLC to separate the individual globin chains using a Vydac C4 column (The Separations Group, Hesperia, CA, USA). This technique is helpful in localizing the abnormality to &alpha; or &beta; (and &gamma;) chains, and in quantifying G&gamma; and A&gamma; chains of HbF in cases with elevated fetal hemoglobin, and thus aid in the diagnosis of different types of hereditary persistence of fetal Hb and &delta;&beta;-thalassemia (",
"    <a class=\"graphic graphic_figure graphicRef77931 \" href=\"UTD.htm?34/9/34967\">",
"     figure 9",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef56378 \" href=\"UTD.htm?10/17/10518\">",
"     figure 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822121\">",
"    <span class=\"h2\">",
"     Capillary electrophoresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A capillary electrophoresis-based system has been developed and marketed (Sebia Electrophoresis, Evry, France). The resolution of this method is superb and comparable to that obtained with HPLC. Quantification of Hb components is accurate and has been validated by a comparison to HPLC. The advantage of this method is its capability to run 8 channels simultaneously, thus allowing rapid processing of multiple specimens at a rate of 34",
"    <span class=\"nowrap\">",
"     samples/hour",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef65032 \" href=\"UTD.htm?14/19/14647\">",
"     figure 11",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11822128\">",
"    <span class=\"h1\">",
"     DEFINITIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final step in the diagnostic approach to the presence of an abnormal hemoglobin is the definitive identification of the unknown or uncommon variant. In the Hemoglobinopathy Laboratory at the Medical College of Georgia, this is achieved by the sequencing of the polymerase chain reaction (PCR)-amplified globin gene in question [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The sequencing reaction can be performed on genomic DNA extracted from peripheral blood (eg, from white blood cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in many cases, we have increasingly applied the method of sequencing the complementary DNAs (cDNAs) of the respective globin gene, which are obtained from the reverse transcription of total red blood cell (RBC) mRNA that contains an abundance of the globin message. The advantage of this method over the sequencing of genomic DNA is that all of the globin cDNAs can easily be sequenced with one set of primers with a single sequencing reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/12\">",
"     12",
"    </a>",
"    ]. In the case of the &beta;-thalassemias, identification of the mutation involves sequencing of the genomic DNA, particularly the important regulatory regions such as the promoter,",
"    <span class=\"nowrap\">",
"     exon/intron",
"    </span>",
"    boundaries, introns, and the 3&rsquo; untranslated region (3&rsquo;UTR) up to the polyadenylation signal (",
"    <a class=\"graphic graphic_figure graphicRef75837 \" href=\"UTD.htm?16/24/16776\">",
"     figure 12",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another application of the molecular diagnostic methods involves the detection of deletions in the globin genes by PCR amplification and the detection of the amplicon sizes (",
"    <a class=\"graphic graphic_figure graphicRef66522 \" href=\"UTD.htm?14/5/14419\">",
"     figure 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef55893 \" href=\"UTD.htm?21/58/22439\">",
"     figure 14",
"    </a>",
"    ) on agarose gels (Gap PCR). These include the detection of common deletional &alpha;+-thalassemias (&minus;&alpha;",
"    <sup>",
"     3.7",
"    </sup>",
"    , &minus;&alpha;",
"    <sup>",
"     4.2",
"    </sup>",
"    ) and &alpha;",
"    <sup>",
"     0",
"    </sup>",
"    -thalassemias (&ndash; &ndash;",
"    <sup>",
"     SEA",
"    </sup>",
"    , &ndash; &ndash;",
"    <sup>",
"     MED",
"    </sup>",
"    , &ndash; &ndash;",
"    <sup>",
"     20.5",
"    </sup>",
"    , &ndash; &ndash;",
"    <sup>",
"     FIL",
"    </sup>",
"    , &ndash; &ndash;",
"    <sup>",
"     THAI",
"    </sup>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/15\">",
"     15",
"    </a>",
"    ]. With this approach, some of the relatively common forms of deletional &beta;-thalassemias (such as the 619 bp Indian deletion and the 1394 bp deletion of African-Americans) can be detected. This approach also allows the molecular characterization of hybrid Hbs such as the &delta;&beta; hybrid Hb Lepore and different types of deletional hereditary persistence of fetal hemoglobin and &delta;&beta;-thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/13,15,16\">",
"     13,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of mutations leading to &beta;-thalassemia requires sequencing of genomic DNA, spanning approximately 1.8 kb from the &beta;-globin promoter, downstream to the polyadenylation signal. This includes the important regulatory elements in the promoter (CACC, CAT, and TATA boxes), the 5&rsquo; untranslated region (UTR), exons, exon-intron boundaries, and the two introns, as well as the 3&rsquo; UTR and the polyadenylation signal. As a result of wide availability of efficient commercial sequencing and the decrease in cost, this approach has now been adopted in many laboratories.",
"     </li>",
"     <li>",
"      Identification of non-deletional &alpha;-thalassemia mutations can be achieved with a similar strategy by sequencing the PCR products of differentially amplified &alpha;2 and &alpha;1 globin genes.",
"     </li>",
"     <li>",
"      A reverse dot-blot technique has been available and widely utilized for the identification of &beta;-thalassemia mutations. In this method, probes for mutations most commonly seen in certain populations (eg, Mediterraneans) are blotted on a strip. The patient&rsquo;s PCR amplified &beta;-globin gene is then hybridized to the commercially available strip. The detection method does not require the use of radioactive isotopes",
"      <span class=\"nowrap\">",
"       (streptavidin/",
"       <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"        biotin",
"       </a>",
"      </span>",
"      labeling) and is relatively rapid. This technique has been utilized in prenatal diagnosis in countries where &beta;-thalassemia is common [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Microarray-based detection methods for the identification of &beta;-globin mutations have been developed and validated in small sample sizes. Although currently in its infancy, this technology has the potential to vastly expedite the molecular diagnosis of hemoglobinopathies. A detailed overview of the application of microarray technology to the detection of globin mutation is available [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/968/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2640489\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of hemoglobin variants (ie, hemoglobinopathies) discovered to date totals more than one thousand. The vast majority do not cause any clinical or hematologic problems, while others are associated with varying degrees of morbidity and mortality (eg, sickle cell anemia, beta thalassemia major).",
"   </p>",
"   <p>",
"    Evaluation of the clinical and hematological picture of the patient in question is an important starting point (eg, presence of anemia or polycythemia, cyanosis, abnormal red blood cell indices, abnormal red cell sizes and shapes on the peripheral smear), followed by characterization of the abnormal hemoglobin using a variety of separation techniques (",
"    <a class=\"graphic graphic_table graphicRef57389 \" href=\"UTD.htm?24/40/25227\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11822071\">",
"     'Initial evaluation'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial screening is classically performed at alkaline pH (pH 8.6) on cellulose acetate. This simple method provides separation of the normal hemoglobins, HbA, HbF, and HbA",
"      <sub>",
"       2",
"      </sub>",
"      , as well as the common variants HbS and HbC. (See",
"      <a class=\"local\" href=\"#H11822078\">",
"       'Hemoglobin electrophoresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional screening can be performed via a second electrophoretic procedure on citrate agar in acid pH. This leads to the definitive identification of HbS, HbC, HbE, and HbO-Arab.",
"     </li>",
"     <li>",
"      In many laboratories, electrophoresis on cellulose acetate and citrate agar have now been replaced with isoelectric focusing (IEF) on agarose gels, pH 6.0&ndash;8.0. (See",
"      <a class=\"local\" href=\"#H11822085\">",
"       'Isoelectric focusing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Additional separation and identification of the mutant hemoglobin can be obtained by using high performance liquid chromatographic methods. (See",
"      <a class=\"local\" href=\"#H11822099\">",
"       'High performance liquid chromatography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Definitive characterization of the abnormal hemoglobin is obtained via DNA sequencing techniques. (See",
"      <a class=\"local\" href=\"#H11822128\">",
"       'Definitive evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Natarajan K, Townes TM, Kutlar A. Disorders of hemoglobin structure: sickle cell anemia and related abnormalities. In: Williams Hematology, 8th ed, Kaushansky K, Lichtman MA, Beutler E, et al. (Eds), McGraw-Hill, 2010. p.ch.48.",
"    </li>",
"    <li>",
"     Huisman TH. The structure and function of normal and abnormal haemoglobins. In: Bailliere's Clinical Haematology, Higgs DR,  Weatherall DJ (Eds), W.B. Saunders, London 1993. p.1.",
"    </li>",
"    <li>",
"     Weatherall DJ. The New Genetics and Clinical Practice, Oxford University Press, Oxford 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/4\">",
"      Trent RJ. Diagnosis of the haemoglobinopathies. Clin Biochem Rev 2006; 27:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/5\">",
"      Steinberg MH, Adams JG 3rd, Dreiling BJ. Alpha thalassaemia in adults with sickle-cell trait. Br J Haematol 1975; 30:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/6\">",
"      Wong SC, Ali MA, Boyadjian SE. Sickle cell traits in Canada. Trimodal distribution of Hb S as a result of interaction with alpha-thalassaemia gene. Acta Haematol 1981; 65:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/7\">",
"      Sciarratta GV, Sansone G, Ivaldi G, et al. Alternate organization of alpha G-Philadelphia globin genes among U.S. black and Italian Caucasian heterozygotes. Hemoglobin 1984; 8:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/8\">",
"      Kutlar F. Diagnostic approach to hemoglobinopathies. Hemoglobin 2007; 31:243.",
"     </a>",
"    </li>",
"    <li>",
"     Huisman TH. Introduction and review of standard methodology for the detection of hemoglobin abnormalities. In: The Hemoglobinopathies, Huisman TH (Ed), Churchill Livingstone, Edinburgh 1986. p.1.",
"    </li>",
"    <li>",
"     Kutlar A, Huisman TH. Detection of hemoglobinopathies. In: Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual, Hommes FA (Ed), Wiley, New York 1991. p.519.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/11\">",
"      Kutlar F, Kutlar A, Huisman TH. Separation of normal and abnormal hemoglobin chains by reversed-phase high-performance liquid chromatography. J Chromatogr 1986; 357:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/12\">",
"      Smetanina NS, Molchanova TP, Huisman TH. Analysis of mRNA from red cells of patients with thalassemia and hemoglobin variants. Hemoglobin 1997; 21:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/13\">",
"      Clark BE, Thein SL. Molecular diagnosis of haemoglobin disorders. Clin Lab Haematol 2004; 26:159.",
"     </a>",
"    </li>",
"    <li>",
"     Coleman WB, Tsongalis GJ. Molecular Diagnostics: for the Clinical Laboratorian, 2nd ed, Human Press, Totowa 2006.",
"    </li>",
"    <li>",
"     Higgs DR. 5 alpha-Thalassaemia. In: Bailliere's Clinical Haematology, Higgs DR,  Weatherall DJ (Eds), W.B. Saunders, London 1993. p.118.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/16\">",
"      Bhardwaj U, McCabe ER. Multiplex-PCR assay for the deletions causing hereditary persistence of fetal hemoglobin. Mol Diagn 2005; 9:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/17\">",
"      Sutcharitchan P, Saiki R, Huisman TH, et al. Reverse dot-blot detection of the African-American beta-thalassemia mutations. Blood 1995; 86:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/968/abstract/18\">",
"      Cremonesi L, Ferrari M, Giordano PC, et al. An overview of current microarray-based human globin gene mutation detection methods. Hemoglobin 2007; 31:289.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13941 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-122.72.80.101-7A5059B635-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_968=[""].join("\n");
var outline_f0_60_968=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2640489\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11822024\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11822052\">",
"      GLOBIN CHAIN PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822192\">",
"      Prevalence of the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822149\">",
"      Public health issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11822059\">",
"      GLOBIN CHAIN MUTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822211\">",
"      Clinical consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2640222\">",
"      Expression of the abnormal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2640236\">",
"      - Factors affecting the type and amount of abnormal hemoglobin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2640300\">",
"      Alpha globin mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2640307\">",
"      Beta globin mutations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2640293\">",
"      Surface charge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2640329\">",
"      Concomitant alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11822071\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822078\">",
"      Hemoglobin electrophoresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822085\">",
"      Isoelectric focusing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822099\">",
"      High performance liquid chromatography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2640398\">",
"      - Cation exchange",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2640405\">",
"      - Reverse phase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11822121\">",
"      Capillary electrophoresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11822128\">",
"      DEFINITIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2640489\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/13941\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13941|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?8/51/9023\" title=\"diagnostic image 1\">",
"      Hemoglobin electrophoresis at alkaline pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13941|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/32/6656\" title=\"figure 1\">",
"      Alpha and beta globin gene clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/24/18821\" title=\"figure 2\">",
"      Hemoglobin tetramer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/58/942\" title=\"figure 3\">",
"      Effect of globin charge on hemoglobin assembly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/6/43106\" title=\"figure 4\">",
"      Isoelectric focusing of hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/54/11108\" title=\"figure 5\">",
"      Isoelectric focusing Hgb variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/56/21376\" title=\"figure 6\">",
"      HPLC normal hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/58/12199\" title=\"figure 7\">",
"      HPLC alpha chain variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/56/14215\" title=\"figure 8\">",
"      HPLC beta chain variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/9/34967\" title=\"figure 9\">",
"      Beta chain variants reverse HPLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/17/10518\" title=\"figure 10\">",
"      Alpha chain variants reverse HPLC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/19/14647\" title=\"figure 11\">",
"      Capillary electrophoresis of hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/24/16776\" title=\"figure 12\">",
"      Beta globin gene sequencing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/5/14419\" title=\"figure 13\">",
"      Alpha thalassemia variants by gap PCR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/58/22439\" title=\"figure 14\">",
"      Alpha thalassemia by gap PCR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/13941|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/8/4236\" title=\"table 1\">",
"      Clinically significant hemoglobin variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/17/16667\" title=\"table 2\">",
"      Sickle trait alpha thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/40/25227\" title=\"table 3\">",
"      Detection methods for abnormal hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41783?source=related_link\">",
"      Community public health issues and the thalassemic syndromes: Lessons from other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42055?source=related_link\">",
"      Genetic disorders of hemoglobin oxygen affinity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/46/4841?source=related_link\">",
"      Genetics and pathogenesis of methemoglobinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16984?source=related_link\">",
"      Introduction to hemoglobin mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/45/35543?source=related_link\">",
"      Mean corpuscular volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/58/9129?source=related_link\">",
"      Molecular pathology of the thalassemic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/38/616?source=related_link\">",
"      Unstable hemoglobin variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_60_969="Clinical characteristics of carcinoid tumors";
var content_f0_60_969=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical characteristics of carcinoid tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/969/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/969/contributors\">",
"     Stephen E Goldfinger, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/969/contributors\">",
"     Jonathan R Strosberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/969/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/969/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/969/contributors\">",
"     David C Whitcomb, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/969/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/969/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/60/969/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;carcinoid&rdquo; is generally applied to well-differentiated neuroendocrine tumors originating in the digestive tract, lungs, or rare primary sites such as kidneys or ovaries. Use of the term carcinoid implies well-differentiated (low- to intermediate-grade) histology and is not traditionally used to describe high-grade or poorly differentiated neuroendocrine tumors (which are rare). In the digestive system, well-differentiated neuroendocrine tumors of the luminal gastrointestinal tract have been designated carcinoid tumors while those arising in the pancreas (and rarely in the duodenum) have been referred to as pancreatic neuroendocrine (islet cell) tumors (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link&amp;anchor=H440387068#H440387068\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on 'Pathology, tumor classification, and nomenclature'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &ldquo;Carcinoid syndrome&rdquo; is the term applied to a constellation of symptoms mediated by various humoral factors that are elaborated by some carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"UTD.htm?34/59/35771\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/1\">",
"     1",
"    </a>",
"    ]. The typical carcinoid syndrome, consisting primarily of flushing and diarrhea (",
"    <a class=\"graphic graphic_table graphicRef63079 \" href=\"UTD.htm?37/54/38763\">",
"     table 3",
"    </a>",
"    ), occurs predominantly in patients with metastatic carcinoid tumors originating in the small intestine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carcinoid tumors are rare overall, but their age-adjusted incidence in the United States has increased significantly, partly due to increased detection on radiographic imaging and endoscopy.",
"   </p>",
"   <p>",
"    This topic will cover the epidemiology, classification, and clinical features of primary carcinoid tumors arising in the gastrointestinal and genitourinary systems. The pathology and nomenclature of carcinoid tumors, clinical features and diagnosis of the carcinoid syndrome, issues related to tumor localization, bronchial carcinoid tumors, thymic carcinoid tumors, and the management of patients with non-metastatic and metastatic carcinoid tumors are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link\">",
"       \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"       \"Clinical features of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link\">",
"       \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathology of mediastinal tumors\", section on 'Thymic neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link\">",
"       \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949019#H190949019\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Poorly differentiated tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoids are relatively rare tumors. In a series of 35,618 neuroendocrine tumors (which included pancreatic neuroendocrine tumors as well as carcinoids at all sites) reported to the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute, the age-adjusted incidence for non-pancreatic primaries was 4.7 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/2\">",
"     2",
"    </a>",
"    ]. The annual incidence rate for African Americans was higher than for Caucasians (6.46 versus",
"    <span class=\"nowrap\">",
"     4.60/100,000),",
"    </span>",
"    and the incidence for males was slightly higher than for females (4.97 versus",
"    <span class=\"nowrap\">",
"     4.49/100,000).",
"    </span>",
"    The median age at diagnosis for all patients with neuroendocrine tumors was 63 years.",
"   </p>",
"   <p>",
"    Roughly similar incidence rates were found in a database study from a Swedish registry that focused on 5184 carcinoid tumors seen between 1958 and 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/3\">",
"     3",
"    </a>",
"    ]. Incidence rates for men and women were 2.0 and",
"    <span class=\"nowrap\">",
"     2.4/100,000,",
"    </span>",
"    respectively. Although clear risk factors have not been identified, a regression analysis of this database suggested that risk was increased in the setting of a family history of carcinoid in a first-degree relative (relative risk 3.6).",
"   </p>",
"   <p>",
"    The incidence of carcinoid tumors has been rising over time in the US and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. As an example, in the above mentioned SEER analysis of 35,618 neuroendocrine tumors, there was a significant increase in the age-adjusted incidence for both pancreatic and nonpancreatic primary sites [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/2\">",
"     2",
"    </a>",
"    ]. For all neuroendocrine tumors, the incidence rose from 1.09 to 5.25 per 100,000 between 1973 and 2004. The increase is probably partly due to increased detection on radiographic imaging and endoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3796865\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a report from the SEER database of 11,427 carcinoid cases treated between 1973 and 1997, the majority were located in the gastrointestinal (GI) tract (55 percent) and bronchopulmonary system (30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/5\">",
"     5",
"    </a>",
"    ]. Within the GI tract, most carcinoids arose in the small intestine (45 percent, most commonly in the ileum), followed by rectum (20 percent), appendix (16 percent), colon (11 percent), and stomach (7 percent).",
"   </p>",
"   <p>",
"    Distribution may differ in other geographic areas. As an example, colorectal carcinoids may be more frequent in the",
"    <span class=\"nowrap\">",
"     Asia/Pacific",
"    </span>",
"    region as compared to Europe, where carcinoids are more commonly found in the stomach and ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. An important point is that the SEER database may be inconsistent in recording tumors that are not considered &ldquo;malignant&rdquo; (ie, trivial gastric carcinoids that are encountered at endoscopy in patients with chronic atrophic gastritis). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND GRADING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors were so named because they seemed morphologically different and clinically less aggressive than the more common GI tract adenocarcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/8\">",
"     8",
"    </a>",
"    ]. Carcinoids arise from enterochromaffin (neuroendocrine) cells of the aerodigestive tract. The term enterochromaffin refers to the ability to stain with potassium chromate (chromaffin), a feature of cells that contain serotonin.",
"   </p>",
"   <p>",
"    While most carcinoid tumors are relatively slow-growing neoplasms, some behave aggressively. Histologic grade and differentiation correlate closely with clinical behavior. Grade refers to the proliferative activity of tumors, commonly measured by the mitotic rate (number of mitotic figures per 10 high-powered fields) or the Ki-67 index. In contrast, differentiation refers to the extent to which neoplastic cells resemble their non-neoplastic counterparts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most recent nomenclature for neuroendocrine tumors of the digestive system from the World Health Organization (WHO) distinguishes two broad subgroups (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated neuroendocrine tumors, which are further subdivided into low-grade and intermediate grade according to proliferative rate. Intermediate grade carcinoid tumors arising in the lung (but not elsewhere) are referred to as atypical carcinoids. In general, clinical behavior is relatively indolent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine tumors are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung (",
"      <a class=\"graphic graphic_picture graphicRef74630 \" href=\"UTD.htm?26/10/26794\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/11\">",
"       11",
"      </a>",
"      ]. They generally behave in a biologically aggressive fashion. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A more detailed discussion of pathology and classification of neuroendocrine tumors arising in the digestive tract is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=see_link\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EMBRYONIC CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors have traditionally been classified based upon their origin from the embryonic divisions (foregut, midgut, or hindgut) of the alimentary tract (",
"    <a class=\"graphic graphic_figure graphicRef83185 \" href=\"UTD.htm?2/9/2198\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/12\">",
"     12",
"    </a>",
"    ]. In general, midgut carcinoid tumors produce serotonin and other vasoactive substances that give rise to the typical carcinoid syndrome (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 4",
"    </a>",
"    ). In contrast, tumors derived from the embryonic hindgut are rarely associated with a hormonal syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While this classification has some utility as a means of grouping together carcinoid tumor sites according to their likelihood of producing a hormonal syndrome, it is increasingly evident that each specific primary site possesses its own unique clinical characteristics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     FOREGUT TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms associated with foregut carcinoid tumors vary with the site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Stomach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastric carcinoids are subdivided into three categories that have differing biologic behavior and prognoses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 gastric carcinoids account for 70 to 80 percent of all gastric carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. They are associated with chronic atrophic gastritis and often pernicious anemia (65 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/14\">",
"     14",
"    </a>",
"    ]. The disease is more common in women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=see_link\">",
"     \"Metaplastic (chronic) atrophic gastritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopically, the tumors are usually smaller than 1 cm, often multiple, and may appear as polypoid lesions with a small central ulceration (",
"    <a class=\"graphic graphic_picture graphicRef81095 graphicRef73158 graphicRef53130 \" href=\"UTD.htm?7/26/7593\">",
"     picture 2A-C",
"    </a>",
"    ). The tumors are derived from enterochromaffin-like (ECL) cells.",
"   </p>",
"   <p>",
"    The prevailing hypothesis is that ECL cells develop into carcinoid tumors after chronic stimulation by the high gastrin levels that occur in patients with atrophic gastritis. This is supported by the observation that regression of gastric carcinoids can be achieved by antrectomy, which is occasionally recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Stomach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The importance of gastrin in ECL transformation is supported by the observation that carcinoid tumors develop in certain animals treated with high doses of proton pump inhibitors, which are associated with hypergastrinemia, because of loss of feedback [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/20\">",
"     20",
"    </a>",
"    ]. However, carcinoid tumors have not been observed in humans treated with proton pump inhibitors, suggesting that other factors may be important.",
"   </p>",
"   <p>",
"    Patients with gastric carcinoids related to chronic atrophic gastritis are usually diagnosed in their 60s or 70s during endoscopic evaluation for abdominal pain or anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/14\">",
"     14",
"    </a>",
"    ]. They are usually non-functioning tumors. These gastric carcinoid tumors are usually indolent and generally represent a benign condition. Metastases occur in less than 10 percent of tumors &le;2 cm, but in approximately 20 percent of larger tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 gastric carcinoids occur in association with gastrinomas (Zollinger-Ellison syndrome), often in the setting multiple endocrine neoplasia (MEN) type 1. They account for approximately 5 percent of gastric carcinoids. Similar to carcinoids in atrophic gastritis, the tumors are thought to arise from ECL cells stimulated by elevated serum gastrin levels. The hypergastrinemia is produced by a gastrinoma in the pancreas or duodenum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=see_link\">",
"     \"Multiple endocrine neoplasia type 1: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=see_link\">",
"     \"Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .) &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Type 2 gastric carcinoids behave similarly to type 1 tumors; they are frequently multifocal, and usually indolent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/22\">",
"     22",
"    </a>",
"    ]. Management is addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Stomach'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 gastric carcinoids are known as sporadic carcinoids because they occur in the absence of atrophic gastritis or the Zollinger-Ellison or MEN1 syndromes. They account for 20 percent of gastric carcinoids, and are the most aggressive; local or hepatic metastases are present in up to 65 percent of patients who come to resection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/13,22\">",
"     13,22",
"    </a>",
"    ]. Unlike type 1 and 2 gastric carcinoids, the fasting serum gastrin is usually normal in patients with type 3 gastric carcinoid tumors.",
"   </p>",
"   <p>",
"    Type 3 gastric carcinoids often contain a variety of endocrine cells and they may be associated with an atypical carcinoid syndrome (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 4",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Gastric carcinoid variant syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Lung",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchial carcinoids are classified among other pulmonary neuroendocrine tumors such as small cell and large cell neuroendocrine lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"     \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with bronchial carcinoids rarely develop carcinoid syndrome in the absence of liver metastases. They may have a variant carcinoid syndrome with flushes or sweats that are severe and prolonged, lasting hours to days. These flushes may be associated with disorientation, anxiety, and tremor. The clinical features of bronchial carcinoid tumors are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Bronchial carcinoid variant syndrome'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H9#H9\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     MIDGUT TUMORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Jejuno-ileal small bowel tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Small bowel carcinoids have increased in frequency in the last several decades, in part due to increased detection on endoscopy and imaging studies [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/23\">",
"     23",
"    </a>",
"    ]. In the year 2000, carcinoid tumors surpassed adenocarcinomas as the most common small bowel tumor reported to the National Cancer Data Base [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/24\">",
"     24",
"    </a>",
"    ]. Between 1985 and 2005, the proportion of patients with carcinoids increased from 28 to 44 percent, while the proportion of adenocarcinoma decreased from 42 to 33 percent. Patients usually present in their 60s or 70s. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology, clinical features, and types of small bowel neoplasms\", section on 'Malignant tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Small bowel carcinoids are thought to arise from intraepithelial endocrine cells, in contrast to appendiceal carcinoids, which arise from subepithelial endocrine cells [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/25\">",
"     25",
"    </a>",
"    ]. Small intestinal carcinoid tumors are most commonly located in the ileum within 60 cm of ileocecal valve; they may arise from a Meckel&rsquo;s diverticulum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/23,26-28\">",
"     23,26-28",
"    </a>",
"    ]. Approximately 25 percent of patients will have more than one small bowel carcinoid at the time of discovery.",
"   </p>",
"   <p>",
"    Many small bowel carcinoids are asymptomatic at presentation and found incidentally [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/29\">",
"     29",
"    </a>",
"    ]. Among symptomatic patients, abdominal pain is the most common initial symptom, occurring in approximately 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/30\">",
"     30",
"    </a>",
"    ]. The pain is usually vague and nonspecific, and may be incorrectly assumed to represent irritable bowel syndrome for years before the diagnosis is made. Intermittent obstruction occurs in 25 percent of small intestinal carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Duodenal carcinoids may produce duodenal or biliary obstruction.",
"   </p>",
"   <p>",
"    Abdominal pain may be due to intussusception, the mechanical effect of the tumor, or mesenteric ischemia. Obstruction may be caused by intussusception or by intraluminal tumor bulk, but often results from mesenteric kinking and distortion brought on by tumor invasion, lymph node metastases,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a secondary desmoplastic response (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef78186 \" href=\"UTD.htm?42/57/43921\">",
"     image 1",
"    </a>",
"    ). The latter produces a characteristic radiographic abnormality: a combination of abrupt angulation with a filling defect in the small bowel (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60836 \" href=\"UTD.htm?31/63/32767\">",
"     image 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Pain may also arise from ischemia that is due to local fibrosis or vascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/31\">",
"     31",
"    </a>",
"    ]. Vascular compromise may be secondary to large bulky mesenteric nodal metastasis, mesenteric vascular invasion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    microvascular metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/31\">",
"     31",
"    </a>",
"    ]. Possibly contributing to the ischemic process is the vasospastic effect of serotonin produced by the tumor.",
"   </p>",
"   <p>",
"    Patients often have metastases to lymph nodes or the liver, even if the primary tumor is small (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"UTD.htm?14/6/14444\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The carcinoid syndrome is present in the majority of patients who have a small bowel primary carcinoid and liver metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/32,34-36\">",
"     32,34-36",
"    </a>",
"    ]. Staging, treatment, and prognosis of small bowel carcinoid tumors are addressed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Appendix",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid tumors are the most common neoplasms in the appendix. In approximately 1 in 300 appendectomies, carcinoid tumors are discovered incidentally, most often in the tip of the appendix. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appendiceal carcinoids are detected most commonly in the patients in their 40s or 50s, which most likely reflects the younger age of patients who undergo appendectomy. They are probably more common in women, although this association has in part been attributed to the greater frequency of incidental appendectomies in women who undergo pelvic surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H2#H2\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Carcinoid tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The majority of carcinoids are submucosal and located in the distal one-third of the appendix where they are unlikely to cause obstruction (",
"    <a class=\"graphic graphic_picture graphicRef50408 graphicRef80087 \" href=\"UTD.htm?21/28/21958\">",
"     picture 4A-B",
"    </a>",
"    ). As a result, most patients are asymptomatic. Symptoms are more likely with large tumors and in the rare patient with metastases beyond the regional lymph nodes. Approximately 10 percent of appendiceal carcinoids are located at the base of the appendix, where they can cause obstruction, leading to appendicitis.",
"   </p>",
"   <p>",
"    The likelihood of regional and distant metastases is related to tumor size, but generally lower than for small intestinal carcinoids (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"UTD.htm?14/6/14444\">",
"     table 5",
"    </a>",
"    ). Features of the carcinoid syndrome may be present in patients with tumors that have metastasized to the liver. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare type of appendiceal tumor, sometimes referred to as an adenocarcinoid (also termed &ldquo;goblet cell&rdquo; or &ldquo;mucous&rdquo; carcinoid) contains chromogranin A and is composed largely of goblet cells. These tumors are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H15#H15\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Goblet cell carcinomas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Staging, prognosis and treatment of appendiceal carcinoids are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Staging and prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H5#H5\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     HINDGUT TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hindgut carcinoids (transverse and descending colon and rectum) are usually nonsecretory and not associated with the carcinoid syndrome, even when metastatic (",
"    <a class=\"graphic graphic_table graphicRef56015 \" href=\"UTD.htm?17/7/17531\">",
"     table 4",
"    </a>",
"    ) . When symptoms do occur, they are the same as those of a colorectal adenocarcinoma: changes in bowel habits, obstruction, or bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Colon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonic carcinoids are usually detected in patients who are in their 70s during evaluation for diarrhea, abdominal pain, anorexia, or weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The incidence of functioning tumors is very low. Features of the carcinoid syndrome were present in only 1 of 36 patients in one series from the Alberta Cancer registry [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of colonic carcinoids are located in the right colon, particularly in the cecum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/37,39,40\">",
"     37,39,40",
"    </a>",
"    ]. Most patients do not become symptomatic until the tumors are large. In two series, the average size of tumors was approximately 5 cm at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/37,40\">",
"     37,40",
"    </a>",
"    ], and approximately two-thirds were associated with local nodal or distant metastasis (",
"    <a class=\"graphic graphic_table graphicRef82306 \" href=\"UTD.htm?14/6/14444\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Staging, treatment, and prognosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H432448#H432448\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Colon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Rectum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of rectal carcinoids are asymptomatic and found incidentally by rectal examination or endoscopy that is performed for another reason [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/38,41\">",
"     38,41",
"    </a>",
"    ]. They are most commonly diagnosed in patients in their 60s [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/42\">",
"     42",
"    </a>",
"    ]. Uncommon manifestations include rectal bleeding, change in bowel habits or pain; the carcinoid syndrome is rare because most are nonsecretory.",
"   </p>",
"   <p>",
"    The majority of rectal carcinoids (75 to 85 percent) are localized at diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/38\">",
"     38",
"    </a>",
"    ]. However, as with other gastrointestinal tract carcinoids, size correlates closely with the likelihood of metastases. Tumors smaller than 1 cm are rarely metastatic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/21,43\">",
"     21,43",
"    </a>",
"    ], while approximately 6 percent of tumors between 1 and 1.9 cm, and 24 percent of those over 2 cm metastasize to the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/26,43-45\">",
"     26,43-45",
"    </a>",
"    ]. Other poor prognostic features include deep invasion (into the muscularis propria or deeper), lymphovascular invasion, and a high mitotic rate (&ge;2 per 50 high-power fields) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Staging, prognosis, and treatment are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Rectum'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hindgut carcinoids rarely arise in the genitourinary system; however, both renal and testicular primary carcinoid tumors have been described in case reports and case series [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/47-50\">",
"     47-50",
"    </a>",
"    ]. In addition to primary tumors, renal and testicular carcinoids may represent metastatic spread from another site [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. These lesions commonly present as an abdominal or testicular mass, but some have manifestations of the carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OVARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ovarian carcinoid tumors are rare neoplasms that may be primary or metastatic. Primary ovarian carcinoid tumors are usually unilateral, localized to the ovary, and composed of gastrointestinal or respiratory epithelium; they often arise within a cystic teratoma or dermoid tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=see_link\">",
"     \"Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The coexistence of an ovarian germ cell tumor may have prognostic implications. In one report, 189 of 329 primary ovarian carcinoids (57 percent) coexisted with cystic",
"    <span class=\"nowrap\">",
"     teratomas/dermoid",
"    </span>",
"    tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/53\">",
"     53",
"    </a>",
"    ]. When compared to carcinoids without associated germ cell tumors, these carcinoids were significantly smaller (45 versus 90 cm), less likely to have liver metastases (2 versus 15 percent) or the carcinoid syndrome (14 versus 23 percent), and the five-year survival rates were modestly better (94 versus 84 percent).",
"   </p>",
"   <p>",
"    Metastatic ovarian carcinoids are less common, and most arise from a primary tumor within the small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/54\">",
"     54",
"    </a>",
"    ]. Unlike primary ovarian carcinoid tumors, which are typically unilateral, metastatic carcinoid tumors to the ovaries are usually bilateral, originate in the small intestine, and are associated with peritoneal carcinomatosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ovarian carcinoids can produce the carcinoid syndrome without hepatic metastases due to their direct drainage into the systemic circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1304714531\">",
"    <span class=\"h1\">",
"     METASTATIC CARCINOID TUMORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of primary site, carcinoid tumors are characterized by a strong propensity to metastasize to the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients with liver metastases may experience symptoms related to tumor burden (eg, pain, jaundice, early satiety) or hormonal symptoms (eg, flushing and diarrhea). Even when extensive, metastatic well-differentiated carcinoid tumors can often cause significant hepatomegaly without any abnormalities of liver function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features of the carcinoid syndrome\", section on 'Clinical features'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Other common metastatic sites associated with small-intestinal (midgut) carcinoid tumors include mesentery and peritoneum. Tumors in the root of the mesentery may be unresectable and lead to recurrent bowel obstruction or ischemia. Likewise, patients with peritoneal carcinomatosis may experience chronic obstruction, weight loss and malnutrition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bone metastases are a relatively late occurrence in patients with metastatic carcinoid tumors and typically affect the axial skeleton [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/969/abstract/55\">",
"     55",
"    </a>",
"    ]. Other metastatic sites include retroperitoneal lymph nodes, ovaries, breasts, and supraclavicular lymph nodes. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carcinoid tumors are rare neuroendocrine tumors that can arise at several body sites. The majority originate in the gastrointestinal tract (55 percent) and bronchopulmonary system (30 percent). (See",
"      <a class=\"local\" href=\"#H3796865\">",
"       'Distribution'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carcinoid tumors arise from enterochromaffin cells. They have traditionally been classified based upon their origin from the embryonic divisions of the alimentary tract; the foregut (bronchial, stomach), midgut (small intestine, appendix, cecum), or hindgut (distal colon, rectum, genitourinary). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Embryonic classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologically, neuroendocrine tumors such as carcinoid tumors are classified based upon histologic grade and differentiation (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathology and grading'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Well-differentiated neuroendocrine tumors, which are further subdivided into low-grade and intermediate grade according to proliferative rate. In general, clinical behavior is relatively indolent.",
"     </li>",
"     <li>",
"      Poorly differentiated carcinoids are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung. They generally behave in a biologically aggressive fashion. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The metastatic potential of localized carcinoid tumors correlates with tumor size, location, and histologic grade.",
"     </li>",
"     <li>",
"      Clinical symptoms may be general, or they may correlate with the location of the tumor and be organ related. Symptoms of the carcinoid syndrome (eg, flushing and diarrhea) typically occur in patients with metastatic carcinoid tumors of the small bowel. Rarely, the carcinoid syndrome is observed in non-metastatic tumors which can release hormones directly into the systemic circulation (eg, lungs, ovaries). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Lung'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Ovary'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Gastric tumors are subclassified into three types which have different clinical presentation and malignant potential. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Stomach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Small intestinal carcinoids often present with abdominal pain",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intermittent obstruction. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Jejuno-ileal small bowel tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Appendiceal carcinoids are the most common neoplasm found in the appendix; they are most often discovered incidentally during appendectomy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Appendix'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transverse and descending colon and rectal carcinoids may present with changes in bowel habit, obstruction, or bleeding. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hindgut tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The great majority of rectal carcinoids are discovered incidentally at the time of rectal examination or endoscopy.",
"     </li>",
"     <li>",
"      Ovarian carcinoids may be primary or metastatic. Primary ovarian carcinoids are often associated with an ovarian germ cell tumor. They can produce the carcinoid syndrome without hepatic metastases due to their direct drainage into the systemic circulation. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Ovary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/1\">",
"      Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/2\">",
"      Yao JC, Hassan M, Phan A, et al. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008; 26:3063.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/3\">",
"      Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer 2001; 92:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/4\">",
"      Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010; 21:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/5\">",
"      Maggard MA, O'Connell JB, Ko CY. Updated population-based review of carcinoid tumors. Ann Surg 2004; 240:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/6\">",
"      Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010; 45:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/7\">",
"      Niederle MB, Hackl M, Kaserer K, Niederle B. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer 2010; 17:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/8\">",
"      Caplin ME, Buscombe JR, Hilson AJ, et al. Carcinoid tumour. Lancet 1998; 352:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/9\">",
"      Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/11\">",
"      Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/12\">",
"      WILLIAMS ED, SANDLER M. The classification of carcinoid tum ours. Lancet 1963; 1:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/13\">",
"      Bordi C. Endocrine tumours of the stomach. Pathol Res Pract 1995; 191:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/14\">",
"      Borch K, Ahr&eacute;n B, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 2005; 242:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/15\">",
"      Sculco D, Bilgrami S. Pernicious anemia and gastric carcinoid tumor: case report and review. Am J Gastroenterol 1997; 92:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/16\">",
"      Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992; 102:1409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/17\">",
"      Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996; 20:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/18\">",
"      Thomas RM, Baybick JH, Elsayed AM, Sobin LH. Gastric carcinoids. An immunohistochemical and clinicopathologic study of 104 patients. Cancer 1994; 73:2053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/19\">",
"      Dakin GF, Warner RR, Pomp A, et al. Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006; 93:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/20\">",
"      Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 Suppl 1:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/21\">",
"      Soga J. Early-stage carcinoids of the gastrointestinal tract: an analysis of 1914 reported cases. Cancer 2005; 103:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/22\">",
"      Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/23\">",
"      Modlin IM, Champaneria MC, Chan AK, Kidd M. A three-decade analysis of 3,911 small intestinal neuroendocrine tumors: the rapid pace of no progress. Am J Gastroenterol 2007; 102:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/24\">",
"      Bilimoria KY, Bentrem DJ, Wayne JD, et al. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg 2009; 249:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/25\">",
"      Capella C, Heitz PU, H&ouml;fler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/26\">",
"      Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003; 97:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/27\">",
"      Solcia E, Fiocca R, Rindi G, et al. Endocrine tumors of the small and large intestine. Pathol Res Pract 1995; 191:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/28\">",
"      Wolff BG, Park JJ. Meckel's diverticulum, a \"hot spot\" for cancer. Ann Surg 2011; 253:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/29\">",
"      Pape UF, Perren A, Niederle B, et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 2012; 95:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/30\">",
"      Saha S, Hoda S, Godfrey R, et al. Carcinoid tumors of the gastrointestinal tract: a 44-year experience. South Med J 1989; 82:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/31\">",
"      Eckhauser FE, Argenta LC, Strodel WE, et al. Mesenteric angiopathy, intestinal gangrene, and midgut carcinoids. Surgery 1981; 90:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/32\">",
"      Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer 1997; 79:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/33\">",
"      Loftus JP, van Heerden JA. Surgical management of gastrointestinal carcinoid tumors. Adv Surg 1995; 28:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/34\">",
"      MOERTEL CG, SAUER WG, DOCKERTY MB, BAGGENSTOSS AH. Life history of the carcinoid tumor of the small intestine. Cancer 1961; 14:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/35\">",
"      Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 2009; 89:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/36\">",
"      Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/37\">",
"      Rosenberg JM, Welch JP. Carcinoid tumors of the colon. A study of 72 patients. Am J Surg 1985; 149:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/38\">",
"      Caplin M, Sundin A, Nillson O, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 2012; 95:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/39\">",
"      Spread C, Berkel H, Jewell L, et al. Colon carcinoid tumors. A population-based study. Dis Colon Rectum 1994; 37:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/40\">",
"      Ballantyne GH, Savoca PE, Flannery JT, et al. Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry. Cancer 1992; 69:2400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/41\">",
"      Jetmore AB, Ray JE, Gathright JB Jr, et al. Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 1992; 35:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/42\">",
"      Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/43\">",
"      Koura AN, Giacco GG, Curley SA, et al. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer 1997; 79:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/44\">",
"      Mani S, Modlin IM, Ballantyne G, et al. Carcinoids of the rectum. J Am Coll Surg 1994; 179:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/45\">",
"      Shields CJ, Tiret E, Winter DC, International Rectal Carcinoid Study Group. Carcinoid tumors of the rectum: a multi-institutional international collaboration. Ann Surg 2010; 252:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/46\">",
"      Fahy BN, Tang LH, Klimstra D, et al. Carcinoid of the rectum risk stratification (CaRRs): a strategy for preoperative outcome assessment. Ann Surg Oncol 2007; 14:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/47\">",
"      Hansel DE, Epstein JI, Berbescu E, et al. Renal carcinoid tumor: a clinicopathologic study of 21 cases. Am J Surg Pathol 2007; 31:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/48\">",
"      Shurtleff BT, Shvarts O, Rajfer J. Carcinoid tumor of the kidney: case report and review of the literature. Rev Urol 2005; 7:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/49\">",
"      Zavala-Pompa A, Ro JY, el-Naggar A, et al. Primary carcinoid tumor of testis. Immunohistochemical, ultrastructural, and DNA flow cytometric study of three cases with a review of the literature. Cancer 1993; 72:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/50\">",
"      Stroosma OB, Delaere KP. Carcinoid tumours of the testis. BJU Int 2008; 101:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/51\">",
"      Tal R, Lask DM, Livne PM. Metastatic renal carcinoid: case report and review of the literature. Urology 2003; 61:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/52\">",
"      Davis KP, Hartmann LK, Keeney GL, Shapiro H. Primary ovarian carcinoid tumors. Gynecol Oncol 1996; 61:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/53\">",
"      Soga J, Osaka M, Yakuwa Y. Carcinoids of the ovary: an analysis of 329 reported cases. J Exp Clin Cancer Res 2000; 19:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/54\">",
"      Strosberg J, Nasir A, Cragun J, et al. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol 2007; 106:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/969/abstract/55\">",
"      Zuetenhorst JM, Hoefnageli CA, Boot H, et al. Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002; 23:735.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2613 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-853D91569B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_969=[""].join("\n");
var outline_f0_60_969=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3796865\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOLOGY AND GRADING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EMBRYONIC CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      FOREGUT TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Stomach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Type 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Type 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      MIDGUT TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Jejuno-ileal small bowel tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Appendix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HINDGUT TUMORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Colon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Rectum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OVARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1304714531\">",
"      METASTATIC CARCINOID TUMORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2613\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2613|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/57/43921\" title=\"diagnostic image 1\">",
"      Malignant carcinoid ileum CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/63/32767\" title=\"picture 3\">",
"      Carcinoid ileum UGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2613|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/9/2198\" title=\"figure 1\">",
"      Classification carcinoid tumors by embryonic derivation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2613|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/10/26794\" title=\"picture 1\">",
"      Histologic appearance of neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/19/3378\" title=\"picture 2A\">",
"      Pedunculated gastric carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/4/12352\" title=\"picture 2B\">",
"      Gastric carcinoids Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/54/41825\" title=\"picture 2C\">",
"      Gastric carcinoid CPC Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/9/13456\" title=\"picture 4A\">",
"      Appendiceal carcinoid tumor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/5/10322\" title=\"picture 4B\">",
"      Carcinoid tumor appendix",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2613|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/14/17644\" title=\"table 1\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/59/35771\" title=\"table 2\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/54/38763\" title=\"table 3\">",
"      Carcinoid symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/7/17531\" title=\"table 4\">",
"      Characteristics of carcinoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/6/14444\" title=\"table 5\">",
"      Incidence mets carcinoid size",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/31/18938?source=related_link\">",
"      Epidemiology, clinical features, and types of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/51/6968?source=related_link\">",
"      Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24185?source=related_link\">",
"      Metaplastic (chronic) atrophic gastritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/61/38871?source=related_link\">",
"      Multiple endocrine neoplasia type 1: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/37/5721?source=related_link\">",
"      Ovarian germ cell neoplasms: Pathology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_60_970="Classification and evaluation of dystonia";
var content_f0_60_970=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and evaluation of dystonia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/970/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/970/contributors\">",
"     Cynthia Comella, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/970/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/970/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/60/970/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/60/970/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/60/970/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION AND DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia is a movement disorder characterized by involuntary, sustained muscle contractions that result in twisting and repetitive movements or abnormal postures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dystonia can be classified by the age of onset, body distribution, and etiology. Primary dystonia is defined as dystonia without any additional neurologic signs or history of possible acquired causes. There are now at least 15 genetic subtypes of dystonia.",
"   </p>",
"   <p>",
"    This topic will review the classification, clinical features, and evaluation of dystonia. Treatment options for dystonia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link\">",
"     \"Treatment of dystonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia is classified in three ways: according to age of onset, body areas affected (anatomic distribution), and etiology (",
"    <a class=\"graphic graphic_table graphicRef59278 \" href=\"UTD.htm?38/52/39755\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classification by age of onset [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/4\">",
"       4",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early onset (childhood and young adulthood, generally &lt;26 years old)",
"     </li>",
"     <li>",
"      Late onset (generally &ge;26 years old)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classification by anatomic distribution [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/5\">",
"       5",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Focal (involving a single body area)",
"     </li>",
"     <li>",
"      Segmental (involving two or more contiguous body areas)",
"     </li>",
"     <li>",
"      Generalized (involving at least one leg, the trunk, and another body area)",
"     </li>",
"     <li>",
"      Multifocal (involving two or more noncontiguous body areas)",
"     </li>",
"     <li>",
"      Hemidystonia (involving one side of the body)",
"      <br/>",
"      <br/>",
"      Of these, multifocal dystonia and hemidystonia are less common than focal, segmental, or generalized dystonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Classification by etiology (",
"      <a class=\"graphic graphic_table graphicRef59044 \" href=\"UTD.htm?33/63/34813\">",
"       table 2",
"      </a>",
"      ), which broadly separates the spectrum of dystonia into two main categories, primary and secondary:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Primary dystonia presents with signs related solely to dystonia and lacks additional neurologic, laboratory, or imaging abnormalities. The onset and progression of symptoms is gradual and usually without fixed postures. However, contractures may sometimes develop in areas chronically affected by dystonia, particularly if the dystonia is present at rest as well as with action.",
"      <br/>",
"      <br/>",
"      Primary torsion dystonia, previously called idiopathic torsion dystonia, may be sporadic or inherited. Most early-onset primary torsion dystonia is inherited in an autosomal dominant pattern with a reduced penetrance of 30 percent. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Genetic etiologies'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Historically, primary torsion dystonia has also been called dystonia musculorum deformans and Oppenheim dystonia. These terms are no longer used.",
"     </li>",
"     <li>",
"      Secondary dystonia is associated with a known acquired cause or additional neurologic signs, such as muscle weakness, spasticity, ataxia, ocular motility abnormalities, retinal abnormalities, cognitive impairment, or seizures. Secondary dystonia usually arises from a specific underlying condition, such as perinatal asphyxia or exposure to dopamine receptor blocking drugs (eg, tardive dystonia). The presence of other neurologic abnormalities may provide the clue to the cause of the dystonia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/6\">",
"       6",
"      </a>",
"      ]. Brain MRI findings vary with the etiology.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age of onset and anatomic distribution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age and anatomic distribution of dystonia at onset are important clinical clues.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early onset dystonia most often begins with symptoms in the limbs, typically the leg, and spreads to other body areas to become generalized in over 50 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Early onset primary dystonia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In contrast, late onset dystonia most frequently begins in the neck, arm, or face and tends to remain focal or segmental. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Late onset primary dystonia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Atypical presentations of dystonia (eg, a child with onset in the neck or face, or an adult with onset in the leg, or an adult who develops generalized dystonia) indicate the need to evaluate for an underlying cause. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia affects approximately 0.6 to 732 per 100,000 people, depending on the populations assessed and the methods of ascertainment, with focal dystonia being the most frequent in an office setting [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/8-14\">",
"     8-14",
"    </a>",
"    ]. In a 2012 systematic review and meta-analysis, the overall prevalence of primary dystonia was 16.4 per 100,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/15\">",
"     15",
"    </a>",
"    ]. The variability among these studies may arise from different methodologies of case identification, and differences in the demographic and ethnic composition of the populations assessed. However, focal dystonia is more common in all studies, and is estimated to be approximately 10 times more frequent than generalized dystonia. Cervical dystonia is the most frequent type of focal dystonia.",
"   </p>",
"   <p>",
"    Efforts are ongoing to develop a practical, reliable, and validated screening tool for dystonia that can be applied to large populations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In the absence of such an instrument, under-diagnosis and misdiagnosis are likely major confounders. As an example, a study of familial dystonia found that one-half of the cases were not previously diagnosed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dystonia is characterized by involuntary, sustained muscle contractions that result in twisting and repetitive movements or abnormal postures [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The sustained movements of dystonia may have overlying spasms that resemble tremor but can be distinguished from essential tremor by the directional quality of the movement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Dystonia is a dynamic disorder that changes in severity, depending upon activity and posture. An example of this is writer's cramp, a dystonia that involves the hand and arm, which is present only during the action of writing but not during any other activity.",
"   </p>",
"   <p>",
"    A common feature of dystonia is the sensory trick or \"geste antagoniste\". The sensory trick is a maneuver (eg, lightly touching the affected body part) that reduces or abolishes the dystonic symptoms. It is found in approximately 60 percent of patients. In some patients, these tricks may be effective if imagined but not performed physically [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Early onset primary dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early onset dystonia usually begins in a leg, often as inversion of the foot. Initially, the dystonia might be triggered only by vigorous physical activity such as running. Over time, the posturing becomes susceptible to triggering by minimal physical activity, such as walking or standing. Subsequently, the dystonia may be present even at rest.",
"   </p>",
"   <p>",
"    With early onset focal dystonia, spread from one leg to other body areas, including the other leg, torso, arms, and upper body, occurs in approximately 50 to 90 percent of children, usually within five years of onset. However, when early onset dystonia begins in the arm in late childhood and adolescence, it tends to have a lower likelihood of subsequent spread.",
"   </p>",
"   <p>",
"    In primary dystonia, cognition and intellectual abilities remain intact despite the presence of significant movement abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Late onset primary dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to early onset dystonia, late onset primary dystonia often begins in the upper body, usually in the arm, neck, face, or larynx [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/21\">",
"     21",
"    </a>",
"    ]. Although symptoms may worsen in the area of involvement or spread to contiguous body regions (segmental dystonia), adult-onset dystonia rarely becomes generalized [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/7\">",
"     7",
"    </a>",
"    ]. Regional spread to contiguous body areas is most frequently observed with blepharospasm [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infrequently, late onset primary dystonia begins in the leg. However, onset in the leg in an adult is usually secondary to an underlying etiology such as early onset Parkinson disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted earlier, generalized dystonia is rare with adult onset. In such cases, a secondary etiology should be sought, such as exposure to dopamine receptor antagonists. Hemidystonia is infrequent, and is usually due to an underlying structural or metabolic cause. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Late onset primary focal dystonia may involve different body areas. Common",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    important types of focal dystonia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical dystonia (dystonia of neck and shoulders)",
"     </li>",
"     <li>",
"      Blepharospasm (dystonia of periocular muscles)",
"     </li>",
"     <li>",
"      Oromandibular, lingual, or facial dystonia (dystonia of jaw, oral muscles, tongue, or facial muscles)",
"     </li>",
"     <li>",
"      Spasmodic dysphonia (dystonia of laryngeal muscles)",
"     </li>",
"     <li>",
"      Limb dystonia (dystonia of arm or leg)",
"     </li>",
"     <li>",
"      Occupational or task-specific dystonia (dystonia that occurs only with certain activities such as writer's cramp, musicians dystonia, or embouchure dystonia)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cervical dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical dystonia, also known as spasmodic torticollis, is the most common primary focal dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/11\">",
"     11",
"    </a>",
"    ]. It affects the muscles of the neck and shoulders. It may appear as horizontal turning of the head (torticollis), lateral flexion of the neck (laterocollis), forward flexion of the head (anterocollis), or posterior extension of the head (retrocollis). Overlying spasms may give rise to a head tremor that is distinguished from essential tremor by the directional preponderance of the movement. Approximately one-half of patients with cervical dystonia will complain of pain associated with the dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Blepharospasm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blepharospasm is a focal dystonia involving the orbicularis oculi muscles and other periocular muscles, including the procerus and corrugator muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Clinical manifestations include increased blinking and spasms of involuntary eye closure. Symptoms are usually bilateral but may be asymmetric. Involuntary eye closure caused by dystonic spasms of the orbicularis oculi should be distinguished from apraxia of eyelid opening due to failure of levator palpebrae contraction. In some patients, the two conditions can coexist.",
"   </p>",
"   <p>",
"    Blepharospasm may be mild and nondisabling, or it may cause significant disability through interference with vision as a result of the eye closure. Patients with blepharospasm typically complain of increased spasms under conditions of bright light or stress, such as driving a car in traffic. Pain is infrequently associated with blepharospasm, although a feeling of irritation in the eyes may be one of the first symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Blepharospasm may be associated with dystonia of the lower face",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    jaw (Meige syndrome or Brueghel syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Oromandibular dystonia and facial dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oromandibular dystonia and facial dystonia are characterized by involuntary movements involving masticatory, lingual, and pharyngeal muscles.",
"   </p>",
"   <p>",
"    Oromandibular dystonia can manifest as jaw clenching, jaw opening, jaw deviation, and tongue protrusion. It is often found in combination with dystonia of adjacent body regions, including blepharospasm and cervical dystonia. Symptoms can result in difficulty speaking and swallowing and may be cosmetically disfiguring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Spasmodic dysphonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasmodic dysphonia is a focal dystonia involving the laryngeal muscles. The most common type of spasmodic dysphonia is the adductor type, with apposition of the vocal cords only during the action of vocalization. This causes voice breaks and a strained pattern of vocalization. Abductor spasmodic dysphonia is characterized by an abduction of the vocal cords during vocalization, resulting in a voice that is whispering and breathy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Vocal tremor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vocal tremor occurs with oscillation of the vocal cords and can be seen in association with craniofacial and cervical dystonia, and in patients with essential tremor of the hands and head [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Arm dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arm dystonia is manifested as a posturing of the hand",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arm. This problem may be variably present with arms outstretched, but is often not present at rest. Overlying dystonic spasms may occur and resemble essential tremor. However, in contrast to essential tremor, dystonia is often unilateral, and triggered by specific activities, such as writing or typing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of tremor\", section on 'Essential tremor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Occupational or task-specific dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occupational or task-specific dystonia is manifested only during particular activities. Writer's cramp is the most common form. Other types of task-specific dystonia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Typist's dystonia",
"     </li>",
"     <li>",
"      Golfer's dystonia (yips)",
"     </li>",
"     <li>",
"      Musician's dystonia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Occupational facial dystonia may manifest as embouchure dystonia, a dystonia of the lips, jaw, or tongue that affects musicians only during the act of playing reed or brass instruments, and is absent during other activities such as eating or speaking [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Writer's cramp",
"    </span>",
"    &nbsp;&mdash;&nbsp;Writer's cramp is a focal dystonia elicited by the act of writing. It appears as an involuntary flexion, extension",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    rotation of the fingers, wrist, and less frequently the elbow and shoulder. The act of writing requires more effort, and handwriting may become so distorted that it is no longer legible [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     GENETIC ETIOLOGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been many advances in the area of dystonia genetics, with identification of new genetic loci, increased understanding of genotype-phenotype interactions, and investigations into the role of the mutant gene products. Since the discovery of DYT1, the first gene mutation to be cloned, many additional genetic forms of dystonia have been described (",
"    <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the more common",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    important types of dystonia related to gene mutations are described in greater detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     DYT1 dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with hereditary dystonia have DYT1 dystonia, which is caused by a mutation in the TOR1A gene that encodes torsinA, an ATP-binding protein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/37\">",
"     37",
"    </a>",
"    ]. A three-base pair deletion results in loss of a glutamic acid residue in the C-terminal region of the torsinA protein [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DYT1 dystonia typically begins in childhood with limb onset, followed by progression to generalized dystonia. However, the phenotypic spectrum of DYT1 dystonia is broad, and late onset can occur. In one study with 176 TOR1A carriers, the mean age at onset was 17.6 years, with a range from three to 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    DYT1 dystonia accounts for approximately 40 to 65 percent of early onset primary dystonia in non-Jewish populations and 90 percent of early onset limb dystonia in the Ashkenazi Jewish population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/39\">",
"     39",
"    </a>",
"    ]. Inheritance is autosomal dominant, but penetrance is reduced approximately 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, most mutation carriers do not express clinically apparent disease.",
"   </p>",
"   <p>",
"    The pathogenic mechanism for DYT1 dystonia is uncertain. The primary abnormality is a mutation in the DYT1 protein product, torsinA [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/40\">",
"     40",
"    </a>",
"    ]. Although the function of torsinA is not known, it is associated with the endoplasmic reticulum and nuclear envelope, and has been hypothesized to play an important role in protein folding. Mutant torsinA also demonstrates perinuclear staining and forms distinct globular inclusions that contain vesicular monoamine transporter 2 (VMAT2). Since VMAT2 plays an important role in the exocytosis of monoamines in neurons, it may be that mutant torsinA may interfere with VMAT2 expression and dopamine release.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     DYT6 and other primary dystonias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetics of late onset focal and segmental dystonia have been more difficult to delineate than early onset DYT1 dystonia (",
"    <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"     table 3",
"    </a>",
"    ). Many late onset cases are likely to have a hereditary component [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. In most patients with late onset dystonia, DYT1 testing is not recommended unless there a family history of early onset dystonia.",
"   </p>",
"   <p>",
"    DYT6 was initially described in Amish-Mennonite families and characterized as an early-onset, cranial-cervical dystonia with autosomal dominant inheritance and a penetrance of 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Mutations responsible for DYT6 dystonia in the THAP1 gene on chromosome 8 were discovered as founder mutations in the Amish-Mennonite families [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Involvement of cranial muscles, leading to disabling dysarthria or dysphonia, was thought to be characteristic of DYT6 dystonia.",
"   </p>",
"   <p>",
"    Subsequent investigations of patients with non-DYT1, familial, early onset, generalized dystonia showed that there were additional mutations in the THAP1 gene besides those reported in the Amish-Mennonite families [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. These additional THAP1 mutations were found in 25 percent of the families studied [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/47\">",
"     47",
"    </a>",
"    ], suggesting that THAP1 mutations (DYT6) could be responsible for a substantial proportion of familial non-DYT1 early-onset primary dystonia in patients of European descent, including those of German, Irish, and Italian ancestry. In another study that screened over 1200 subjects with dystonia and 600 controls, a mutation in THAP1 was found in 18 affected subjects and one asymptomatic carrier from 16 families with primary dystonia, and in one normal control [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/49\">",
"     49",
"    </a>",
"    ]. The phenotype of the patients with THAP1 dystonia was highly variable, with age of onset ranging from 8 to 69 years (mean 48 years), and with site of onset predominantly cervical and laryngeal. The dystonia remained focal in 15 of 18 patients (83 percent).",
"   </p>",
"   <p>",
"    THAP1 encodes for a transcription regulating protein that modulates other target genes, including the TOR1A gene associated with DYT1 dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Genetic studies in humans and animals have shown that the wild-type THAP1 protein binds to the TOR1A gene promoter region and represses the expression of torsinA, while pathophysiologic DYT6 mutations of THAP1 abolish the interaction between THAP1 protein and the TOR1A promoter, leading to decreased repression of TOR1A [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Thus, these findings suggest a common molecular pathway linking DYT1 and DYT6.",
"   </p>",
"   <p>",
"    Other genetic forms of focal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    segmental dystonia (",
"    <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"     table 3",
"    </a>",
"    ) have also been reported (eg, DYT4, DYT7, DYT13) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/52-55\">",
"     52-55",
"    </a>",
"    ]. Cohort analysis suggests an autosomal dominant inheritance with variable penetrance. Although these families are rare, additional gene loci are certain to be identified in the future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Dopa-responsive dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dopa-responsive dystonia (DRD) manifests primarily as a focal dystonia with onset in early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/56-59\">",
"     56-59",
"    </a>",
"    ]. Parkinsonism, including rigidity and bradykinesia, may be present at onset or develop during the course of untreated disease. Often, children with DRD experience a long delay in diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/60\">",
"     60",
"    </a>",
"    ] or are initially misdiagnosed as having a primary dystonia or cerebral palsy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the original description of DRD, the investigators observed a diurnal fluctuation in symptoms, which worsened over the course of a day and improved following sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/56\">",
"     56",
"    </a>",
"    ]. However, this diurnal fluctuation may not be present in all patients with DRD [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark of DRD is a clinically significant, sustained response to levodopa. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=see_link\">",
"     \"Treatment of dystonia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent form of DRD is autosomal dominant DYT5 dystonia caused by a mutation in the guanosine triphosphate (GTP) cyclohydrolase 1 gene (GCH1) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/64\">",
"     64",
"    </a>",
"    ]. The GTP cyclohydrolase 1 protein encoded by this gene is involved in the biosynthesis of tetrahydrobiopterin, which is a cofactor for tyrosine hydroxylase, the rate-limiting enzyme in the synthesis of dopamine. It is also a cofactor for phenylalanine and tryptophan hydroxylase. Numerous mutations of the GCH1 gene can cause DRD, making gene testing difficult.",
"   </p>",
"   <p>",
"    An autosomal recessive form of DRD (Segawa syndrome) is caused by mutation in the tyrosine hydroxylase gene [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/65-67\">",
"     65-67",
"    </a>",
"    ]. Other rare entities that can present with a phenotype of DRD include mutations in the sepiapterin reductase gene (SPR gene) and the 6-pyruvoyl-tetrahydropterin synthase gene (PTS gene) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the clinical setting, the most practical and useful diagnostic test for DRD is a markedly positive response to a trial of levodopa, slowly increased to doses of 600 to 1,000 mg daily. However, a positive response to levodopa does not differentiate DRD from juvenile onset Parkinson disease. Typically, patients with DRD will have a sustained benefit from low doses of levodopa without developing motor fluctuations and dyskinesia, in contrast to juvenile Parkinson disease, in which these motor complications are a frequent occurrence.",
"   </p>",
"   <p>",
"    Other proposed diagnostic methods for DRD include assessment of tetrahydrobiopterin and neopterin in the cerebrospinal fluid, and the phenylalanine-loading test [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. However, most clinicians rely on confirmation with levodopa and do not undertake more extensive laboratory testing. Genetic testing for GCH1 is available, although there are many mutations that may give rise to the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Myoclonus-dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myoclonus-dystonia is a genetically heterogeneous autosomal dominant movement disorder characterized by myoclonic jerks primarily affecting the neck, arms, and axial muscles, combined with variable features of dystonia. Onset is typically in the second decade. The dystonia may be mild, and may improve dramatically after alcohol intake. At least two genetic loci have been identified (DYT11, DYT15).",
"   </p>",
"   <p>",
"    Myoclonus-dystonia is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=see_link&amp;anchor=H15#H15\">",
"     \"Classification and evaluation of myoclonus\", section on 'Myoclonus-dystonia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dystonia plus parkinsonism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other genetic forms of dystonia combine features of dystonia with parkinsonism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked dystonia-parkinsonism (DYT3), also known as Lubag dystonia, is characterized by progressive dystonia, often accompanied by parkinsonism. This disorder mainly affects Filipino men in their fifth decade, but woman can also be affected [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/73\">",
"       73",
"      </a>",
"      ]. Prominent pathologic findings include pronounced atrophy of the caudate and putamen. The disorder is poorly responsive to medication and patients usually survive for only 10 to 12 years. However, a case series found that the clinical course is much more benign in women [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/74\">",
"       74",
"      </a>",
"      ]. The responsible mutation involves the TATA-binding protein-associated factor 1 gene (TAF1 gene) on chromosome Xq13.1 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapid onset dystonia-parkinsonism (DYT12) is an autosomal dominant disorder in which dystonia, parkinsonism, prominent dysarthria and dysphagia emerge and evolve over a period of hours to weeks. Onset occurs in adolescence and early adulthood. The disorder is linked to chromosome 19q13 and six missense mutations in the ATP1A3 gene that encodes the",
"      <span class=\"nowrap\">",
"       Na+/K+",
"      </span>",
"      -ATPase alpha3 subunit have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/77\">",
"       77",
"      </a>",
"      ]. Genetic testing for the ATP1A3 gene is recommended when abrupt onset, rostrocaudal gradient and prominent bulbar findings are present [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/78\">",
"       78",
"      </a>",
"      ]. Despite reduced cerebrospinal homovanillic acid levels, this syndrome responds poorly to dopaminergic agents.",
"     </li>",
"     <li>",
"      Early onset dystonia-parkinsonism (DYT16) is an apparently autosomal recessive disorder characterized by early onset of focal dystonia followed by rapid spread of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/79\">",
"       79",
"      </a>",
"      ]. Parkinsonism is variably present, and was observed in four of the original seven cases [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/79\">",
"       79",
"      </a>",
"      ]. The syndrome does not respond to levodopa or high-dose anticholinergic treatment. Early onset dystonia-parkinsonism is linked to a mutation in the PRKRA gene on chromosome 2q31.3 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Paroxysmal dyskinesia with dystonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several rare genetic forms of dystonia are characterized by paroxysmal dyskinesia (",
"    <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Paroxysmal nonkinesigenic dyskinesia (PNKD) is characterized by spontaneous episodes of dystonia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      choreoathetosis not triggered by exercise or activity. Alcohol, coffee, tea, fatigue, stress, or excitement may be precipitating factors. Episodes last minutes to hours and recur two or three times a month. One type of PNKD (DYT8) is caused by mutations in the myofibrillogenesis 1 regulator gene (MR1 gene) on chromosome 2q35 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. Another maps to chromosome 2q31 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paroxysmal choreoathetosis with episodic spasticity and ataxia (DYT9) manifests with episodes of dystonia, diplopia, and paresthesia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/84,85\">",
"       84,85",
"      </a>",
"      ]. Exercise, emotional stress, sleep deprivation, and alcohol consumption may be precipitating factors. Some patients have a spastic paraparesis. DYT9 maps to chromosome 1p [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paroxysmal kinesigenic choreoathetosis, also known as paroxysmal kinesigenic dyskinesia, is characterized by episodic choreoathetosis and dystonia brought on by voluntary movement [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/84,86\">",
"       84,86",
"      </a>",
"      ]. The disorder is genetically heterogeneous; episodic kinesigenic dyskinesia 1 is caused by mutations in the PRRT2 gene on chromosome 16p11.2 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/87-91\">",
"       87-91",
"      </a>",
"      ], and episodic kinesigenic dyskinesia 2 maps to chromosome 16q13-q22.1 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/92\">",
"       92",
"      </a>",
"      ]. A third locus does not link to chromosome 16 [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Paroxysmal exertion-induced dyskinesia is an autosomal dominant disorder with reduced penetrance that begins in childhood with dyskinesia and dystonia induced by prolonged exertion (eg, &ge;15 minutes), fasting and stress [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/94-96\">",
"       94-96",
"      </a>",
"      ]. Associated features include absence",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      partial complex seizures. Affected members of one family also had hemolytic anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/97\">",
"       97",
"      </a>",
"      ]. The condition is linked to mutation or deletion of the SLC2A1 gene on chromosome 1p35-p31.3 that encodes the GLUT1 facilitated glucose transporter [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no consistent neuropathologic findings in primary dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/98-102\">",
"     98-102",
"    </a>",
"    ]. The lack of cell degeneration suggests that primary dystonia is a dynamic disorder, arising from abnormal cell function.",
"   </p>",
"   <p>",
"    The anatomic localization and specific neurotransmitter defects of dystonia have also been elusive. In patients with hemidystonia, lesions of the basal ganglia on head CT or neuropathologic examination were associated with contralateral dystonia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/103\">",
"     103",
"    </a>",
"    ]. Neuroimaging studies with positron emission tomography (PET) and functional MRI have shown that dystonia can be associated with abnormal activity in multiple regions of the brain, including motor cortex, supplementary motor areas, cerebellum, and basal ganglia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/104,105\">",
"     104,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from electrophysiologic testing (eg, blink reflex recovery) and functional imaging studies suggest that the pathophysiology of dystonia, in particular the task specific dystonias, may arise from a decrease of central inhibitory mechanisms, an increase of plasticity, or an impairment in sensory function [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/3,106\">",
"     3,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Direct microelectrode recordings obtained in patients with dystonia during electrode implantation for deep brain stimulation have shown alterations in mean discharge rates, somatosensory responsiveness, and altered patterns of neuronal activity in the globus pallidus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/107\">",
"     107",
"    </a>",
"    ]. These recordings have given rise to new constructs for diagrams of the basal ganglia and its involvement in dystonia, in which the modulating influences within the basal ganglia change with activity, reflecting the movement-dependent nature of dystonia.",
"   </p>",
"   <p>",
"    The underlying neurochemistry of dystonia is not known, but dopaminergic and cholinergic neurotransmitter systems may be involved.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abnormal dopaminergic activity in the basal ganglia is indirectly suggested by extrapolation from observations that dopamine receptor antagonism can cause acute and chronic dystonic symptoms (eg, oculogyric crisis and tardive dystonia) and that dystonia is often associated with Parkinson disease, a disorder with marked dopamine depletion. The co-occurrence of parkinsonism and dystonia in dopa-responsive dystonia further implicates a role for dopamine in the pathogenesis of dystonia.",
"     </li>",
"     <li>",
"      Cholinergic mechanisms are suggested by the success of anticholinergic therapy, mainly in children with dystonia [",
"      <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/108\">",
"       108",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of dystonia is based mainly upon clinical features, although the diagnostic laboratory can provide supportive evidence. In the absence of specific diagnostic tests, expert observation by a movement disorder specialist is suggested to confirm the diagnosis of dystonia in cases where there is uncertainty or confusion [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/109,110\">",
"     109,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary dystonia is separated from secondary dystonia by the absence of additional neurologic abnormalities and the lack of possible acquired cause (",
"    <a class=\"graphic graphic_table graphicRef70065 \" href=\"UTD.htm?28/4/28747\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As noted earlier, the age and anatomic distribution of dystonia at onset are important clinical clues for diagnosis. Atypical presentations (eg, a child with onset of dystonia in the neck or face, or an adult with onset in the leg, or an adult who develops generalized dystonia) indicate the need to evaluate for an underlying cause. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Clinical features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Laboratory testing in primary dystonia is of minimal usefulness, but essential in the evaluation of secondary dystonia, or dystonia with atypical features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Levodopa trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with focal or generalized dystonia of unknown etiology should have a trial of levodopa (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"     carbidopa-levodopa",
"    </a>",
"    <span class=\"nowrap\">",
"     25/100",
"    </span>",
"    mg three times daily) to confirm or exclude the diagnosis of dopa-responsive dystonia. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Dopa-responsive dystonia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with early onset dystonia, or those with late onset who have an affected relative with early onset dystonia, DYT1 gene testing is indicated with appropriate genetic counseling [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/4,110\">",
"     4,110",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'DYT1 dystonia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Molecular genetic testing is possible but NOT widely available for dopa-responsive dystonia (DYT5), myoclonus-dystonia (DYT11), rapid-onset dystonia-parkinsonism (DYT12), and deafness-dystonia-optic neuronopathy syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The assessment of atypical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    secondary dystonia is extensive [",
"    <a class=\"abstract\" href=\"UTD.htm?0/60/970/abstract/6\">",
"     6",
"    </a>",
"    ]. Laboratory evaluations and brain imaging should be obtained and appropriately directed. When there is clinical suspicion for secondary or heredodegenerative dystonia, we suggest obtaining the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CT or MRI of brain (basal ganglia calcifications or necrosis and other abnormalities)",
"     </li>",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Electrolytes",
"     </li>",
"     <li>",
"      Renal and liver function tests",
"     </li>",
"     <li>",
"      Antinuclear antibodies",
"     </li>",
"     <li>",
"      Ceruloplasmin, serum copper, and 24-hour urinary copper (for Wilson disease)",
"     </li>",
"     <li>",
"      Erythrocyte sedimentation rate",
"     </li>",
"     <li>",
"      Rapid plasma reagent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/2/34849?source=see_link\">",
"       \"Patient information: Dystonia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/8/21633?source=see_link\">",
"       \"Patient information: Spasmodic dysphonia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dystonia is a movement disorder characterized by involuntary, sustained muscle contractions that result in twisting and repetitive movements or abnormal postures. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction and definition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dystonia is classified by anatomic distribution, age of onset, and etiology (",
"      <a class=\"graphic graphic_table graphicRef59278 \" href=\"UTD.htm?38/52/39755\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Dystonia may be classified anatomically as focal (involving a single body area), segmental (involving contiguous body areas), generalized (involving at least one leg, the trunk, and another body area), multifocal (involving two or more noncontiguous body areas), and hemidystonia (involving one side of the body).",
"     </li>",
"     <li>",
"      Early onset dystonia presents in childhood or young adulthood (before age 26). It most often begins with symptoms in the limbs, typically the leg. It spreads to other body areas to become generalized in over 50 percent of patients. Late onset dystonia (age 26 or older) most frequently begins in the neck, arm, or face and tends to remain focal or segmental.",
"     </li>",
"     <li>",
"      Classification by etiology (",
"      <a class=\"graphic graphic_table graphicRef59044 \" href=\"UTD.htm?33/63/34813\">",
"       table 2",
"      </a>",
"      ) broadly separates the spectrum of dystonia into two main categories, primary and secondary. Primary dystonia presents with signs related solely to dystonia. Secondary dystonia is associated with additional neurologic abnormalities and usually arises from a specific underlying condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of dystonia is estimated to be between 2 to 7500 per million people, depending on the populations assessed and the methods of ascertainment. Focal dystonia is approximately 10 times more frequent than generalized dystonia. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical features of dystonia vary according to anatomic location, age of onset, and etiology. Early onset dystonia usually begins in a leg, often as intorsion of the foot. Spread from one leg to other body areas occurs in approximately 50 to 90 percent of children, usually within five years of onset. Late onset primary focal dystonia may involve different body areas. Common",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      important types of focal dystonia include (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervical dystonia (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Cervical dystonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Blepharospasm (see",
"      <a class=\"local\" href=\"#H9\">",
"       'Blepharospasm'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Oromandibular dystonia and facial dystonia (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Oromandibular dystonia and facial dystonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Spasmodic dysphonia (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Spasmodic dysphonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Arm dystonia (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Arm dystonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Occupational or task-specific dystonia such writer's cramp (see",
"      <a class=\"local\" href=\"#H14\">",
"       'Occupational or task-specific dystonia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Writer's cramp'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are numerous genetic causes of dystonia (",
"      <a class=\"graphic graphic_table graphicRef56658 \" href=\"UTD.htm?7/8/7310\">",
"       table 3",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Genetic etiologies'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      DYT1 primary dystonia is caused by a mutation in the TOR1A gene. Other genetic types of primary dystonia include DYT4, DYT6, DYT7, and DYT13 (see",
"      <a class=\"local\" href=\"#H17\">",
"       'DYT1 dystonia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'DYT6 and other primary dystonias'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Dopa-responsive dystonia manifests primarily as a focal dystonia with onset in early childhood. The most frequent form of DRD is autosomal dominant DYT5 dystonia with a mutation in the GCH1 gene (see",
"      <a class=\"local\" href=\"#H19\">",
"       'Dopa-responsive dystonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Myoclonus-dystonia (DYT11, DYT15) is an autosomal dominant movement disorder characterized by alcohol-sensitive myoclonic jerks, primarily affecting the arms and axial muscles, combined with variable features of dystonia (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Myoclonus-dystonia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Genetic forms of dystonia with parkinsonism include X-linked dystonia-parkinsonism (DYT3), rapid onset dystonia-parkinsonism (DYT12), and early onset dystonia-parkinsonism (DYT16) (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Dystonia plus parkinsonism'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Several rare genetic forms of dystonia are characterized by paroxysmal dyskinesia (DYT8, DYT9, DYT10) (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Paroxysmal dyskinesia with dystonia'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathogenesis of most forms of primary dystonia is largely unknown. There are no consistent neuropathologic features, suggesting that dystonia occurs because of cellular dysfunction. Multiple brain areas may be involved, including basal ganglia, motor cortex, supplementary motor areas, and cerebellum. Postulated mechanisms include a decrease of inhibition, an increase of plasticity, or impairment in sensory function. Abnormalities in dopaminergic and cholinergic neurotransmitter systems may play a role. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of dystonia is mainly clinical. Expert observation by a movement disorder specialist is suggested to confirm the diagnosis of dystonia in cases where there is uncertainty or confusion (",
"      <a class=\"graphic graphic_table graphicRef70065 \" href=\"UTD.htm?28/4/28747\">",
"       table 4",
"      </a>",
"      ). Atypical presentations",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      suspicion for secondary etiologies should prompt further investigations (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Diagnosis'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with focal or generalized dystonia of unknown etiology, we recommend a trial of levodopa (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/36/36423?source=see_link\">",
"       carbidopa-levodopa",
"      </a>",
"      <span class=\"nowrap\">",
"       25/100",
"      </span>",
"      mg three times daily, slowly increased to total levodopa doses of 600 to 1,000 mg daily) to confirm or exclude the diagnosis of dopa-responsive dystonia.",
"     </li>",
"     <li>",
"      For patients with early onset dystonia, or those with late onset who have an affected relative with early onset dystonia, we suggest TOR1A genetic testing for DYT1 dystonia.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/1\">",
"      Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/2\">",
"      Geyer HL, Bressman SB. The diagnosis of dystonia. Lancet Neurol 2006; 5:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/3\">",
"      Phukan J, Albanese A, Gasser T, Warner T. Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol 2011; 10:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/4\">",
"      Bressman SB, Sabatti C, Raymond D, et al. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000; 54:1746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/5\">",
"      Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv Neurol 2004; 94:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/6\">",
"      Friedman J, Standaert DG. Dystonia and its disorders. Neurol Clin 2001; 19:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/7\">",
"      Greene P, Kang UJ, Fahn S. Spread of symptoms in idiopathic torsion dystonia. Mov Disord 1995; 10:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/8\">",
"      Nutt JG, Muenter MD, Melton LJ 3rd, et al. Epidemiology of dystonia in Rochester, Minnesota. Adv Neurol 1988; 50:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/9\">",
"      Nutt JG, Muenter MD, Aronson A, et al. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/10\">",
"      Butler AG, Duffey PO, Hawthorne MR, Barnes MP. An epidemiologic survey of dystonia within the entire population of northeast England over the past nine years. Adv Neurol 2004; 94:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/11\">",
"      Defazio G, Abbruzzese G, Livrea P, Berardelli A. Epidemiology of primary dystonia. Lancet Neurol 2004; 3:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/12\">",
"      Le KD, Nilsen B, Dietrichs E. Prevalence of primary focal and segmental dystonia in Oslo. Neurology 2003; 61:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/13\">",
"      Fukuda H, Kusumi M, Nakashima K. Epidemiology of primary focal dystonias in the western area of Tottori prefecture in Japan: Comparison with prevalence evaluated in 1993. Mov Disord 2006; 21:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/14\">",
"      Almasy L, Bressman S, de Leon D, Risch N. Ethnic variation in the clinical expression of idiopathic torsion dystonia. Mov Disord 1997; 12:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/15\">",
"      Steeves TD, Day L, Dykeman J, et al. The prevalence of primary dystonia: a systematic review and meta-analysis. Mov Disord 2012; 27:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/16\">",
"      Saunders-Pullman R, Soto-Valencia J, Costan-Toth C, et al. A new screening tool for cervical dystonia. Neurology 2005; 64:2046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/17\">",
"      Bressman SB, Raymond D, Wendt K, et al. Diagnostic criteria for dystonia in DYT1 families. Neurology 2002; 59:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/18\">",
"      Klein C, Ozelius LJ. Dystonia: clinical features, genetics, and treatment. Curr Opin Neurol 2002; 15:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/19\">",
"      Bressman SB. Dystonia update. Clin Neuropharmacol 2000; 23:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/20\">",
"      Greene PE, Bressman S. Exteroceptive and interoceptive stimuli in dystonia. Mov Disord 1998; 13:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/21\">",
"      O'Riordan S, Raymond D, Lynch T, et al. Age at onset as a factor in determining the phenotype of primary torsion dystonia. Neurology 2004; 63:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/22\">",
"      Weiss EM, Hershey T, Karimi M, et al. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord 2006; 21:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/23\">",
"      Svetel M, Pekmezovi�� T, Jovi�� J, et al. Spread of primary dystonia in relation to initially affected region. J Neurol 2007; 254:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/24\">",
"      Schneider SA, Edwards MJ, Grill SE, et al. Adult-onset primary lower limb dystonia. Mov Disord 2006; 21:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/25\">",
"      Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord 1991; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/26\">",
"      Jankovic J, Leder S, Warner D, Schwartz K. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/27\">",
"      Hallett M. Blepharospasm: recent advances. Neurology 2002; 59:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/28\">",
"      Hallett M, Evinger C, Jankovic J, et al. Update on blepharospasm: report from the BEBRF International Workshop. Neurology 2008; 71:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/29\">",
"      Jankovic J, Ford J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol 1983; 13:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/30\">",
"      Marsden CD. Blepharospasm-oromandibular dystonia syndrome (Brueghel's syndrome). A variant of adult-onset torsion dystonia? J Neurol Neurosurg Psychiatry 1976; 39:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/31\">",
"      Brin MF, Blitzer A, Stewart C. Laryngeal dystonia (spasmodic dysphonia): observations of 901 patients and treatment with botulinum toxin. Adv Neurol 1998; 78:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/32\">",
"      Cook MJ, Lewin JS. Spasmodic dysphonia: new diagnosis and treatment opportunities. Nurse Pract 1994; 19:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/33\">",
"      Frucht SJ. Focal task-specific dystonia in musicians. Adv Neurol 2004; 94:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/34\">",
"      Thompson PD. Writers' cramp. Br J Hosp Med 1993; 50:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/35\">",
"      Bressman S. Genetics of dystonia. J Neural Transm Suppl 2006; :489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/36\">",
"      Klein C. Movement disorders: classifications. J Inherit Metab Dis 2005; 28:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/37\">",
"      Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/38\">",
"      Ozelius LJ, Page CE, Klein C, et al. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics 1999; 62:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/39\">",
"      Bressman SB, Heiman GA, Nygaard TG, et al. A study of idiopathic torsion dystonia in a non-Jewish family: evidence for genetic heterogeneity. Neurology 1994; 44:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/40\">",
"      Misbahuddin A, Placzek MR, Taanman JW, et al. Mutant torsinA, which causes early-onset primary torsion dystonia, is redistributed to membranous structures enriched in vesicular monoamine transporter in cultured human SH-SY5Y cells. Mov Disord 2005; 20:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/41\">",
"      Waddy HM, Fletcher NA, Harding AE, Marsden CD. A genetic study of idiopathic focal dystonias. Ann Neurol 1991; 29:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/42\">",
"      Dhaenens CM, Krystkowiak P, Douay X, et al. Clinical and genetic evaluation in a French population presenting with primary focal dystonia. Mov Disord 2005; 20:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/43\">",
"      Walsh R, O'Dwyer JP, Sheikh IH, et al. Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives. J Neurol Neurosurg Psychiatry 2007; 78:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/44\">",
"      Almasy L, Bressman SB, Raymond D, et al. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 1997; 42:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/45\">",
"      Saunders-Pullman R, Raymond D, Senthil G, et al. Narrowing the DYT6 dystonia region and evidence for locus heterogeneity in the Amish-Mennonites. Am J Med Genet A 2007; 143A:2098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/46\">",
"      Fuchs T, Gavarini S, Saunders-Pullman R, et al. Mutations in the THAP1 gene are responsible for DYT6 primary torsion dystonia. Nat Genet 2009; 41:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/47\">",
"      Bressman SB, Raymond D, Fuchs T, et al. Mutations in THAP1 (DYT6) in early-onset dystonia: a genetic screening study. Lancet Neurol 2009; 8:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/48\">",
"      Djarmati A, Schneider SA, Lohmann K, et al. Mutations in THAP1 (DYT6) and generalised dystonia with prominent spasmodic dysphonia: a genetic screening study. Lancet Neurol 2009; 8:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/49\">",
"      Xiao J, Zhao Y, Bastian RW, et al. Novel THAP1 sequence variants in primary dystonia. Neurology 2010; 74:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/50\">",
"      Gavarini S, Cayrol C, Fuchs T, et al. Direct interaction between causative genes of DYT1 and DYT6 primary dystonia. Ann Neurol 2010; 68:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/51\">",
"      Kaiser FJ, Osmanoric A, Rakovic A, et al. The dystonia gene DYT1 is repressed by the transcription factor THAP1 (DYT6). Ann Neurol 2010; 68:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/52\">",
"      Ahmad F, Davis MB, Waddy HM, et al. Evidence for locus heterogeneity in autosomal dominant torsion dystonia. Genomics 1993; 15:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/53\">",
"      Ozelius LJ. Update on the genetics of primary torsion dystonia loci DYT6, DYT7, and DYT13 and the dystonia-plus locus DYT12. Adv Neurol 2004; 94:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/54\">",
"      Chouery E, Kfoury J, Delague V, et al. A novel locus for autosomal recessive primary torsion dystonia (DYT17) maps to 20p11.22-q13.12. Neurogenetics 2008; 9:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/55\">",
"      Weber YG, Kamm C, Suls A, et al. Paroxysmal choreoathetosis/spasticity (DYT9) is caused by a GLUT1 defect. Neurology 2011; 77:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/56\">",
"      Segawa M, Hosaka A, Miyagawa F, et al. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976; 14:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/57\">",
"      Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003; 54 Suppl 6:S32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/58\">",
"      Nygaard TG, Trugman JM, de Yebenes JG, Fahn S. Dopa-responsive dystonia: the spectrum of clinical manifestations in a large North American family. Neurology 1990; 40:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/59\">",
"      Trender-Gerhard I, Sweeney MG, Schwingenschuh P, et al. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry 2009; 80:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/60\">",
"      Tadic V, Kasten M, Br&uuml;ggemann N, et al. Dopa-Responsive Dystonia Revisited: Diagnostic Delay, Residual Signs, and Nonmotor Signs. Arch Neurol 2012; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/61\">",
"      Boyd K, Patterson V. Dopa responsive dystonia: a treatable condition misdiagnosed as cerebral palsy. BMJ 1989; 298:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/62\">",
"      Jan MM. Misdiagnoses in children with dopa-responsive dystonia. Pediatr Neurol 2004; 31:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/63\">",
"      Nygaard TG, Marsden CD, Duvoisin RC. Dopa-responsive dystonia. Adv Neurol 1988; 50:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/64\">",
"      Ichinose H, Ohye T, Takahashi E, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/65\">",
"      L&uuml;decke B, Dworniczak B, Bartholom&eacute; K. A point mutation in the tyrosine hydroxylase gene associated with Segawa's syndrome. Hum Genet 1995; 95:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/66\">",
"      Knappskog PM, Flatmark T, Mallet J, et al. Recessively inherited L-DOPA-responsive dystonia caused by a point mutation (Q381K) in the tyrosine hydroxylase gene. Hum Mol Genet 1995; 4:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/67\">",
"      Verbeek MM, Steenbergen-Spanjers GC, Willemsen MA, et al. Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. Ann Neurol 2007; 62:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/68\">",
"      Steinberger D, Blau N, Goriuonov D, et al. Heterozygous mutation in 5'-untranslated region of sepiapterin reductase gene (SPR) in a patient with dopa-responsive dystonia. Neurogenetics 2004; 5:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/69\">",
"      Hanihara T, Inoue K, Kawanishi C, et al. 6-Pyruvoyl-tetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord 1997; 12:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/70\">",
"      Bandmann O, Goertz M, Zschocke J, et al. The phenylalanine loading test in the differential diagnosis of dystonia. Neurology 2003; 60:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/71\">",
"      Saunders-Pullman R, Blau N, Hyland K, et al. Phenylalanine loading as a diagnostic test for DRD: interpreting the utility of the test. Mol Genet Metab 2004; 83:207.",
"     </a>",
"    </li>",
"    <li>",
"     Furukawa, Y. GTP cyclohydrolase 1-deficient dopa-responsive dystonia. GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1508/ (Accessed on April 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/73\">",
"      Evidente VG, Advincula J, Esteban R, et al. Phenomenology of \"Lubag\" or X-linked dystonia-parkinsonism. Mov Disord 2002; 17:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/74\">",
"      Evidente VG, Nolte D, Niemann S, et al. Phenotypic and molecular analyses of X-linked dystonia-parkinsonism (\"lubag\") in women. Arch Neurol 2004; 61:1956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/75\">",
"      Wilhelmsen KC, Weeks DE, Nygaard TG, et al. Genetic mapping of \"Lubag\" (X-linked dystonia-parkinsonism) in a Filipino kindred to the pericentromeric region of the X chromosome. Ann Neurol 1991; 29:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/76\">",
"      Makino S, Kaji R, Ando S, et al. Reduced neuron-specific expression of the TAF1 gene is associated with X-linked dystonia-parkinsonism. Am J Hum Genet 2007; 80:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/77\">",
"      de Carvalho Aguiar P, Sweadner KJ, Penniston JT, et al. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 2004; 43:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/78\">",
"      Brashear A, Dobyns WB, de Carvalho Aguiar P, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007; 130:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/79\">",
"      Camargos S, Scholz S, Sim&oacute;n-S&aacute;nchez J, et al. DYT16, a novel young-onset dystonia-parkinsonism disorder: identification of a segregating mutation in the stress-response protein PRKRA. Lancet Neurol 2008; 7:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/80\">",
"      Seibler P, Djarmati A, Langpap B, et al. A heterozygous frameshift mutation in PRKRA (DYT16) associated with generalised dystonia in a German patient. Lancet Neurol 2008; 7:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/81\">",
"      Rainier S, Thomas D, Tokarz D, et al. Myofibrillogenesis regulator 1 gene mutations cause paroxysmal dystonic choreoathetosis. Arch Neurol 2004; 61:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/82\">",
"      Bruno MK, Lee HY, Auburger GW, et al. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia. Neurology 2007; 68:1782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/83\">",
"      Spacey SD, Adams PJ, Lam PC, et al. Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. Neurology 2006; 66:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/84\">",
"      M&uuml;ller U, Steinberger D, N&eacute;meth AH. Clinical and molecular genetics of primary dystonias. Neurogenetics 1998; 1:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/85\">",
"      Auburger G, Ratzlaff T, Lunkes A, et al. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. Genomics 1996; 31:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/86\">",
"      Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 1967; 17:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/87\">",
"      Tomita Ha, Nagamitsu S, Wakui K, et al. Paroxysmal kinesigenic choreoathetosis locus maps to chromosome 16p11.2-q12.1. Am J Hum Genet 1999; 65:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/88\">",
"      Chen WJ, Lin Y, Xiong ZQ, et al. Exome sequencing identifies truncating mutations in PRRT2 that cause paroxysmal kinesigenic dyskinesia. Nat Genet 2011; 43:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/89\">",
"      M&eacute;neret A, Grabli D, Depienne C, et al. PRRT2 mutations: a major cause of paroxysmal kinesigenic dyskinesia in the European population. Neurology 2012; 79:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/90\">",
"      van Vliet R, Breedveld G, de Rijk-van Andel J, et al. PRRT2 phenotypes and penetrance of paroxysmal kinesigenic dyskinesia and infantile convulsions. Neurology 2012; 79:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/91\">",
"      Silveira-Moriyama L, Gardiner AR, Meyer E, et al. Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations. Dev Med Child Neurol 2013; 55:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/92\">",
"      Valente EM, Spacey SD, Wali GM, et al. A second paroxysmal kinesigenic choreoathetosis locus (EKD2) mapping on 16q13-q22.1 indicates a family of genes which give rise to paroxysmal disorders on human chromosome 16. Brain 2000; 123 ( Pt 10):2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/93\">",
"      Spacey SD, Valente EM, Wali GM, et al. Genetic and clinical heterogeneity in paroxysmal kinesigenic dyskinesia: evidence for a third EKD gene. Mov Disord 2002; 17:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/94\">",
"      Plant GT, Williams AC, Earl CJ, Marsden CD. Familial paroxysmal dystonia induced by exercise. J Neurol Neurosurg Psychiatry 1984; 47:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/95\">",
"      Margari L, Perniola T, Illiceto G, et al. Familial paroxysmal exercise-induced dyskinesia and benign epilepsy: a clinical and neurophysiological study of an uncommon disorder. Neurol Sci 2000; 21:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/96\">",
"      M&uuml;nchau A, Valente EM, Shahidi GA, et al. A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study. J Neurol Neurosurg Psychiatry 2000; 68:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/97\">",
"      Weber YG, Storch A, Wuttke TV, et al. GLUT1 mutations are a cause of paroxysmal exertion-induced dyskinesias and induce hemolytic anemia by a cation leak. J Clin Invest 2008; 118:2157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/98\">",
"      Altrocchi PH, Forno LS. Spontaneous oral-facial dyskinesia: neuropathology of a case. Neurology 1983; 33:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/99\">",
"      Zweig RM, Hedreen JC, Jankel WR, et al. Pathology in brainstem regions of individuals with primary dystonia. Neurology 1988; 38:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/100\">",
"      Gibb WR, Lees AJ, Marsden CD. Pathological report of four patients presenting with cranial dystonias. Mov Disord 1988; 3:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/101\">",
"      McNaught KS, Kapustin A, Jackson T, et al. Brainstem pathology in DYT1 primary torsion dystonia. Ann Neurol 2004; 56:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/102\">",
"      Holton JL, Schneider SA, Ganesharajah T, et al. Neuropathology of primary adult-onset dystonia. Neurology 2008; 70:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/103\">",
"      Marsden CD, Obeso JA, Zarranz JJ, Lang AE. The anatomical basis of symptomatic hemidystonia. Brain 1985; 108 ( Pt 2):463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/104\">",
"      Eidelberg D, Moeller JR, Antonini A, et al. Functional brain networks in DYT1 dystonia. Ann Neurol 1998; 44:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/105\">",
"      Carbon M, Su S, Dhawan V, et al. Regional metabolism in primary torsion dystonia: effects of penetrance and genotype. Neurology 2004; 62:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/106\">",
"      Hallett M. Pathophysiology of writer's cramp. Hum Mov Sci 2006; 25:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/107\">",
"      Vitek JL. Pathophysiology of dystonia: a neuronal model. Mov Disord 2002; 17 Suppl 3:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/108\">",
"      Pisani A, Bernardi G, Ding J, Surmeier DJ. Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 2007; 30:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/109\">",
"      Logroscino G, Livrea P, Anaclerio D, et al. Agreement among neurologists on the clinical diagnosis of dystonia at different body sites. J Neurol Neurosurg Psychiatry 2003; 74:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/60/970/abstract/110\">",
"      Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol 2006; 13:433.",
"     </a>",
"    </li>",
"    <li>",
"     Nemeth AH. Dystonia overview. In: GeneReviews. www.ncbi.nlm.nih.gov/books/NBK1155/ (Accessed on January 18, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4886 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-37992F4EF2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_970=[""].join("\n");
var outline_f0_60_970=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION AND DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age of onset and anatomic distribution",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Early onset primary dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Late onset primary dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cervical dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Blepharospasm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oromandibular dystonia and facial dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Spasmodic dysphonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Vocal tremor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Arm dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Occupational or task-specific dystonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Writer's cramp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      GENETIC ETIOLOGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DYT1 dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DYT6 and other primary dystonias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Dopa-responsive dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Myoclonus-dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dystonia plus parkinsonism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Paroxysmal dyskinesia with dystonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Levodopa trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4886\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4886|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/52/39755\" title=\"table 1\">",
"      Classification dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/63/34813\" title=\"table 2\">",
"      Etiology dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/8/7310\" title=\"table 3\">",
"      Genetic forms dystonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/4/28747\" title=\"table 4\">",
"      Features primary dystonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7689?source=related_link\">",
"      Classification and evaluation of myoclonus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10984?source=related_link\">",
"      Overview of tremor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/2/34849?source=related_link\">",
"      Patient information: Dystonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/8/21633?source=related_link\">",
"      Patient information: Spasmodic dysphonia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/52/12105?source=related_link\">",
"      Treatment of dystonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_60_971="Risk factors surgery obstructive jaundice";
var content_f0_60_971=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for morbidity and mortality in patients with obstructive jaundice undergoing surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Azotemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hematocrit &lt; 30 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypoalbulminemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malignant cause of biliary obstruction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serum bilirubin level &gt; 11 mg/dL (188 &micro;mol/liter)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Friedman LS. The risk of surgery in patients with liver disease. Hepatology 1999; 29:1617. Copyright &copy; 1999 Elsevier Science.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_971=[""].join("\n");
var outline_f0_60_971=null;
var title_f0_60_972="Motor automatisms";
var content_f0_60_972=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Motor automatisms in Neonatal seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Ocular signs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Random and roving eye movements or nystagmus (distinct from tonic eye deviation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be provoked or intensified by tactile stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed pathophysiology: nonepileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Oral-buccal-lingual movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sucking, chewing, tongue protrusions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be provoked or intensified by stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed pathophysiology: nonepileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Progression movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rowing or swimming movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Pedaling or bicycling movements of the legs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be provoked or intensified by stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be suppressed by restraint or repositioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed pathophysiology: nonepileptic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Complex purposeless movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Sudden arousal with transient increased random activity of limbs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        May be provoked or intensified by stimulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presumed pathophysiology: nonepileptic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Mizrahi, EM, Kellaway, P. Diagnosis and Management of Neonatal Seizures. Lippincott-Raven, Philadelphia 1998. p.181. Copyright &copy; 1998 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_972=[""].join("\n");
var outline_f0_60_972=null;
var title_f0_60_973="Classification of epileptic seizures";
var content_f0_60_973=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International classification of epileptic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Partial (focal, local) seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Simple partial seizures (conciousness not impaired)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       With motor symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Focal motor without march",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Focal motor with march (Jacksonian)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Versive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Postural",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Phonatory (vocalization or arrest of speech)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       With somatosensory or special sensory symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Somatosensory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Visual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Auditory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Olfactory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Gustatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Vertiginous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       With autonomic symptoms or signs (including epigastric, pallor, sweating, etc)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       With psychic symptoms (disturbance of higher cerebral function). Usually occur with impairment of consciousness and classified as complex partial.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Dysphasic",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Cognitive (eg, distortions of time sense)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Dysmnesic (eg, deja-vu)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Affective (eg, fear)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Illusions",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       Hallucinations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Complex partial (with impairment of consciousness)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Simple partial onset followed by impairment of consciousness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2_start\">",
"       Impairment of consciousness at onset",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       With impairment of consciousness only",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist2\">",
"       With automatisms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Partial seizures (simple or complex) evolving to secondarily generalized seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Generalized seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Nonconvulsive (absence)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Typical (3/sec spike and slow wave complexes on EEG)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Atypical (&lt;3/sec spike and slow wave complexes on EEG)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Convulsive",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Myoclonic seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Clonic seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tonic seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tonic-clonic seizures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Atonic (\"drop attacks\")",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Unclassified seizure",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Commission on Classification and Terminology of the International League against Epilepsy, Epilepsia 1981; 22:489.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_973=[""].join("\n");
var outline_f0_60_973=null;
var title_f0_60_974="Electrolyte patterns PFTs";
var content_f0_60_974=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82081&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 504px\">",
"   <div class=\"ttl\">",
"    The characteristic electrolyte secretory concentration patterns observed in pancreatic fluid in response to secretin administration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 484px; height: 403px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sodium and potassium are maintained at stable concentrations and isotonic to plasma. There is a gradual rise in bicarbonate concentration to a peak of approximately 120 mEq/L. Chloride exhibits a reciprocal decrease in concentration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cleveland Clinic Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_974=[""].join("\n");
var outline_f0_60_974=null;
var title_f0_60_975="Evaluation intractable hiccups";
var content_f0_60_975=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79155&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Diagnostic evaluation of persistent or intractable hiccups",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 338px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CXR: chest x-ray; sx: symptoms; ENT: ear, nose, and throat; LP: lumbar puncture; LFTs: liver function tests.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_60_975=[""].join("\n");
var outline_f0_60_975=null;
